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Abstract  
Senescent cells accumulate in the body with age, and drive organismal ageing and tissue dysfunction. 
Senescence is not a simple growth arrest, but is accompanied by a host of phenotypic changes, 
including the generation of pro-inflammatory molecules, and is maintained by a network of auto- and 
paracrine reinforcement. Senescence is now also understood to occur in post-mitotic cells, including 
neurons – contrary to the former definition of senescence occurring exclusively in proliferating cells. 
This is called the senescent-like phenotype. While senescent cells can be seen to increase with age, 
little is known about their relation to cognitive function with age or pathological states such neuro-
inflammation.  
Using a model of chronic inflammation, the nfkb1-/- mouse, I investigated neuro-inflammation, 
cognitive function and the frequency of senescent-like neurons with age and treatment with the COX-
2 inhibitor ibuprofen. Increasing microglial proliferation and neuro-inflammation could be observed, 
together with deficits in spatial memory. This was accompanied by an increase in the numbers of 
senescent-like neurons. Increased accumulation of persistent DNA damage in pyramidal neurons, and 
a deficit in the generation and propagation of Carbachol induced gamma frequency oscillations, could 
be seen in the CA3. COX-2 appears to have a role in mediating these effects, as treatment with 
ibuprofen was effective in ameliorating levels of neuro-inflammation, cognitive dysfunction and 
senescent-like neurons. 
Ageing INK-ATTAC mice were given pharmacogenetic and pharmacological treatments to investigate 
if these could clear senescent-like neurons. Pharmacological clearance (Dasatinib and Quercetin) was 
effective in reducing the numbers of senescent like neurons, and these mice showed an improvement 
in cognitive function, while pharmacogenetic treatment had a lesser effect. 
The data presented in this thesis implicate the senescence and the senescent-like phenotype in neuro-
inflammation and ageing, and in driving the accompanying declines in cognitive function.  
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1.0: Introduction 
1.1 – Brain ageing and cognitive deficits 
There is an unprecedented demographic shift from young to old occurring in many countries around 
the world. As the population ages, there are increased difficulties in dealing with age associated 
conditions; namely frailty and chronic diseases. These conditions increase the burden on health-
services and contribute towards economic withdrawal of not only those affected, but the family 
members who must care for them. These are serious human and economic threats that must be 
effectively countered to ensure the progress of civilisation. As such, understanding the biological 
mechanisms underlying the ageing process, and seeking effective therapies, is of paramount 
importance. 
Cognitive deficits are a common feature in ageing, but are not universal and present with differing 
symptoms, rates of onsets and pathologies [1]. Even ‘mild’ changes can be distressing and damage 
self-image and self-reliance. The onset of neurodegenerative conditions, such as Alzheimer’s Disease 
(AD), is especially devastating. These changes not only rob people of their memories and identity, but 
are one of the leading causes of death. In the UK, Dementia and AD are the leading cause of death in 
women over 80, and second in men over 80. As the majority can now expect to live to this age, 
cognitive impairment and dementias represent a major source of disability in the population. It is 
important to understand what processes contribute towards this during ageing, and if existing 
knowledge and therapies in the Biology of Ageing field can be applied. 
1.1.1 – Changes in the brain with age 
Despite significant incidence of neurodegenerative conditions, the majority will not suffer from 
dementia; however, they will experience some age-associated cognitive decline – primarily presenting 
as defects in memory, navigation, and executive capacity [2, 3]. Ageing does not show a uniform 
decrease across all types of memory; generally, while the speed of memory recall without a verbal or 
object cue is delayed, recognition and memory following a cue remains stable [2]. The ability to recall 
the source of learned information and remembering to perform a future action declines, but the actual 
memory of how to do a task and chronological order remain stable [2]. Cognitive speed and memory, 
reasoning and spatial visualisation capacity decline, while other factors such as vocabulary improve 
with age, peaking at age 60 [4]. As a rule, while sum knowledge increases, efficiency decreases. 
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Given that declines in cognitive function occur in normal ageing, and the frequency of 
neurodegenerative diseases increases with age, one might assume that neurodegeneration presents 
a form of accelerated ageing. However, this is not supported by the evidence, as clinical diagnosis of 
cognitive impairment and dementia do not show a linear relationship with the presence of the 
associated pathology [5, 6]. Neuropathological assessment of cognitively unimpaired aged individuals 
from 50 to 102 has shown a great deal of variability in the protein pathologies of ‘normally’ ageing 
brains [5]. These brains frequently contain protein aggregates associated with neurodegenerative 
conditions, such as amyloid plaques, hyper-phosphorylated tau and alpha-synuclein aggregates, often 
in combination, but with a great degree of variability between lesions and areas affected [5]. A study 
of individuals age 90 and above, with and without dementia, reported a strong association between 
multiple protein pathologies and dementia; however, in non-demented individuals they also found at 
least one form of pathology in 49% of brains and mixed pathologies in 14% of individuals, suggesting 
a complex interplay of mechanisms in causing clinically diagnosable dementia [6]. 
There are changes in brain volume with age. In humans, total grey matter declines from early life, 
initially in the pre-frontal cortex, and there are age-related reductions in the hippocampus [7, 8]. 
Cerebrospinal fluid volume, found primarily in the ventricles, increases linearly with age; while white 
matter shows an inverse U-shaped progression, peaking at age 40-50 before declining again [8]. 
Similar patterns are observed in mice, with a slight reduction in total brain volume and the volume of 
the hippocampus at 12 months, but with increases in ventricular size [9]. However, whether volume 
is an important measure is difficult to establish. Meta-analysis of studies has suggested that a larger 
volume of brain structures such as the hippocampus is often correlated with improved performance 
in cognitive parameters in ‘healthy’ aged individuals [10]. Most commonly these showed a correlation 
in the hippocampal formation and global cognition and memory, and with executive function in the 
frontal formation [10]. 
Declines in brain volume and cognitive impairment in neurodegenerative diseases are associated with 
neuronal cell-death and apoptosis [11-13], but the rates of cell death in normally aged brains is less 
clear [14-16]. Certainly, there are some reductions in brain mass with aged cognitively healthy 
humans; with a ~5-15% reduction between those aged 50-59 years old and those over 90 [5]. In mice, 
while there are declines in the mass of sub-structures, including the hippocampus [17], the actual 
gross brain weight appears to remain fairly constant throughout ageing [15]. Yet, examination of 
neuron numbers in healthy aged humans aged 56 to 103 has shown no significant loss in actual 
number - despite the presence of age-related atrophy [14]. The same can be seen in mice, with a lack 
of significant cell death with age [15, 16]. 
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Instead, the loss of volume in ‘healthy’ ageing may be related to changes in neuronal morphology [3], 
rather than gross loss of neurons [14, 18, 19]. With ageing, some loss of complexity in axonal and 
dendritic processes of neurons appears to occur [19-21]. Early reports suggested a drastic 
deterioration of dendritic branch length and complexity in areas such as the hippocampus [22]. Yet 
these included demented individuals along with the cognitively healthy and later analysis has reported 
that these changes are not as severe [19, 23]. No great loss of dendritic length appears to occur in 
aged neurons across the brain [24, 25] Instead the changes appear more subtle, with some declines 
in spine density and size in normally aged mice, but not in all regions [26]. 
Many neurochemical changes have been observed within synapses, with shifts in receptor densities 
and types [27, 28] and a decline in pre-synapse receptor density in human brains with age [29]. 
Synapses are highly dynamic structures that undergo complex regulation cascades and can be formed 
or pruned, their activity potentiated or reduced through stimulus. Accelerated ageing models show 
reductions in synapse numbers and apical dendrites [30], however, in normally aged wild-type mice 
this is less clear. In fact, studies have reported no age-related loss in synapse number in normally aged 
mice [31]. However, when cognitive function was assessed, there was a significant association with 
performance in memory tasks, such as the Morris water maze, and synapse number [31]. Levels of 
neuro-transmitter in these synapses do decline with age [32], however, no relation was found 
between these levels and performance in the tasks. Instead, an association was found between 
performance in memory tasks and increased levels of synaptic structural stability proteins and 
decreased activity-dependent signalling factors [32]. These changes suggest that a decreased ability 
to alter synapses in response to stimuli (synaptic plasticity), rather than raw synapse number [31], 
differentiates cognitive decline in ageing. 
Changes in plasticity can be seen on both a network and individual cell level in the brain with ageing 
[23]. Cognitively impaired aged animals show altered synaptic plasticity, especially in areas such as the 
hippocampus [33-35]. In electrophysical parameters, while basal parameters are similar, young 
rodents maintain increased synaptic strength following high-frequency stimulation for longer than 
aged animals, which show an almost immediate decline  [36]. This matches their performance in 
spatial tasks such as the Barnes Maze, with comparable performance to younger controls in spatial 
parameters during early training, and no  divergence until after repeated trials  [36]. Increased after-
hyperpolarisation has been observed with ageing that might increase the threshold to induce the long-
term potentiation cascade [37] or interfere with activity-dependent network dynamics, such as 
gamma-frequency oscillations [38], that influence spatial navigation and retention. Yet in physiological 
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conditions, neuron firing rates either remain the same, or even exhibit hyper-excitability and increased 
firing rates depending on region [39]. 
1.1.2. Ageing in specific brain structures 
While both ‘normal’ ageing and neurodegenerative conditions share vulnerable circuits, the effects 
that lead to the dysfunction are seemingly different. The brain is an incredibly complex overall 
structure, with a complex interplay of neuronal circuits running between populations and broken 
down into definable structures, with complex and differing roles. There is much variation in the effects 
of ageing between different brain regions and sub-populations therein; as such it is necessary to focus 
on key areas affected with age, and to discuss these in more depth (Figure 1.1.2.3A). 
1.1.2.1 – Ageing in the Hippocampus 
First described as a flexible structure with shape of a ‘Hippocampus, that being a small sea-horse’ [40], 
the Hippocampus plays an important role in cognition for episodic and working spatial memory  [41, 
42]. These functions can either be through direct firing of hippocampal neurons and through the 
binding and co-ordination of inputs from other areas; indeed it has strong connections to many 
regions of the brain and its correct functioning supports global cognition [41]. 
1.1.2.1.1 – Hippocampal structure 
The hippocampus is a highly structured formation, with distinct subfields with different connections, 
cell-types and functions that form a uni-directional circuit [43-45]. In the tri-synaptic model, the 
perforant pathway connects layer II of the Entorhinal Cortex (EC) to the Dentate Gyrus (DG), which 
projects mossy fibres to the stratum lucidum of the Cornu Ammonis (CA) 3 (Figure 1.1.2.3B). CA3 
neurons connect to other neurons in the CA3 and project Shaffer collaterals to CA1 stratum radiatum 
(and to the CA1 in the contralateral hippocampus), which then projects to the subiculum. This model 
simplifies affairs somewhat; the EC layer II connects to the CA3, layer III also connects to the CA1 and 
subiculum, while CA1 and the subiculum feed back into the EC, completing the circuit, but also project 
to other brain areas directly [43]. Further, the CA2 is often excluded from studies due to its small size, 
but is now beginning to be re-examined with differences in connectivity, gene expression and soma 
size being observed [44, 45]; CA2 receives input from both the DG at the stratum lucidum and CA3 at 
stratum radiatum, but in contrast to CA3 it projects to the stratum oriens of CA1, as well as to the CA3 
stratum oriens to a smaller degree [44, 45]. 
6 
 
Damage to the Hippocampus in rodents results in a hyperactive response to new environments, and 
defects to both spatial memory and learning [46, 47]. Although, there still debate over spatial 
navigation and its integration with other hippocampal roles [48]; it was initially proposed that the 
hippocampus forms an internal map of the surrounding world with pyramidal layer ‘Place cells’ holding 
the self’s location [49]. Since then, data has suggested that these place cells are perhaps not a cohesive 
group that gives a location, but instead work as arrays of ‘grid’, ‘head direction’ and ‘boundary’ cells 
that act encoding different cues, events and stimuli together to form a spatial map [42, 48, 50]. 
The CA1 and CA3 have distinct roles with the learning of new environments and remembering spatial 
cues. When exposed to a new environment, both the CA1 and CA3 are active, but the CA3 shows much 
more distinct changes in firing when alterations are made to local and distal cues [51]. The CA3 is 
highly interconnected and generates the synchronous firing of neuronal populations, termed neuronal 
oscillations; these ensure that specific arrays of cells fire in response to stimuli [52]. They are 
generated by the excitatory and inhibitory firing of pyramidal neurons and interneurons (Figure 
1.1.2.3C) and are categorised by the frequency of their firing [53]. 
The CA3 appears to be key in learning new spatial environments and the location of a target together 
with CA1, encoding a representation of this information, and ensuring its retention, in the CA1 array 
[54]. The CA3, working together with the DG, is important for pattern separation, which is the storing 
of similar representations into distinct memories and the retrieval of the correct information in 
response to similar external stimuli [55]. The CA3 co-ordinates the specific firing of CA1 neurons 
through the generation of gamma frequency neuronal oscillations, and this activity allows for the 
retrieval of spatial memories [52]. Together, this firing encodes spatial representations of an 
environment [56], stores information about it into short-term memory, and allows for the retrieval of 
the correct information when required [52, 54, 55, 57]. 
1.1.2.1.2 – Ageing in hippocampal pyramidal neurons  
The hippocampus shows a number of age-related macro changes, with a reduction in hippocampal 
volume and weight [9, 17], but little to no loss of neurons in the pyramidal and granule cells in healthy 
human and aged C57Bl/6 mice, even in those showing cognitive impairment [13, 31, 58, 59]. Defects 
in learning the spatial-location of targets and recall can be observed when relying purely on non-target 
spatial cues, such as markers or objects outside of a maze [36, 60-62], but performance is comparable 
when the target is visible directly [60]. Meaning there appears to be little defect in the ability to 
remember that there is a target, or the need to move to it, in normal ageing, but the capacity to 
remember and relate its precise location within an internal spatial map does suffer. 
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There are differences in the pattern of degeneration and dysfunction with age between regions of the 
hippocampus. The CA1 and subiculum often receive attention, as there is widespread loss of neurons 
and shrinkage in these regions in Alzheimer’s disease [63] and, as the main output point of the 
hippocampus, defects here can have severe effects on cognition [43]. Yet, while these areas are 
heavily affected in early Alzheimer’s, the CA3 and DG are both comparatively preserved from neuronal 
death [43, 64]. However, in ageing these two regions show significant changes [39, 64, 65]. 
Interestingly, the CA1 remains comparatively stable with age [39, 66, 67]. There are some changes in 
morphology, with reduced dendritic spine number [26], but many other parameters remain 
comparable to those in the young. The basic electrical firing properties of CA1 neurons remain 
comparatively constant with age [39, 66, 67] and synapse number does not shift extensively [31]. 
Studies have shown comparable induction of long-term potentiation and depression in aged and 
young rodent CA1 neurons [39, 67]. They also retain their ability to adapt their response when exposed 
to familiar and novel environments with age, suggesting that there are not great declines in their 
plasticity [39].  
The vulnerability of the CA3 in ageing, and the biological mechanisms underpinning it, are now 
receiving more attention [39, 68]. With age, CA3 neurons show increased basal rates of firing, termed 
hyper-excitability [39, 68]. When aged rats are exposed to novel changes to the environment, CA3 
neurons fail to adjust their firing, unlike young animals [39]. Hyper-excitability in the CA3 has the 
capacity to affect other regions, as it may interfere with its ability to bind arrays of CA1 neurons to 
encode spatial information, store it in short-term memory and retrieve the correct information [52, 
54, 55, 57]. The failure to adjust firing when exposed to changes in the environment suggests a 
decreased capacity for pattern separation [39]. This is in line with human data, which finds that healthy 
aged people with deficits in pattern separation have increased activity by fMRI in the CA3/DG 
compared to intact controls [69]. Hyper-activity in the CA3 has been suggested as a marker for age-
related cognitive impairment [70], and treatment with anti-epileptics that reduce this hyper-activity 
show improvement in patients with mild cognitive impairment [71]. 
1.1.2.2 – The Cerebellum 
 
The cerebellum, meaning ‘little brain’, appears to respond differently with normal ageing and shows 
a higher vulnerability to age-related changes than most other structures. The cerebellum plays a key 
role in regulating motor and sensory behaviours, taking in multiple complex inputs such as the signals 
for muscle movements, and integrating them into a coordinated and cohesive response. It receives 
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input from the cerebral cortex and outputting, via the thalamus, to the frontal lobe areas controlling 
cognitive, motor and language functions [72].  
Input from outside the cerebellum comes through the pre-cerebellar nucleus cells, which extend 
mossy fibres to innervate granule cells (Figure 1.1.2.3D) [72]. Granule neurons are the most populous 
neuron in the brain (making up to 75% of all neurons) and extend parallel fibres into the molecular 
layer of cerebellum, innervating Purkinje cell’s apical dendrites. They also innervate basket and stellate 
cells, which make inhibitory connections onto Purkinje cells and each other. Purkinje cells reside in a 
layer between the molecular layer and the granule layer, and receive and integrate input from a wide 
range of cells and cell-types. They are the sole output from the cerebellar cortex and inhibit deep 
cerebellar nuclei. These receive their excitatory innervation from mossy and climbing fibre pathways 
and output information from the cerebellum to the premotor cortex [72]. 
The Purkinje cell is one of the most recognisable cells in the brain and are often studied due to their 
large size and ease of identification.  Mouse models which display significant defects in Purkinje cells 
provide insights into the function of the cerebellum. Transgenic ‘Lurcher’ mice, named after their 
lurching gait, show significant loss of Purkinje cells during development and present with severe 
defects in their movement, with a poor coordination, staggered gait and a resting tremor [73]. The 
loss of Purkinje and granule cells leads to early onset of deficits in motor learning and ability with age 
[74], and suggest a minor, or indirect, role in spatial learning [73]. ‘Staggerer’, also named after their 
gait, mice show significant morphological abnormalities, and earlier onset and exaggerated loss of 
Purkinje neurons with age [75]. 
In ageing humans there is a 26% reduction in cerebellar white matter and in total, a 16% decrease in 
total cerebellar volume [76]. Purkinje cells appear especially sensitive to damage and ageing, seeing a 
number of age-related changes in both their morphology and function [77]. Yet, unlike the 
hippocampus, the cerebellum, in particular the anterior lobe, shows a 40% reduction in both Purkinje 
and granule cell numbers in late age, although, while volume loss is global the neuronal loss is largely 
restricted to this region [76]. Similar is seen in C57Bl/6 mice, where Purkinje neurons are one of the 
few neuronal populations that show actual age-related loss [78].  
With age, Purkinje cells undergo a number of morphological alterations. Soma size reduces 
progressively after adulthood in humans [76] and rodents [79]. They also appear to show atrophy in 
their dendritic processes, with decreased dendrite thickness and the loss of distal connections [77]; 
which may limit their ability to receive and integrate incoming signals. Studies in rodents have 
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indicated that Purkinje cells lose up to a third of their synapses on the dendrites [80]. In rodents, age 
associated declines in a broad range of electrophysical characteristics can be observed, with a reduced 
activation threshold and increased inhibitory thresholds [81]. These age-related changes typically 
occur at a younger age than in the hippocampus, with deficits in long-term depression occurring as 
early on as 8 months [82]. 
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Figure 1.1.2.3: Structure and circuitry of the hippocampus and cerebellum 
A) Sagittal view of the mouse brain, with both the hippocampus and cerebellum highlighted. B) An overview of 
the basic hippocampal circuitry. Input from layer II of the Entorhinal cortex via the perforant pathway excites 
neurons (>-) in the dentate gyrus and CA3. Neurons in the dentate gyrus can excite neurons in the CA3 via 
mossy fibre projections. Pyramidal neurons in the CA3 (dark blue) project to neurons in the CA1 via the 
Schaffer collateral, where they excite both CA1 pyramidal neurons (light blue). In addition, they can excite and 
inhibitory interneurons (purple) within the CA3 and CA1, which inhibit (˫) pyramidal neurons in turn. Pyramidal 
neurons in the CA2 (omitted here) can also excite neurons in the CA3 and CA1, via projections along the 
stratum oriens. Pyramidal neurons in the CA1 additionally receive input from layer III of the entorhinal cortex, 
and themselves project to the subiculum and layers V and VI of the entorhinal cortex. C) Excitatory pyramidal 
neurons (blue) and inhibitory interneurons (purple) form feedback loops of excitation and inhibition. Electrical 
gap junctions between interneurons shown in black. D) Overview of cerebellar circuitry. Excitatory mossy 
fibres project into the cerebellum and excite the deep cerebellar nuclei (dark green) and granule cells (blue). 
Deep cerebellar nuclei neurons are also excited by climbing fibre projections from neurons in the inferior olive 
nucleus (red), and excites these in turn, as well as projecting to the pre-motor cortex. Granule cells project into 
the molecular layer where they excite golgi cells (orange), which in turn inhibit granule cells, stellate (light 
purple) and basket cells (dark purple) and purkinje neurons (light green). Purkinje neurons are also excited by 
neurons in inferior olive nucleus, and inhibited by stellate and basket cells. Purkinje neurons themselves 
provide inhibitory input to the deep cerebellar nuclei.   
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1.1.3 – Inflammation and brain ageing 
 
Inflammation and immune regulation with age can be summarised thusly: there is a decline in the 
adaptive immune system and its capacity to mount an appropriate response to specific threats 
(Immuno-senescence) [83], but a shift towards increased non-specific inflammation in the tissue 
micro-environment. This is characterised by increased levels of specific cytokines such as Interleukin-
6 (IL-6), TNF-α (Tumour Necrosis Factor-α), and the release of reactive oxygen species (ROS) [83, 84], 
and has been linked more to cellular level ageing, the regulation of inflammation and ‘Cellular 
senescence’ [85, 86] which will be discussed in depth later. 
1.1.3.1 – Inflammation induces cognitive deficits 
 
Neuro-inflammation is a prominent aspect of many neurodegenerative diseases, it is linked to ageing 
associated cognitive impairment [87]. Increased levels of pro-inflammatory cytokines are often 
observed in patients with cognitive decline [88]. The brain can be affected by both systemic and 
localised inflammatory insults, and drives inflammation and ageing elsewhere in the body [89, 90]. 
Inflammatory factors such as cytokines, chemokines, complement and acute phase proteins can 
transfer from systemic circulation across the blood brain barrier; in turn, the brain can regulate the 
immune-system via endocrine signalling, and the stimulation of lymphoid cells via the Hypothalamic 
Pituitary Adrenal axis [89, 90]. Ageing mice brains show shifts in gene expression, with elevated 
expression of inflammatory and pro-oxidative genes, combined with reduced neurotrophic and anti-
oxidant gene expression [91]. 
Inflammation induces cognitive impairments in a number of different domains. Short-term cytokine 
overexpression, such as IL-1β in the hippocampus leads to mild learning impairment, activation of glial 
cells and increased expression of other pro-inflammatory cyto- and chemokines[92]. 
Lipopolysaccharide (LPS) administration to the ventricles leads to impairments in working memory, 
increased numbers of microglia and elevated expression of IL-1β, IL-6 and TNF-α in the hippocampus, 
with the largest effects seen in the neuron dense granule-cell and pyramidal layers [93]; These effects 
are exacerbated in the older animals, with young animals showing relatively little impairment in spatial 
learning and memory. 
Indeed, most research concentrates on the role of secondary inflammatory insults, as age appears to 
prime the brain, leading to a much more significant inflammatory and cognitive effect. Older people 
experience greater declines in cognitive function following insults, such as infection [94]  and surgery 
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[95, 96], while also being more likely to experience them. These see significant inflammatory 
responses, with perioperative inflammation believed to be the underlying cause of post-operative 
cognitive dysfunction [95]. Indeed, the driving risk factor for long-term cognitive impairment after 
surgery is age [96]. The same can be observed in rodents, where peripheral infections produce 
retrograde amnesia and anterograde deficits in long-term memory in aged rats, but not young rats 
[97]. Further, following surgery, aged but not young rats, show persistent deficits in spatial reversal-
learning with upregulation of cytokines, such as IL-1β and IL-6, and glial activation in the hippocampus 
[98]. 
These effects seem to be regulated by a number of processes. Even a single inflammatory insult can 
lead to reduced expression of genes associated with memory and learning, and increased pro-
inflammatory gene expression after 24 hours [99]. It impacts further on a broad range of neuronal 
functions, reducing neurogenesis following cranial radiation exposure [100], cytokine exposure can 
increase hyper-active firing in neurons [101] and chronic exposure impairs neuro-plasticity in the 
hippocampus [102]. 
1.1.3.2 – Sources of inflammation within the brain 
 
This inflammation is heavily mediated through the brains native and most numerous immune cell, the 
microglia. These cells constantly monitor the micro-environment to detect signs of damage and 
pathology, and have complex patterns of activation and response [103]. In response to detecting 
microbial antigens, cell death or altered neuronal function; they can scavenge extra-cellular debris, 
kills cells where needed, recruit further immune cells and promote tissue repair [103]; microglia 
normally rest in a ‘quiescent’ state with long dendritic processes that sense the micro-environment, 
but can become ‘primed’. This state sees a shift in cell morphology, with the shortening of dendritic 
processes, and the increased expression of pro-inflammatory genes (IL-1β, TNFα and IL-6), as well as 
anti-inflammatory genes (IL-10) [103, 104]. Microglia can enter an activated state, which sees the 
retraction of their dendritic branches and swelling of the cell-body, and an increased inflammatory 
profile [104, 105]. 
There appears to be no great change in the numbers of microglia with age in male populations of 
C57Bl/6 mice [106], although increased numbers can be seen in female C57Bl/6 mice [107]. Instead 
the increased pro-inflammatory environment that accompanies ageing appears to come from a shift 
towards primed and activated microglia with age (Note: it can be difficult to distinguish these two 
states by morphology alone) [108, 109]; with this mediating the exaggerated size and duration of the 
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inflammation in response to challenge. Aged microglia have elevated basal pro-inflammatory gene 
expression, and following LPS exposure express elevated levels of pro-inflammatory genes (IL-1β, 
TNFα and IL-6) and anti-inflammatory genes (IL-10) [104]. A greater proportion of microglia isolated 
from aged animals were positive for IL-6, and increased IL-6 levels are present in the Cerebellum, 
cortex and hippocampus of aged mice [108]. The inhibition of microglial activation has shown some 
improvements in age-associated reductions in long-term potentiation [110].The increased frequency 
of activated and primed microglia with age likely contributes to general ageing related declines; and 
the exaggerated response to secondary insult by aged microglia underlies the greater cognitive decline 
with inflammatory insult. 
One of the mechanisms underlying the age-related changes in cell morphology, function and the 
secretion of inflammatory factors seen in mitotic tissues is Cellular Senescence [86, 111]. A similar 
phenotype has recently been observed in neurons, and may be a contributing factor in some of the 
changes outlined above [112]. Below, I analyse the mechanisms underlying cellular senescence and, 
potentially, the senescent-like phenotype. 
  
15 
 
1.2 – Cellular Senescence 
1.2.1 – Cellular senescence – an overview 
 
Sub-apoptotic DNA damage at a sufficient level in mitotic cells also induces a cell-cycle arrest [111]. 
However, if this arrest is stable and DDR signalling persists, then the cell can become permanently 
‘locked in’ to this arrest and undergoes a number of phenotypic changes. This is referred to as ‘Cellular 
Senescence’ - in addition to roles in development, anti-cancer action and wound healing - it is now 
regarded as one of the key drivers of organismal and systems ageing in many tissue types. Cellular 
senescence is perhaps a prime example of Antagonistic Pleiotropy in ageing, where processes that is 
beneficial in the young, have a deleterious effects in the old, either through direct action or off-target 
activation [113]. 
In 2012 our lab observed the hallmarks of this phenotype in post-mitotic neurons in mice, termed a 
‘Senescence-like Phenotype’ [112]. This showed that with age, neurons bore many of the same 
markers that are typically associated with cellular senescence in mitotic cell types. However, in order 
to understand the potential relevance of this, it is first it is necessary to describe what senescence in 
mitotic tissues is. 
Cellular Senescence was initially described by Hayflick and Moorhead in the early 1960s as the 
permanent loss of replicative ability, in cultured cells, that occurred after a reproducible number of 
cell divisions [114]. Prior to this, cells were widely regarded as being functionally immortal once 
isolated from the soma, and only lost due to poor cell-culture technique - primarily due to the 
popularised work of Alexis Carrel and his maintenance of long-lived embryonic chicken heart derived 
cell cultures. However, while Carrel’s work was difficult to replicate, Hayflick and Moorhead’s could be 
replicated. This suggested that the cessation of division was not a mere side-effect of poor technique 
killing the cells; indeed, these cells remained alive for long durations once they had stopped dividing. 
Yet no matter the nutrients or cell-density, they did not restart division. 
This is now recognised as replicative senescence, one of many forms of Senescence that can be 
induced. Senescence can be induced by many different stressors, including telomere shortening and 
uncapping, exposure to ROS and genotoxic DNA damage, chromatin modifications, amongst others 
[111]. Multiple mechanisms have now been described as triggering cellular senescence, and the 
phenotype is now understood to consist not of just mere growth arrest, but is characterised by a wide 
and deep range of phenotypic changes [86]. Changes in cell morphology are often observed in cultured 
senescent cells, with swelling of the cell body and the altered expression of genes and proteins. Many 
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of these relate to the cell-cycle, inhibitors are present in increased levels, while cell-cycle activators 
are typically lower, but seemingly not wholly absent [115, 116]. Increases in the Cyclin Dependent 
Kinase Inhibitors p21 and p16 can be observed, largely due to the activation of p53 and phosphorylated 
Retinoblastoma (pRb) [117], and are induced in senescence by multiple mechanisms [118]. Shifts in 
population level gene expression are seen in senescent cells, leading to a general increase in the 
expression of inflammatory cyto- and chemo-kines, growth factors and extra-cellular matrix factors 
[119, 120]. The expression and release of these factors is termed the Senescence Associated Secretory 
Phenotype and appears to contribute to tissue integrity and inflammation [121]. This secretion of bio-
active molecules (in particular the pro-inflammatory cytokines and ROS) into the micro-environment 
appears to have paracrine effects, ideally recruiting immune cells to clear the damaged cells, but is 
also causing DNA damage, activating the DDR and inducing senescence in surrounding cells [122]. 
Yet on an individual cell level, the changes in gene expression are highly variable, even amongst genes 
often associated with senescence  [121]; SASP factor genes show a great deal of variability, with 
subsets of inflammatory genes clustered at genomic loci accounting for much of the population level 
increases, and this further complicates the difficult task of finding specific markers of senescence, as 
even the most accurate markers show less than 90% accuracy, meaning that multiple markers, such as 
p21 and HMGB1, should be used simultaneously [121]. 
Senescent cells are observed in vivo and appear key in driving the ageing process [123, 124]. 
Senescence has previously been speculated to have a role in organismal ageing due to the loss of 
functional cells and the damaging side effects of excreted factors [125], but the lack of specific in vivo 
markers made their presence difficult to analyse. The frequency of senescent cells increases with age, 
as first observed in skin fibroblasts [126] and subsequently in many organs and cell-types, including 
the brain [112]. The rate of accumulation in tissues linearly predicts lifespan in accelerated ageing 
models of mice [127] and targeting these cells with specific drugs and interventions has shown promise 
in slowing the rate of ageing and delaying the onset of numerous age-related conditions [123, 124]. 
1.2.2 – DNA Damage and the DNA Damage Response 
There are myriad exogenous and endogenous sources that can lead to DNA Damage. The brain 
demands a lot of energy, accounting for close to a quarter of the body’s glucose usage, and requires 
high levels of Oxygen [128]. This in turn exposes neurons to oxidative damage. Base alteration and 
single-stranded damage may lead to interference with the transcription of proteins, while double 
strand breaks are potent activators of the DDR and may lead to apoptosis or the induction of 
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senescence-like pathways [112, 129]. With damage such as single-strand breaks potentially occurring 
at a rate of tens of thousands per neuron, per day, effective repair mechanisms must be maintained. 
Indeed, defects in such mechanisms result in severe neurodegenerative conditions [11, 129]. 
Radiation is encountered consistently throughout an organism’s life-span, from sources such as 
‘background radiation’, medical procedures and sun exposure. Background radiation is a catch-all 
term covering sources as diverse as radon gas released from the ground or from cosmic sources - 
which varies by geographic location and altitude, with long-term exposure being a particular concern 
for space travel. Medical treatments such as cranial radiation and chemotherapeutics that have DNA 
damaging actions are of interest, as these are associated with memory impairments and 
neurodegeneration [130, 131]. In mice this irradiation is associated with both reductions in 
neurogenesis and alterations to neuronal morphology, with loss of dendritic branch complexity and 
pre-synaptic synaptophysin expression in the hippocampus [130]. Drugs that induce DNA damage, 
such as chemotherapeutics are often accompanied by neurological side-effects, with memory 
impairment and neuro-degeneration [131, 132]. This DNA damage has been implicated in the 
pathology of brain ageing, injury and neurodegenerative conditions [133-135]. 
1.2.2.1 – Double Stranded Breaks are potent triggers of the DDR 
Double stranded breaks (DSBs) are regarded as one of the most cell-lethal types of DNA damage, and 
act as a potent inducer of DDR signalling; a comparatively small number of breaks are capable of 
inducing senescence or apoptosis within Eukaryotic cells [136, 137]. The ‘choice’ between these two 
outcomes is dependent on not only the level of damage, but the pattern of downstream induction 
(Figure 1.2.2.4). 
DSBs can been seen to accumulate in the cells of various mitotic and post-mitotic tissues in ageing 
mice, and are observed in cultured senescent cells [138, 139]. These breaks are generated through a 
number of multiple mechanisms and from many different sources, both internal and external to the 
cell and organism. Radiation, especially in the X to γ-ray range can cause damage through the direct 
ionisation of DNA bases, or through the generation of free radicals from H2O that then react with the 
sugar backbone [140]. If breaks in both strands are generated within close proximity, typically within 
10 base-pairs of each other, then the strand is liable to break [141]. The generation of ROS can have a 
strong toxic effect with damage to the DNA and other macromolecular structures, it can generate 
double strand breaks in both the euchromatic and heterochromatic DNA of cells in G0 and G1 in a 
similar way to irradiation induced breakages [142]. The exact formation of these breaks varies 
considerably both by the length of single-stranded overhang and the chemical composition of the DNA 
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end points [143], and even low doses can lead to the accumulation of poorly repaired DNA damage 
[144]. 
The replication of DNA is largely absent in neurons and the majority of DSBs are repaired through Non 
Homologous End Joining (NHEJ) [145, 146]. However, as rodent neurons age, the levels of NHEJ 
proteins and repair efficiency is reduced, which may also contribute to the accumulation of damage 
and increased DDR signalling [147-149].  
1.2.2.2 – Sensing DNA Damage 
 
As mentioned previously, the chemical structure of DSBs is diverse, therefore the DDR must have the 
flexibility to recognise these different break forms and then mobilise the DDR in an appropriate way, 
and ideally process the ends in such a way that they can be repaired [145]. Breaks are sensed by 
complexes with are capable of binding to differential, but overlapping break formations [150].  The 
initial DSB sensors are the Ku70-80 heterodimer, which recognises and binds to double-stranded DNA 
ends [151], and the MRN complex, whose subunits can tether linear DNA ends, as might occur in the 
case of long DNA overhangs [152]. The MRN complex (also referred to as the Mre11 complex) is 
formed of 3 proteins – Mre11, Rad50 and Nbs1 – and binds to DSBs immediately after damage [153] 
and can tether break sites in proximity [154]. These can then further recruit and activate 
Phosphatidylinositol-3-OH-Kinase-like Kinases (PI3KK), such as DNA-dependent Protein Kinase (DNA-
PK) and Ataxia-telangiectasia, mutated (ATM) to the break-site leading to the recruitment of DDR 
factors to form DDR protein foci that can span a large region [145]. 
DNA-PK is complex consisting of a Ku70-80 hetero-dimer bound by DNA-PK catalytic subunit (DNA-
PKcs). The Ku70-80 hetero-dimer forms a ring, which wraps double-stranded DNA and binds sterically 
to the major and minor grooves of two full DNA turns proximal to the break-site; which supports the 
DNA end for processing and aligns it into the correct angular phase during repair [155]. Once DNA-
PKcs is bound to Ku70-80 its DNA end binding affinity increases [156], this DNA binding is required as 
a co-factor for the protein’s Serine/Threonine kinase activity. Once activated, this activity signals the 
recruitment and activation of downstream factors (DNA Pol, Artemis, XRCC4, LigIV) to join the DSB, 
with variations in the order and proteins recruited able to lead to multiple resolutions of the same 
breaks. Differential phosphorylation of DNA-PKcs allows for the processing and end-ligation, auto-
phosphorylation is important for allowing physical access to the DNA for ligation, while ATM mediated 
phosphorylation allows for the recruitment of repair factors such as Artemis [157]. 
Like DNA-PK, ATM is a serine/threonine kinase and plays an important role in dictating downstream 
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effects of the DDR, regulating not only repair, but end-stage outcomes such as apoptosis and 
senescence. ATM acts together with the MRN complex in responding to the DNA damage, which 
mediates the initial break detection and ATM’s activation [158]. The MRN complex binds to DSBs 
independently of ATM [153] and promotes ATM dimer dissociation [154]. Following radiation damage 
ATM is auto-phosphorylated, this promotes ATM dimer dissociation and it is these monomers that 
constitute the active form [159]. Once the complex is bound to the DNA, Nbs1 can recruit ATM to the 
site [160] and individual elements of the MRN complex can then be phosphorylated by the active ATM, 
which then mediates ATM’s further phosphorylation of MRN and downstream DDR targets [161]. 
ATM was initially identified in relation to its name-sake, the autosomal-recessive neurodegenerative 
condition Ataxia-telangiectasia [162]. This presents with cerebellar ataxia and multiple system 
disruption, altered neuronal development and decreased neuronal survival later in life. This reduced 
ATM function leads to radio-sensitivity, defects in DNA repair, genome instability and loss of cell-cycle 
control. In neuronal development, this results in the persistence of damaged neurons that would 
otherwise apoptose via ATM-p53 activation in normal development; and in later life leads to neuronal 
dysfunction and cell loss, with prominent cerebellar ataxia and motor dis-coordination [163]. Defects 
in the individual subunits of the MRN complex lead to similar phenotypes with increased radio-
sensitivity and neurological effects, such as Mre11 hypomorphic mutations (which leads to Ataxia-
telangiectasia-like Disorder, displaying with cerebellar atrophy) [164] and Nbs1 hypomorphic 
mutations (which leads to Nijmegen Breakage Syndrome, with developmental microcephaly) [165]. 
1.2.2.3 – Downstream DDR Signalling 
 
DNA-PK and ATM quickly phosphorylate Histone variant H2A.X at the break site, and up to several 
megabases away, after damage [166, 167]. The concentration and size of these foci differs, depending 
on the initial response and ATM involvement is required for more distal H2A.X phosphorylation [167]. 
H2A.X is phosphorylated at the Serine 139 site, and once phosphorylated at this site, it is referred to 
as γH2A.X [168]. H2A.X is highly conserved between species; however, levels vary with age and cell 
type. In cortical rat neurons, the levels of H2A.X on histones increase rapidly by day 30 postnatal, 
before plateauing and then very slightly increases with age. At equilibrium, H2A.X variant represents 
~15% of total H2A histones [169]. 
This phosphorylation mediates the recruitment of chromatin remodelling proteins (including p400 and 
Tip60), which help relax the chromatin to allow access for DDR proteins [170, 171]. Mediator of DNA 
Damage Checkpoint Protein 1 (MDC1) is recruited, MDC1 secures ATM at the foci, allowing for H2A.X 
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to be phosphorylated continuously [172]; together MDC1 and γH2A.X act to form a scaffold that allows 
for the recruitment of more MRN to the site and more DDR proteins, including p53 Binding Protein 1 
(53BP1), BRCA1 and RAP-80 which then allows for increased ATM activation [173, 174]. The activation 
of diffusible downstream kinases, including Checkpoint Kinases 2 (CDK2) [173, 175], propagates and 
amplifies the DDR signal from the initial DSB and engages downstream effectors such as p53 and cyclin-
dependent kinase (Cdk) inhibitor p21 [112, 176, 177]. 
The mode of activation of p53 in the DDR acts as an important decider of the cell fate following DNA 
damage, and can be altered to affect its stability and pattern of activation [178]. Stabilisation of active 
p53 can induce the expression of p21, which has a number of roles in relation to the DDR. p21 can 
silence Cdk2 expression and inhibit Cyclin E-Cdk2 and Cyclin A-Cdk2, preventing transition into S-phase 
by ensuring that Retinoblastoma protein (Rb) is hypo-phosphorylated and remains in inhibitory 
binding to E2F1 [88, 89]. In S-phase, it can displace polymerases from Proliferating Cell Nuclear Antigen 
(PCNA) and block DNA synthesis from occurring [179, 180], and in this role is important in promoting 
nucleotide and base excision repair [181]. When localised to the cytoplasm it can block the activity of 
pro-caspase 3 and the apoptotic cascade [181]. p21 undergoes further regulation and modification, 
both at the mRNA level, such as by RNA-binding proteins such as HuR after damage [182], and through 
phosphorylation by kinases at specific motifs, which blocks or allows cleavage of p21 by caspase-3 in 
apoptosis [183]. p53 is phosphorylated by ATM, and via the ATM-directed interaction with other 
proteins; these modifications effect both its gene trans-activation and its affinity to the inhibitory 
binding protein Mdm2 [184], which blocks the trans-activation domain of p53 and targets it for 
degradation [185]. 
1.2.2.4 – Outcome of the DDR – A choice between survival or apoptosis 
 
The outcome after genotoxic stress is generally between damage repair and survival, or apoptosis. 
This is dependent on the level of damage and the duration of the insult, which leads to differential 
modification of DDR factors leading to different outcomes. One of the most obvious outcomes to 
heavy damage is the loss of the neuron, with this being readily visible in scans and post-mortem 
histology following major traumas, such as ischæmia, and in neurodegenerative conditions such as 
Alzheimer’s disease. A major cause of cell death is apoptosis, an organised programme that removes 
cells that are deemed too damaged or whose survival is no longer required [186-188]. DNA damage 
plays a major regulatory role in the apoptotic pathway, through direct transcriptional inhibition [189] 
and through the DDR [190].  
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Much of the DDR’s role in apoptosis is regulated through p53, which integrates multiple upstream 
inputs to regulate the transactivation of differential transcriptional cassettes to favour repair and 
survival, or apoptosis [178, 191]. This is regulated through the complex interactions of a number of 
factors; the total protein levels of p53 and relative levels of p53 binding proteins, the p53 binding sites 
in gene promotors and post-translational modifications to p53.  
Post-translational modifications to p53 effect not only its interactions with other proteins in the 
pathway, but the susceptibility of other p53 motifs to alteration, and its affinity for p53 DNA binding 
sites [191, 192]. For example, Acetylation of lysine 320 blocks the phosphorylation of NH2-terminal 
serines and switches p53 to binding to high-affinity p53 binding sites in genes, activating transcription 
of pro-survival genes such as p21 [191]. Cooperation between the DNA binding sites of tetrameric p53 
helps binding to low-affinity promotor p53 binding sites in pro-apoptotic genes [193]. Post-
translational modifications to p53 lead to regulation of this cooperation, thus regulating the binding 
to low- or high-affinity p53 binding sites and expression of pro- or anti-apoptotic genes [191]. Direct 
action on p53 at binding sites can also occur, with DNA-PKcs binding directly to p53 bound to the p21 
promotor site, thus blocking p21’s transcription and pro-survival effects [194].  
Whether p53 activation is pro- or anti-apoptotic is complicated and ultimately involves a ‘threshold’ 
effect dependent not only on absolute levels, but duration and mode of p53 activation [195]. Both 
high and low levels of p53 can trigger pro-apoptosis or pro-arrest gene expression, but prolonged high-
level expression is required to trigger actual apoptosis, with the absolute threshold alterable through 
modulation of the ratio of pro- and anti-apoptotic signals such as Bcl-2 type protein levels [195]. 
Alterations to the DDR and p53, as well as levels and duration of activation, act together to generate 
specific p53 regulated transcriptional cassettes with very different outcomes.  
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Figure 1.2.2.4: Overview of DDR pathways showing interactions with gene transcription, cell-cycle 
machinery, and factors promoting survival or apoptosis  
Recognition of DNA damage by sensor proteins (yellow) like PI-3K kinases ATM and DNA-PK leads to 
activation of effector proteins (red) such as p53, p21 and c-Abl that regulate downstream responses, 
specifically apoptosis (purple) and cell cycle arrest/repair (pink). The balance of the response is altered 
through chromatin remodelling factors (green), and numerous other intermediatory and regulating 
factors (blue). Post-Translational Modifications (PTM) of proteins such as p53 and p21 have significant 
effects on their function. These can shift activation of p53 between transcriptional cassettes and affect 
the stability of p21, shifting their roles between apoptosis, and survival and repair. Reproduced from 
Fielder et al. 2017 [196]. 
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1.2.2.5 - A persistent DDR can induce Cellular Senescence in mitotic cells 
 
Replicative senescence is primarily induced through the degradation of telomere repeat sequences at 
the end of DNA during replication [174]. The telomere is protected by a shelterin complex, which is a 
group of proteins that bind to the telomere and acts to inhibit repair mechanisms that might otherwise 
recognise the chromosome end as a double-stranded break [197, 198]. If the end of the DNA is 
recognised as a double-strand break, then it not only triggers DDR signalling (Telomere Induced Foci), 
but it is vulnerable to the erroneous activity of DNA repair pathways such as NHEJ, resulting in 
chromosome fusion [199, 200]. The end of the DNA is protected physically through the formation of a 
DNA ‘t-loop’, mediated by TTAGGG repeat binding factor 2 (TRF-2), which loops the DNA over and 
round onto itself, 3’ overhanging strand is then inserted into the double-stranded helix of the upstream 
DNA in the loop, forming a ‘d-loop’ [201]. With the loss of telomere repeats and the 3’ overhanging 
strand, the stability of this loop is decreased and the chance of it collapsing and exposing the DNA end 
increases [202, 203]. 
Yet this inhibition of repair molecules can have adverse effects; stress induced senescence is at least 
partially induced and maintained by persistent DDR signalling [119, 177]. DNA damage can still occur 
at telomere sites, and while its repair is inhibited, it is still capable of DDR signalling [119, 177]. 
Senescence is not instant, and often takes 10 days to occur and stabilise in cultured cells; the persistent 
DDR innervation that comes from this Telomere-Associated Foci (TAF) contributes towards the 
induction and stabilisation of senescence following DNA damage [119, 177]. 
DNA damage and the activation of the DDR, and its activation of stress induced senescence can be 
seen in the tissues of ageing mice [204]. Of interest is that the number of TAF in mice tissues increases 
with age, regardless of telomere length in the tissues. This is important evidence against the argument 
at the time that laboratory mice were not a suitable model for senescence, on the basis of their active 
telomerase and longer telomeres [205]; and is relevant for post-mitotic tissues, as these cells do not 
undergo telomere extension through telomerase, or loss through replication. 
TAF and DNA damage foci located along the genome are similar in their induction of the DDR and 
associated downstream pathway activation [197]. However, non-TAF are repaired at a comparatively 
fast rate and total levels of damage inside cells vary considerably [206-208]. This can be as part of the 
circadian rhythm [206], and from physiological roles such as gene expression, where it allows access 
to promotors, as in hippocampal neurons [207, 208]. This can limit the use of total foci counts in the 
assessment of cellular senescence, while the longer life-span of TAF acts as a temporal buffer and 
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provides a better estimate of the rates of cellular senescence [209]. This has a role in the induction of 
senescence, as senescence requires a persistent DDR in order to stabilise the phenotype after 
induction. This appears to be the case, as Hewitt et al. have shown that in stress-induced senescence, 
up to half of DNA damage foci were co-localised with telomeres in vitro, regardless of the telomerase 
activity in the cells [209]. 
The DDR continues signalling throughout senescence [210] and it appears that the damage signalling 
is provided, in part, through these persistent foci [209, 211]. New damage is also constantly generated 
through the induction of downstream pathways, forming a positive feedback loop [177]. Yet disrupting 
the DDR alone is not sufficient to reverse senescence once it has become fully established [137]. A 
number of auto- and paracrine feedback loops act to ‘lock in’ the phenotype [212, 213]. These develop 
typically over a number of days and include the production of SASP factors and ROS generation [119, 
120]. 
1.2.3 – Senescence is enforced by positive feedback loops 
 
1.2.3.1 – Mitochondria and ROS 
 
Many of the initial steps in fortifying the transient arrest into senescence are mediated through the 
production of ROS [214-216]. A major source of ROS in senescence is from mitochondrial dysfunction 
[215], termed Senescence-Associated Mitochondrial Dysfunction, and without this mitochondrial 
alteration senescent cells do not develop their morphological, pro-oxidant and pro-inflammatory 
characteristics [217]. Mitochondrial dysfunction, ROS generation and the reinforcement of senescence 
can be mediated by the DDR [177, 216, 217]. In turn, mitochondria induce changes in the expression 
of nuclear genes [218, 219]. This occurs through the mitochondrial retro-grade response following the 
loss of membrane potential [218, 219]. It both enforces the cell-cycle arrest through blockade of S-
phase entry via INK-FOXO mediated activation of Cdk Inhibitors, and through AMPK-p53 signalling 
[220]. 
Following DNA damage, an increase in mitochondrial mass occurs in senescent cells  [217]. The level 
of increase is dependent on the level of damage and is mediated independently through p53 and 
activated Rb [217, 221]. This is downstream of ATM activity and triggers the downstream effectors Akt 
and mTOR, through the cell-cycle inhibitors p21 and p16 [177, 216, 217, 222]. Signalling from the DDR 
via p21 promotes GADD45A-mediated p38MAPK activation and TGF, resulting in increased ROS 
generation that causes further DNA damage [177]. In addition to p16’s roles in Cdk4/6 inhibition and 
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activation of Rb, p16 can activate Protein Kinase PKC  through ROS, which in turn generates further 
ROS forming a positive feedback loop [216]. After DNA damage PKC can translocate to the 
mitochondria, where it leads to loss of membrane potential, and activates NF-B and its pro-survival 
effects [223, 224]. This results in a collapse of membrane potential in the mitochondria, and the 
release of ROS into the intracellular environment [221]. Activation of the Akt and mTOR 
phosphorylation cascades has a number of effects on mitochondria, firstly reducing their degradation 
by mitophagy, and promoting mitochondrial biogenesis [217, 225]. Together, this promotes the 
generation of further DNA damage, contributing to persistent DNA damage foci generation and 
stimulation of the DDR, enforcing the senescent phenotype [177]. Indeed, if mitochondria are 
completely removed from senescent cells, they lose their typical characteristics, including ROS 
generation, the SASP and their altered morphology [217].  
1.2.3.2 – NF-κB signalling and inflammation in senescence – The Senescence Associated 
Secretory Phenotype 
 
The SASP is activated downstream of the DDR, and is one of the key features of senescence [119]. On 
a population level, it results in the release of pro-inflammatory cytokines, chemokines and 
metalloproteinases, including IL-6, IL-8 and TNF-[119]. The production of these pro-inflammatory 
factors and ROS can lead to the reinforcement of senescence via autocrine pathways [212, 213, 226], 
and can be released into the extra-cellular environment, having paracrine effects on surrounding cells 
[122, 213]. The release of SASP factors, especially cytokines and chemokines attracts and stimulates 
immune cells, which should clear senescent cells [227, 228]. However, its paracrine effects induce 
damage in surrounding cells, and the release of SASP factors by senescent cells appears to be a major 
cause of increased chronic, sterile inflammation and associated pathology with age [127, 229, 230]. 
The production of SASP factors is driven by, and drives DNA damage [119, 226], with persistent DDR 
signalling triggering the SASP [119]. ATM-dependent activation of Chk2, and activation of p21 and Akt 
through p53, trigger the production of the cytokines such as IL-6 and IL-8 [119, 222]. 
ATM also triggers the transcription factor NF-κB following DNA damage [231]. NF-κB is a transcription 
factor and one of the primary regulators of inflammatory gene-expression, including many interleukins 
and cytokines [232]. Increased NF-κB activity is strongly associated with ageing in multiple tissues with 
age in humans and mice, and continued signalling through NF-κB appears to drive tissue ageing [233]. 
Increased NF-κB signalling in mice can drive accelerated ageing and increased rates of senescent cells 
through chronic inflammation and oxidative damage [127]. It is also a key regulator of the SASP in 
senescence and regulates more genes than both Rb and p53 [232]. Activation of senescence leads to 
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a large up-regulation of NF-κB activity and SASP genes, which is necessary for both the establishment 
and stabilisation of senescence [232, 234]. 
NF-κB is not a single protein, instead the name covers a family of proteins that form hetero- and homo-
dimers from a pool of five Rel proteins - p50/p105, p52/p100, p65 (Rel-A), Rel-B and c-Rel. Each of 
these has a Rel homology domain allowing dimerization and DNA binding [235, 236]. Rel-A, Rel-B and 
c-Rel contain transcriptional activation domains located at the c-terminus, which allows them to bind 
to DNA and promote gene transcription. Both p105 and p100 can be additionally processed to their 
active subunit forms p50 and p52, respectively, by phosphorylation and subsequent ubiquitination, 
leading to proteasomal processing; while these lack transcriptional activation domains, they can 
promote transcriptional activation through forming a dimer with Rel proteins, or inhibit activation 
through the formation of inhibitory dimers such as p50:p50 [235]. 
In their inactive form, NF-κB dimers are predominantly localised to the cytoplasm thus rendering the 
dimers inactive, primarily due to complexing with inhibitory proteins [235, 237]. These include the 
typical Inhibitor of κB (IκB) proteins (IκBα, IκBβ, IκBε), the atypical IκB proteins (Bcl-3 and IκBζ), and 
the precursors p105 and p100 [235]. The IκB proteins contain ankyrin repeat sequences that bind Rel 
homology domains and mask nuclear localisation sequences of the subunits of NFkB dimers. In the 
binding of IκBα to Rel-A:p50, IκBα can mask the nuclear localisation sequence of Rel-A, however, it 
does not mask the nuclear localisation sequence of p50 [237]. IκB proteins can contain nuclear export 
sequences and combined with the masking of one of the localisation sequences leads to shuttling 
between the nucleus and cytoplasm that heavily favours the cytoplasm [235, 238]. BCL-3 instead 
contains a transactivation domain, and is primarily localised to the nucleus, where binds strongly to 
NF-kB homo-dimers of p50 and p52 as a co-activator of transcription [235]. The precursor proteins 
p105 and p100 can regulate transcriptional activity of NF-κB; their rate of processing of these regulates 
the levels of p50 and p52, and thus their availability to form active dimers. Additionally, they contain 
ankyrin-like repeat domains similar to those in IκB proteins at the C termini and can mask nuclear 
localisation signal [239, 240]. Both p105 and p100 form high molecular weight heterogeneous 
complexes containing multiple NF-kB subunits with IκB function (IκBγ and IκBδ respectively) that may 
act as a buffer for levels of active NF-kB dimers [241]. They can also inhibit active NF-kB dimers, such 
as p100 disrupting the binding of RelA:p50, and form dimers by binding to Rel homology domains in 
NF-kB subunits and ankyrin domains in IκB [235]. 
 
NF-κB is activated by a variety of stimulating factors and pathways through the activation of IκB Kinase 
(IKK), leading to the phosphorylation and subsequent proteosomal degradation, or processing, of 
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inhibitory proteins and the nuclear localisation of NF-kB dimers [235]. These can be categorised as 
occurring via the canonical and non-canonical pathways. Canonical signalling is mediated by dimers 
containing p50 and Rel-A, or c-Rel, and can be triggered by a range of pro-inflammatory cytokines, 
such as TNFα and IL-1β, oxidative damage, and bacterial and viral antigens, such as LPS [235]. Binding 
of these to cell receptors triggers rapid phosphorylation of the IKK complex; in canonical signalling this 
protein complex contains a heterodimer of 2 catalytic subunits (IKKα and IKKβ) and the regulatory 
protein NF-κB Essential Modulator (NEMO), also known as IKKγ [235]. Phosphorylation, primarily at 
the subunit IKKβ, activates IKK which mediates the phosphorylation of IκBα bound to NF-κB dimers 
(such as RelA:p50), and its subsequent ubquitination and proteasomal degradation. This unmasks the 
nuclear localisation sequence, allowing the dimer to translocate to the nucleus and bind to DNA [235]. 
DNA damage signalling can trigger canonical NF-κB signalling through ATM’s interaction with NEMO, 
the regulatory subunit of IKK [231]. ATM can phosphorylate NEMO following DSB formation, leading 
to its ubiquitin-dependent export from the nucleus, while in turn NEMO promotes export of ATM into 
the cytoplasm where it triggers IKK activation via the IKK regulatory subunit ELKS [231]. This 
phosphorylates IκBα leading to its dissociation from Rel-A:p50 dimers, which allows them to 
translocate to the nucleus and activate the expression of target genes [231, 235]. The inhibition of IKK 
activity in ercc1-/- and ercc1/Δ mice models deficient in DNA repair reduces the incidence of cellular 
senescence, and oxidative damage to DNA and proteins [242]. 
Additionally, there is the non-canonical pathway, which is activated by binding of cytokines and ligands 
to TNF receptor family proteins, and the processing of the precursor protein p100. The activation of 
TNF receptor signalling leads to the stabilisation of NF-kB inducing kinase protein levels, which is 
typically degraded rapidly by the E3 ubiquitin ligase complex, which is then disrupted by TNF receptor 
activation [243]. The increased levels of NF-kB inducing kinase leads to the phosphorylation of IKKα, 
which in turn phosphorylates p100, leading to ubiquitination and processing to the active p52 form 
[244]. This allows active dimers containing p52, such as Rel-B:p52 to translocate to the nucleus and 
promote gene transcription. This has been implicated in senescence, where it can act to suppress 
senescence in fibroblasts at lower basal levels of p53, with the subunit p100/p52 regulating the 
expression of Cdk4 and 6, and Rel-B regulating the stability of p21 and p53 [245]; however, again this 
likely depends on the level of p53 expression, as higher p53 levels following DNA damage, can switch 
p52 from binding to Bcl-3 to HDAC1, switching from gene expression to repression [246]. 
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1.2.4 – Senescent cells are resistant to apoptosis 
 
Once senescence has been induced, cells show a decreased vulnerability to apoptosis through p53 
[247] and oxidative stress [248, 249]; even at higher doses than would be survivable prior to induction 
[249]. The p53 axis is an important part of senescent cell’s apoptotic resistance, with the level of 
damage and post-translational modifications made to p53 affecting whether it promotes pro- or anti-
apoptotic gene cassettes [191-195]. When exposed to p53-mediated and p53-dependent apoptotic 
stimuli, non-senescent cells undergo apoptosis [247]. However, senescent cells are unable to undergo 
p53-mediated apoptosis, but are capable of undergoing necrosis [247]. However, rather than just 
switching the type of cell death, senescence also provides resistance to cell death caused by p53-
mediated stimuli, such as high doses of H2O2 [250], and p53-independent stimuli, such as 
Staurosporine, which can stimulate caspase-3 activation [251]. p53 is persistently active in senescent 
cells and maintained in the nucleus through its association with FOXO4, and provides apoptotic 
resistance through the regulation of downstream factors [252]. 
Much of this protective effect comes through alterations in the regulation of ‘Bcl-2 family’ proteins, 
which block PUMA/NOXA-regulated apoptosis following stress, rather than a reduction in pro-
apoptotic factors [248, 253, 254]. Bcl-2 type proteins can be divided three main classes, depending on 
the type and topology of the four types of ‘Bcl-2 Homology Domains’ (BH1-4) present [255].The first 
of these groups is the ‘anti-apoptotic Bcl-2’ proteins, defined by their ‘Bcl-2 core pocket’, which 
consists of BH3, BH1 and BH2 [255]. This includes Bcl-2 itself, Bcl-W, Bcl-XL and a number of other 
variants. These prevent apoptosis through the inhibition of the second class, pro-apoptotic BAX/BAK 
which promote permeabilisation of mitochondria’s outer membranes, the release of Cytochrome C 
and an apoptotic caspase cascade [256]. The third class contains only the BH3 domain and includes 
PUMA and NOXA [255]. These act to integrate apoptotic signalling by directly activating BAX and 
inactivating anti-apoptotic Bcl-2 class proteins [255]. The apoptotic resistance in senescent cells was 
initially thought to be due to the up-regulation of Bcl-2 and the down-regulation of pro-apoptotic 
genes [253]. But down-regulation of Bcl-2 and increased levels of PUMA and BIM have been reported 
in senescent cells [252]. Instead, more recent studies have suggested that the anti-apoptotic effects 
come instead from the upregulation of other Bcl-2 type proteins, namely Bcl-W and –XL [257].  
Furthermore, continued presence and activity of cell-cycle inhibitors also confers apoptotic resistance 
up-stream of Bcl-2 family protein activation  [258, 259]. One of these cell-cycle inhibitors promoted 
by p53’s anti-apoptotic response is p21 [258, 259].  Furthermore, in senescent cells, it feeds back and 
inhibits p53 mediated pro-apoptotic signalling following  DNA damage [258, 259]. Nuclear p21 inhibits 
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Cyclin A-Cdk2 normally as a part of the cell-cycle inhibition, but also prevents the pro-apoptotic effects 
of Cdk2; which is required for chromatin condensation and cell-shrinkage in apoptosis, following 
activation by caspases [260]. In addition to blocking this caspase-activated activity in the nucleus, p21 
can interact with caspases directly [261, 262]. By direct binding to the cleavage domain of pro-caspase 
3, p21 can block the initial steps of the caspase cascade [262]. However, it is itself vulnerable to 
cleavage, by activated caspase-3, as can be seen in cardiomyocytes following hypoxia, leading to Cdk2 
activity and apoptosis  [263]. 
Additionally, cytokines released by the SASP can confer apoptotic resistance by stimulating pro-
survival genes [264-267]. IL-6 can protect against p53-mediated apoptosis [264, 265], not by regulating 
p53 activity, but through the separate up-regulation of anti-apoptotic genes, such as Bcl-2 type 
proteins and IκB type protein Bcl-3, and the down-regulation of pro-apoptotic genes such as Gadd45 
and BAX [266, 268]. NF-B is also protective against apoptotic stimuli, including TNF- and UVB 
radiation [269, 270].  
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1.3 – A Senescence-like Phenotype exists in ageing neurons 
While a great deal is known about senescence and its associated characteristics in mitotic cells, little 
is known about their role in post-mitotic cells. Post-mitotic senescence was initially met with a degree 
of scepticism, as the senescence phenotype is primarily known in relation to its permanent cell-cycle 
arrest, and why would a cell that is already post-mitotic undergo such a phenotype? After reviewing 
the literature, several key points appear [196]; Firstly, significant DNA damage occurs and accumulates 
with neurons with age, stimulating the DDR. Secondly, re-entry into the cell-cycle and some DNA 
replication can occur in neurons.  However, this is not a complete cycle, but instead leads to apoptosis. 
The activation of cell-cycle arrest proteins in these neurons provides protection against apoptosis. 
Thirdly, the time between re-entry and cell death can be considerable, in the range of months to years. 
This suggests that these neurons are undergoing a protracted or permanent period of active cell-cycle 
arrest. And finally, the observation of senescence-associated markers is observed in neurons, with 
increasing levels in ageing mice. [112] 
This suggests that while cell cycle re-entry does lead to apoptosis eventually, it is possible to arrest this 
re-entry for a considerable time, either prior to S-phase or even after DNA replication. If the DDR is 
persistently stimulated, then it may play a role in maintaining this arrest through its actions on the cell-
cycle. This raises a number of questions; firstly, is there evidence of persistent DDR in brain areas 
known to undergo age related changes. Secondly, does a persistent DDR trigger the same downstream 
cell-cycle factors in neurons as it does in mitotic cells?. Thirdly, does this trigger the same downstream 
pathways, feedback loops and changes as senescent cells? And finally, does this correspond to in vivo 
functional changes? 
If this is true, it would indicate that a senescence-like phenotype in post-mitotic cells is due to the 
presence of persistent DNA damage. In addition, there is a mechanism that may contribute to 
functional declines in neuronal function, either in individual neurons and/or affecting surrounding 
cells. Furthermore, it presents a novel target for interventions that have not previously been 
considered. 
Mice show increased frequencies of multiple senescence associated markers in neurons with age 
[112]. This includes Senescence associated Beta Galactosidase activity, activation stress associated 
kinases such as p38, lipid peroxidation, heterochromatinisation and presence of SASP associated 
cytokines such as IL-6. These are consistent with the activation of downstream DDR signalling and the 
SASP, and have been observed in the brain. Senescence associated Beta Galactosidase activity has 
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been observed in Purkinje cells, cortical neurons and in pyramidal CA3 neurons of the hippocampus in 
ageing rodents [112, 271]. Activated p38-MAPK observed in neurons may come from the activation of 
p21 via the DDR, which in senescent cells triggers the production of TGF-B2 and ROS generation  [177]. 
Additionally, neurons have been observed to produce and secrete IL-6 in response to axonal damage 
[272] and membrane depolarisation [273]. IL-8 induces the expression of SASP factors in cultured 
neurons, including matrix metalloproteinases and induces cyclin activity, followed by eventual cell 
death [274]. Elevated levels of these cytokines have negative effects on neuronal networks, with 
impairments in learning and synaptic transmission [275]. DNA damage and the induction of 
downstream DDR markers such as p53 and p16 have been observed in Alzheimer’s Brains [276, 277]. 
Activation of p21 follows inflammatory insult from Lipopolysaccharide injection in mice [278] and co-
localises with nitric oxide synthases expression in AD [279].  
1.3.1 – The Neuronal Senescence-like Phenotype may be activated through the DDR 
 
There is evidence that this phenotype is linked to the induction of the DDR from studies in mice with 
dysfunctional telomeres and knock-out of p21 [112]. Terc knockout mice lack functional telomerase 
and are unable to extend their telomeres, leading to uncapping and telomere dysfunction, this 
worsens with each generation, with increased DNA damage and progeria until they are unable to 
reproduce at all. Late generation knockout mice showed increased DSBs, p38MAPK activation as well 
as IL-6 production and oxidative protein damage [112]. Yet, when p21 is knocked out the levels of these 
markers is reduced [112]. There are two, not mutually exclusive, interpretations for this result; firstly, 
that with DNA damage generation neurons, much like mitotic cells, develop downstream markers of 
senescence through p21 activation [177]. Heterozygote terc+/- mice maintain their telomere length and 
do not show the same DNA damage and progeria, when p21 is knocked out in these mice, there is no 
change in DNA damage levels, but a reduction in factors such as oxidative protein damage and 
p38MAPK in Purkinje cells, suggesting that this may be regulated through p21 [112]. Secondly, the loss 
of p21 in neurons may leave them unable to restrain the cell-cycle from progressing, and with the high 
levels of DNA damage in late generation terc-/- mice, neurons that would develop senescence features 
simply continue progression to the point of apoptosis. p21 has a number of roles in the DDR, regulating 
cell-cycle activity, and in establishing senescence [177]. Its expression in hippocampal pyramidal 
neurons is co-localised with the expression of p16, suggesting that activation of both the p16 and p21 
sides of the DDR are active in these neurons  [279]. p21 is  neuro-protective in cultured neurons when 
exposed to neuro-toxins  [280] and when lost allows progression of the cell-cycle and apoptosis [281]. 
It is neuro-protective in the Dentate Gyrus of the hippocampus following acute systemic inflammation, 
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but restrains the growth of progenitor cells and is accompanied by increased IL-6, IL-1B and TNF-a 
[282].  
The consequences of the activation of senescence-associated features in neurons is not known 
currently. Neurons undergoing a DDR show disruption of insulin and Wnt signalling [283] and are 
associated with early AD and cognitive impairment [284]. The release of SASP factors might stimulate 
glial responses and contribute to inflammatory feed-back loop, in addition to the roles of factors such 
as IL-6 on network function and synaptic plasticity [275]. Disruption of mitochondrial homeostasis 
through p21 [177] would likely have effects on calcium metabolism and disrupt the cellular metabolism 
required to maintain neuronal function. 
1.3.2 – Damage induces neuronal cell-cycle re-entry 
 
Much of the apparent deviation in the DDR between mitotic and post-mitotic tissues relates to its 
heavy involvement in cell-cycle regulation. In mitotic cells, many of the downstream effects of the 
DDR feed into the cell-cycle, arresting in order to repair damage and not pass mutations to daughter 
cells [285]. Post-mitotic cells, such as neurons on the other hand, are often regarded as having 
permanently exited the cell cycle; however, this is an overly simplistic interpretation and they are not 
entirely free of the influence of cell-cycle regulators and cell-cycle progression events. 
The presence of cell-cycle related proteins has been observed in post-mitotic cells [286], most 
commonly relating to neurodegenerative conditions, such as Alzheimer’s Disease and CNS damage, 
such as after stroke [287], ischæmia [288] and traumatic brain injuries [289]. Here the expression of 
cell-cycle proteins such as Cyclin D, Cyclin B, cdc2 can be observed with an association between the 
loss of neurons to apoptosis and increased presence of cell-cycle related proteins [290-292]. 
It would be incorrect to describe this as a full re-entry into the cell-cycle and is better described as an 
aberrant cell-cycle re-entry. This is not mere mis-expression of cell-cycle proteins, but appears to be a 
coordinated re-activation of cell-cycle machinery; as DNA has been fully, or partially, replicated in 
neurons in vulnerable brain areas, such as the hippocampus and basal forebrain in AD suggesting they 
are capable of completing S-phase [293]. While this is mostly observed in the early cell-cycle, at G1 or 
S phase [291, 293, 294], later markers more commonly associated with G2 such as CDK1 and Cyclin B1 
have also been noted [294-296].  
A proper entry into M-phase does not appear to occur and given the morphological complexity of 
neurons would likely end in a mitotic catastrophe, instead this cell-cycle appears to either hold or lead 
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to apoptosis before this stage is reached [297, 298]. This was initially observed by attempts to induce 
neuron replication in the early 90s through expression of simian virus 40 large tumour antigen coupled 
to cell-specific promotors in rod photoreceptors [299] and Purkinje cells [300]; this initiated the cell-
cycle, but lead to photoreceptor degeneration in the first case, and cerebellar ataxia and loss of 
granule cell cohesion in the second. 
This is supported by experiments in ATM knockout mice. ATM double knockout mice present with the 
none-CNS symptoms of Ataxia-telangiectasia but not the characteristic cerebellar ataxia. However, 
both double-knockout and heterozygote mice show evidence of cell-cycle re-entry and DNA 
replication in the cerebellar Purkinje and granule cells at day 30 post-natal, unlike wild-type mice 
[301]. While they do not show ataxia or reductions in neuronal number, this may be due to the lifespan 
of the mice. The mice die at 3 to 4 months, and in humans the ataxia is not present until later 
(appearing before 5 years of age), which supports the theory that cycled neurons are capable of 
surviving for at least this long and that something is preventing the completion of the cycle and 
immediate cell death, instead requiring an additional ‘hit’. 
This additional ‘hit’ that results in neuronal death may, in fact, come from reduced, rather than 
increased, DDR signalling; this is not necessarily a decrease in DNA damage, but rather a loss of 
capacity in the DDR to respond to the damage. The DDR pathway acts to arrest the cell-cycle in many 
situations through the action of proteins such as p21 and its inhibition of cyclin-cdks and PCNA’s 
polymerase activity in S-phase synthesis [302]. A reduction in ATM signalling has been observed in late 
Alzheimer’s Disease areas experiencing neuronal cell-death, together with cell-cycle proteins [303]. 
This is seen with other DDR factors such as BRCA1, which is reduced in pyramidal and granule neurons 
of the hippocampus in AD and MCI [304]. Given that these cell-cycle proteins initially appear early in 
disease pathology and in mild-cognitive impairment [294], it may be a later loss of the DDR’s arrestive 
action on the cell-cycle that allows for further cycling to the point of cell death.  
1.3.3 – Arresting the neuronal cell-cycle is protective against apoptosis 
 
While high-levels of DNA damage can cause cell-cycle re-entry and apoptosis through the ATM-p53 
axis [305], it can also promote a protective cell-cycle arrest [306]. In the first instance the loss of ATM 
was protective against etoposide induced cell-cycling and apoptosis, but in the second the knockout 
of ATM and p53 increased the rates of cell-cycling. There are differences in these experiments, the 
first is done in isolated cortical neurons using etoposide - which targets topoisomerase II that is used 
in neurons to generate breaks in order to regulate neuronal early response gene expression [207] - 
and may represent a severe form of damage. The second is in tau transgenic Drosophila with an 
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entirely different stressor. There hasn’t been a study yet, as far as I’m aware, that has looked for a 
threshold effect of damage and cycling specifically in neurons; however, as discussed previously, in 
mitotic cells there is a threshold effect with p53 that affects whether the response promotes cell-cycle 
arrest or apoptosis depending on factors such as mode and duration of activation [195]. 
Protecting against this cell-cycle re-entry through inhibitors in neurons does appear to be effective in 
reducing rates of neuronal cell-death following insults such as traumatic brain injury, ischæmia and 
excitotoxicity [289, 307]. The use of flavopiridol reduces the expression of Cyclin D1, in culture this 
can reduce re-entry and neuronal death in primary cortical cultures from genotoxic [289] and 
excitotoxic stress [307] in the cortex and hippocampus, and treatment proves protective against both 
neuronal cell death and reactive gliosis following traumatic brain injury in rodents [289] 
However, a degree of re-entry into G1 also appears to be of use in actually repairing DNA damage in 
neurons [281, 308]. In vitro, high levels of ROS induce neuronal apoptosis, however, lower levels 
induced DNA damage without apoptosis, but with G1 entry via Cyclin-C-pRb activation [281]; this 
appears to be a requirement for NHEJ, as blocking entry through either Cyclin C or Cdc25A [281] or 
Cdk4/6 inhibition also blocks repair [308]. At the same time, forcing entry via suppressing p21 activity 
leads to the activation of NHEJ machinery without DNA damage, however, unless further progression 
is restrained by knocking down Cdk2, the neurons die by apoptosis within 24 hours [281].  
The same appears to occur in vivo following exposure to ionising radiation [309].  Sub-lethal irradiation 
induces DNA damage in mice brains and transient transcription inhibition, but not widespread 
immediate apoptosis [309]. This is coupled with the expression of Cyclin D and p21 soon after insult, 
and still present and gradually diminishing, respectively, at later time points; suggesting that at these 
doses G1 entry does happen to perhaps enable repair, but the activation of p21 is sufficient to prevent 
further cycling and apoptosis [309]. Likely the degree of damage affects the balance of cell-cycle 
inhibition and progression. If low level damage is below the level sufficient to induce outright 
apoptosis, but is persistently generated or unable to be repaired, then it may activate the same 
downstream DDR pathways that occur in mitotic cells.  
1.3.4 – Cell-Cycle re-entry in neurons is associated with cognitive impairment and 
neurodegenerative diseases 
 
Neurons with cell-cycle reactivation are found at lower rates in non-diseased brain areas of 
neurodegenerative patients and control patients without cognitive impairment [310]. In fact the 
presence of this re-entry can be can be observed in patients with mild cognitive impairment (MCI), 
prior to any progression to clinical Alzheimer’s diagnosis (MCI does not imply that they will progress 
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to AD, merely there is an increased likelihood); the frequencies of these neurons vary between 5 and 
10% of pyramidal neurons (and less than 1% in non-demented controls) by in situ hybridisation of 
chromosomes [293], and by immune-histochemical staining of cell-cycle proteins [292]. 
This, as Yang et al. suggest, may mean that the re-entry to the cell cycle is not an event that occurs 
immediately prior to apoptosis. Given the known rates of neuronal loss in neurodegenerative disease, 
if this process occurred immediately prior to death, the chance of observing a neuron in this process 
at the time of fixation would be incredibly small. As the actual observed frequencies in fixed brains 
are much higher; this process must occur a considerable time before cell death, possibly months or 
years prior [293]. 
Neurons with replicated DNA are found at much lower rates in young wild-type mice, forming 
approximately 0.1-0.2% of neurons in the motor cortices and olfactory bulb of two-month old mice, 
as measured by X and Y-chromosome fluorescence in situ hybridisation (FISH) [311]. Many of these 
neurons appeared to maintain distal axonal connections, measured through FluoroGold retrograde 
tracer (10 to 50% depending on area). Immediate early gene expression is often taken as a measure 
of neuron activity, and a subset of these hyperploid neurons showed expression for gene products of 
Egr-1 and C-Fos. This suggests that these neurons are at least somewhat capable of function, at least 
at younger ages, which may explain why it is evolutionarily not preferable to immediately dispose of 
these neurons. 
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Figure 1.3.4.1: DDR in neuronal cell-fate decision and potential place of the senescence-like 
phenotype. The potential role of activation of a senescence-like phenotype in response to a DDR, and 
its relation to the decision between repair, cell-cycle re-entry and arrest, and apoptosis is shown. 
Replicated from Fielder et al. [196]. 
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1.4 – Approaches for treating and targeting senescent and senescent-like 
cells 
1.4.1 – Targeting the DDR 
 
There are multiple strategies for targeting the DDR and senescence, and given that induction of the 
DDR and associated features can be seen in neurons, there may be cross-over between existing anti-
ageing and anti-cancer treatments [Fielder 2017]. However, it can be a double edged sword, for 
example while too heavy a DDR can trigger apoptotic response, it also regulates pro-survival 
mechanisms. Indeed, ATM activation can protect against neuronal apoptosis through its suppression 
of cyclin D1 following damage [312], and using inhibitors actually promotes aberrant re-entry into the 
cell-cycle and neuronal death [313]. The same is true with p53; in line with this, the use of small-
molecule inhibitors of p53, such as Pifithrin-beta in vitro, is effective in protecting neurons from 
exposure to Aβ fragments at low drug doses, but at higher doses is neuro-toxic [314]. This is potentially 
due to higher levels of inhibition blocking p53’s pro-survival signalling, as p53 inhibitors have not been 
effective in vivo in reducing damage after ischæmia [314].  
More in vivo success has been had with CdK inhibitors that block apoptotic cell-cycle re-entry [315] 
[316-318]. Anti-cancer drugs targeting the cell-cycle, such as the non-selective CdK Inhibitor 
Flavopiridol, have shown promising results in animal models [315]. These have shown promise in 
blocking cell-cycle re-entry in neurons in response to specific insults, such as neurotoxic colchicine 
[316], traumatic [317] and ischæmic brain injury [318]. This likely blocks the initial apoptosis and 
allows time for the levels of damage to be repaired, or reduced to a non-apoptotic level. Selective-
inhibitors of CDKs, such as the E2F1-Cdk1 inhibitors have also reduced neuronal cell-death and 
activation of glia in the hippocampus following traumatic injury [319, 320] and have shown promise 
in vitro by reducing levels of Aβ production [321, 322]. 
1.4.2 – Treating Inflammation and COX-2 
 
One of the major risks from senescent cells is due to their release of pro-inflammatory factors and 
spread through bystander action. The release of cyto- and chemo-kines should stimulate immune 
clearance of senescent cells through T-cell and macrophage action [228], however, with age it 
becomes increasingly difficult to keep the rate of clearance in line with the rate of accumulation. This 
is partially due to immunosenescence, and also from the ‘run-a-way’ effects of the bystander effect. 
The bystander effects can be blocked through the suppression of the SASP and ROS generation [122, 
323]. The SASP is one of the most damaging aspects of DDR activation to the tissue micro-
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environment. With both p16 and p53-p21, and activation of NF-κB, contributing to it  [121, 265, 324, 
325].  
COX-2 is a downstream mediator of inflammation and is activated by DNA damage through p53 
signalling [324], and pro-inflammatory cytokines via activation of NF-κB and JNK [326, 327]. COX-2 
converts arachidonic acid into precursors for pro-inflammatory protanoids, such as Prostaglandin E2 
[328]. The enzyme is not typically expressed in most tissues until inflammatory insult and is important 
in the mediation of inflammation and inflammatory cytotoxicity [329]. However, COX-2 expression is 
important for regular neurological functions such as neuro-transmission and long-term potentiation 
[330], while over-activity has pro-inflammatory effects and is linked to neurodegeneration [331]. 
Elevated levels of COX-2 have been observed in neurons together with phospho-Rb at early Braak 
stages in AD, prior to peak astrocyte and microglia expression [332, 333]. Further, COX-2 has been 
seen to co-localise with Cyclin D1 and Cyclin E expression in neurons in AD [334]. Together this 
suggests that COX-2 may be an important target in neurons that might be in a senescent-like state, 
and may prime or trigger glial activation.  
 In normal non-inflamed rodent brains, COX-2 expression is only really seen in small populations of 
excitatory neurons in the cortex, hippocampus and amygdala and is compartmentalised within these 
cells to post-synaptic dendrites [329]. However, with stress, such as neuro-inflammation and 
ischæmia, the levels of COX-2 and downstream products increase across the brain with neuronal 
damage, such as excito-toxicity, which can be reduced with the administration of COX-2 inhibitors 
such as NS-398 [331, 335]. Over-expression of COX-2 can induce oxidative stress in neurons and 
eventually apoptosis, additionally it has been associated with age-dependent declines in spatial 
memory, and anxiety [336].  
COX-2 activity is associated with ROS production; however, oxygen radical species are not directly 
present in the catalytic pathways of COX-2, with production of other radical species, such as reactive 
carbon-centred radicals featuring instead [337]. Carbon-centred radicals produced by COX-2 can lead 
to lipid oxidation such as attack of Phosphatidylserine (a cytosolic cell-membrane Phospholipid), an 
effect that is countered through NS-398 administration [337]. COX-2 inhibition also counters the 
formation of the radical Dopamine-quinone [338], which is formed from Dopamine and is capable of 
attacking sulf-hydryl groups on glutathione and cysteine residues of proteins [339]. 
Early Non-Steroidal Anti-Inflammatory Drug (NSAID) studies suggest reduced risk of AD in later life 
[340, 341] and a possible protective effect in PD [342]. Chen et al. have investigated the incidence of 
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PD with NSAID use in approximately 150,000 people across 8 years [343]. The use of Ibuprofen 
resulted in a relative risk of 0.65 (95% CI: 0.46-0.88) for new cases of PD, showing little difference in 
the level of protection with sex, age or smoking. The level of risk reduction also appeared to depend 
on the dosage, increasing from a 30% reduction in risk with 2 tablets per week to 40% reduction in 
risk with every-day use. However, this effect appeared to be specific to Ibuprofen and they found no 
differences with other NSAIDs, such as Aspirin and Paracetamol. While generally showing 
improvements, the evidence for an exact effect is still mixed, with one study even finding that long-
term non-aspirin NSAID appeared to be beneficial only in males, with the relative risk actually 
increasing in females [344].  
1.4.3 – Killing senescent cells – Senolytics 
 
If senescence-like neurons are contributors to cognitive impairment and neurodegeneration; then the 
emerging therapies that target cellular senescence in other tissue-types may be potential therapeutic 
candidates for these conditions. Many of these therapies are targeted primarily at alleviating the 
negative aspects of senescence such as the SASP while retaining the cell-cycle arrest [345], but others 
instead target and eliminate senescent cells themselves [346]. 
Even if these therapies have only limited direct effects on neurons, then the countering of senescence 
in glial and progenitor cell populations [347] should provide a positive benefit to cognitive function. 
Additionally, reductions in the whole-body senescent load should improve the circulatory 
environment [123, 124, 127] and reduce the infiltration of inflammatory molecules and immune-cells. 
This is particularly important in ageing, where the blood-brain barrier shows increased permeability 
(See Farrall & Wardlaw for meta-analysis [348]). 
However, there are risks. Neurons are complex and far reaching structures, and any loss can have 
further effects via glial reactions and the release of intra-cellular factors, which may induce further 
damage. Yet, if the effect of these neurons is negative on the surrounding environment (promoting 
inflammation, mis-folding proteins, or inducing apoptosis in surrounding cells) and forms 
inflammatory feedback loops, then it may be worth this cost - akin to burning a fire-line to fight a 
forest fire. 
1.4.3.1 – Pharmacogenetic clearance of senescent cells: The INK-ATTAC Mouse – Clearing 
senescent cells through transgenic kill-genes 
The initial studies showing the role of cellular senescence in the ageing have relied on the 
pharmacogenetic targeting of senescent cells in transgenic mice [123, 124]. Although there isn’t a true 
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universal marker of senescence, p16 is positive in many senescent cells and increases in multiple 
mouse tissues in aged mice, including areas such as the heart and cortex [349]. Additionally, the 
expression of p16 in the brain has been noted previously in neurons in Alzheimer’s Disease [277, 279, 
291]. Research so far has not been focused on the brain, and no cognitive deficits, or improvements, 
following senolytic clearance have been reported. 
This pharmacogenetic approach [123, 124] involves replacing the promotor of dimerising caspase (a 
fusion protein consisting of the membrane bound dimersing protein, FK506-binding-protein and fused 
caspase 8, with a promotor region of p16 that is activated in senescent cells, together with eGFP under 
the same promotor control to visualise these cells (Termed INK-ATTAC). When a drug (AP20187) is 
added, which promotes the dimerization of FK506-binding-protein, the two caspase-8s are also 
brought together. This activates them and promotes apoptosis in cells where this is expressed. Thus, 
addition of the drug should selectively promote the apoptosis of cells expressing high levels of p16. 
That the elimination of senescent cells can improve age-related declines in function was first shown 
by Baker et al in 2011 using INK-ATTAC mice bred on a prematurely ageing mouse, BubR1H/H [123]. 
BubR1H/H mice have a defect in BubR1, a protein kinase that is involved in the spindle checkpoint [350]. 
These mice present progressive aneuploidy and a number of ‘premature ageing’ phenotypes including 
a much reduced life-span, sarcopenia, reduced wound healing, dermal thinning and cataracts. p16 
positive cells accumulate in tissues associated with these conditions in BubR1 mice [351]; knockout of 
p16 mildly improved life-span in BubR1 mice (but not wild-types), as well as ageing-associated 
phenotypes, including sarcopenia, cataracts and dermal thinning [351]. However, it also increased the 
rate of lung cancers, likely in relation to senescence and p16’s role as a tumour suppressor. 
Treatment with AP20187 after weening delayed onset of age-related pathologies previously 
associated with p16, such as sarcopenia and cataracts [351]. This delayed onset correlated with the 
burden of senescent cells. While treatment later in life was not particularly effective at resolving 
pathology already acquired, it did help to delay further degeneration. Interestingly there was no real 
effect in life-span after treatment, but they suggest this is accounted for by the mice dying primarily 
from cardiac failure (a common cause of death in the model), which was not affected by p16 removal.  
While this shows that senescent cells drive accelerated ageing related pathology and that clearance is 
effective in what is essentially a severe disease condition, it did not answer if senescent cells truly 
drive ‘natural’ ageing. This has since been repeated in INK-ATTAC mice bred on a wild-type 
background, which showed an extension of median life-span and health-span  [124] 
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1.4.3.2 – Pharmacological clearance of Senescent Cells 
While highly promising, there is little prospect of implanting humans with such kill-genes, as 
identifying small molecule compounds that target senescent cells with a good degree of specificity is 
vital [346]. These drugs must be able to target and eliminate senescent cells, while not killing 
proliferating, quiescent or terminally differentiated cells. A number of these have been tested, 
targeting varying aspects of the senescent signalling pathway [252, 257, 346]. 
Transcript analysis of irradiation induced senescent cells by Zhu et al. 2015 identified a complex 
network of pro-survival and anti-apoptotic pathways active in senescent cells [346]. Many of these 
pathways centred around several key proteins, including p21, BCL-XL and PI3Kδ. These were first 
targeted with silencing RNAs in vitro to suppress this activity.  siRNAs for p21 and PI3KCD showed 
selective toxicity in senescent adipocytes, without significant harm to cell-viability or survival in non-
senescent cells. However, siRNA for BXL-xL showed little effect in these cells, but was more toxic in 
senescent human umbilical vein cells (HUVECs), while p21 and PI3KCD were not. This showed that 
senescent cells could be targeted with a degree of specificity. 
In vitro screening was performed with 46 compounds and identified Dasatinib, and Quercetin, as two 
promising senolytics. These are both already approved for human use in the United States by the FDA. 
Dasatinib is a Src family kinase and tyrosine kinase inhibitor used to treat cancer [352]. Dasatinib was 
able to selectively target pre-adipocytes in culture, but was not as effective against HUVEC cells. In 
contrast, Quercetin, a flavonol PI3K kinase inhibitor [353] reduced the viability of senescent HUVECs 
selectively at lower doses (0-10µM), with effects on proliferating cells beginning at higher doses (>20 
µM), but with no effect on pre-adipocytes. Dasatinib and Quercetin combination therapy (DQ) proved 
effective in reducing the viability of both cell types. Short-term and single treatments have showed 
effectiveness in vivo in reducing the levels of cells with senescent markers in normally aged mice in 
the liver and fat, and also muscle of those exposed to acute irradiation of the leg. Furthermore, there 
was a degree of improvement in cardiac function (predominantly made up of post-mitotic 
cardiomyocytes) of aged mice and in the leg motor function of the irradiated mice. Long-term 
administration showed improvements in the healthspan of ercc1 mice, which have defective DNA 
repair, progeria and motor neuron degeneration [346].  
Since then long-term DQ administration has shown promise in treating age-related diseases [354, 
355]. Slight improvements in vascular function in aged mice and significant improvements in diseased 
hypercholesterolemic mice were observed, which matched the same pattern as in pharmacogenetic 
clearance in INK-ATTAC mice [354]. Additionally, early intervention in bleomycin-induced idiopathic 
pulmonary fibrosis with DQ and INK-ATTAC has been shown to improve lung-function and health 
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[355]. Other compounds such as ABT263 Navitoclax, a specific inhibitor of Bcl-2 and Bcl-xL [356, 357] 
have since been identified and tested in vitro and in vivo. Like Quercetin, Navitoclax has shown 
effectiveness in vitro against HUVECs, but not pre-adipocytes [356]. In vivo, it has shown effectiveness 
in reducing senescence in bone marrow and muscle stem-cell niches, and countering the premature 
ageing effects of total body irradiation [357].  
The targeting of senescent cells via transgenic and chemotherapeutic mechanisms has shown great 
promise in delaying, preventing and alleviating diseases associated with senescence, and ageing itself 
[124, 354, 358]. However, there are a number of questions that remain to be answered in relation to 
the use of genetic and chemotherapeutic senolytic therapies in the brain. If senolytic treatments can 
target senescent-like neurons has yet to be established. INK-ATTAC models targeted against p16 may 
have some effect, as p16 activity has been observed in the neurons of patients with AD [277, 291, 
359].  
It is not yet clear if the senescent-like phenotype is simply a protective mechanism by the neurons to 
prevent cell-cycle related death, or if it can trigger negative effects through senescence-associated 
pathway induction. Indeed, p16 is capable of preventing neuronal cell death from elevated Cyclin D1 
expression [360] and neurons with aneuploidy (which might have resulted through ACCR that has 
presumably since been arrested) are active to a degree, and maintain axonal connections to distant 
brain areas [311]. If they are still integrated and not harmful to network connectivity and function, 
then instead of trying to counter the negative effects of senescence-pathways, such as the production 
of SASP factors, would be preferential. So far, treatments in other post-mitotic tissues such as skeletal 
and cardiac muscle have shown improvements in function [123, 124], although whether this is through 
the clearance of senescent-like cells or through improvements to stem cell niches is not yet known.  
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1.5 - Aims and Objectives 
 
Although an increase in senescent-like neurons can be seen with age, little is known about its role in 
brain ageing, inflammation or cognitive deficits. The general aim of this thesis is to understand the 
potential theoretical underpinnings of the senescent-like phenotype, and to understand if there is a 
link between senescent-like neurons and deficits in cognitive function. 
 
Specific aims: 
1) To characterise if ageing and chronic inflammation induce telomere dysfunction and the 
senescent-like phenotype in neurons, and if this is associated with the onset of neuro-
inflammation and cognitive deficits. 
2) To investigate if the clearance of senescent-like neurons could be achieved using 
pharmacogenetic and pharmacological methods that have shown efficacy in clearing 
traditionally senescent cells, and if this was associated with improved cognitive performance. 
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2.0 - Materials and methods 
 
2.1 - Reagents and antibodies 
 
Reagent Supplier Catalogue number 
Aluminium potassium sulphate dodecahydrate >98% Sigma 7210 
Bovine Serum Albumin, >99.9 Sigma A3059 
Calcium chloride, Mw 147.02 VWR 10035-04-08 
Citric acid, Mw 192.12 Sigma C2404 
De-ionised Formamide Amresco 606 
Formamide, Mw 45.04 Sigma F-7508 
Glacial acetic acid, 100% BDH UK 1001CU 
Glycerin Sigma G2289 
Haematoxylin, Mw 302.28 Sigma H3136 
Halt Protease & phosphatase inhibitor cocktail (100X) Thermofisher 78442 
Histoclear 100% LAMB UK HS-200 
Hydrogen peroxide, 30% 
Fisher 
Scientific 
H/1800/15 
M.O.M. Kit Vector UK PK-2200 
Magnesium chloride, Mw 203.30 BDH UK 101494V 
Magnesium sulfate >99.9% Sigma 203726 
Maleic acid, Mw 116.07 BDH UK 103944L 
NovaRed Substrate Kit Vector UK PK-2800 
Paraformaldehyde 100% Sigma P6148 
PBS 10x Sigma D1408 
Potassium chloride, >99% Sigma P9541 
Potassium Phosphate monobasic, Mw 136.09 Sigma P5655 
Roche blocking reagent  Roche 11 096 176 001 
Sodium bicarbonate, Mw 84.01 Sigma S5761 
Sodium iodate, Mw 197.89 Sigma S4007 
Sodium phosphate monobasic, Mw 119.98 Sigma S0751 
Sucrose >99.5%, Mw 342.30 Sigma S0389 
Tris base, Mw 121.14 Sigma T6066 
Trisodium citrate, Mw 294.1 Sigma S4641 
Triton X100 100% Sigma T-9284 
Vestastain Elite ABC (Rabbit IgG) Vector UK PK-6101 
Xylazine hyrdochloride >99% Sigma X1251 
 
Table 2.1.1: Reagents and suppliers 
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1° Antibody 2° Antibody 3° Antibody, 
Development Kit 
Antigen Provider Species Conc. Info Conc.   
γH2AX / P-
Histone H2A.X 
(S139) 
Cell 
Signalling 
#9718 Rabbit 1:250 
Goat Anti-rabbit, 
biotinylated 
1:200 
DCS-fluorescein 
(Vector Lab) 
NeuN Abcam ab104224 Mouse 1:500 
Goat Anti-
mouse, Alexa 
647 
1:500 n/a 
HMGB1 Abcam ab18526 Rabbit 1:400 
Goat Anti-rabbit, 
biotinylated 
1:200 
ABC kit (Horseradish 
Peroxidase), 
NovaRed (Vector 
Lab) 
Iba1 Abcam ab5076 Goat 1:400 
Horse Anti-goat, 
biotinylated 
1:200 
ABC kit (Horseradish 
Peroxidase), 
NovaRed (Vector 
Lab) 
Doublecortin/
DCX 
Abcam ab18723 Rabbit 1:250 
Goat Anti-rabbit, 
biotinylated 
1:200 
ABC kit (Horseradish 
Peroxidase), 
NovaRed (Vector 
Lab) 
 
Table 2.1.2: Antibodies and development systems 
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2.2 – Stock solutions 
 
Solution Ingredients 
Citric Acid Buffer (0.01M) pH6.0 29.41g Trisodium Citrate, 1L Milli-Q H2O. Kept at x10 
stock at 4°C 
Immuno-FISH hybridisation buffer 2.5μl 1M Tris pH 7.2, 21.4μl Magnesium chloride 
buffer, 175μl De-ionised Formamide (Amresco), 1μl 
Cy-3 CCCTAA peptide nuclei acid probe (Applied 
Biosystems), 12.5μl Blocking buffer (1:9 Roche 
Blocking re-agent in Autoclaved Maleic Acid) and 
33.6μl deionised H2O 
Haematoxylin 5g Haematoxylin (Sigma), 300ml Glycerin (Sigma), 
50g Aluminium potassium sulphate (Sigma), 0.5g 
Sodium iodate (Sigma), 40ul Glacial acetic acid 
(Sigma) in 700ml Milli-Q H2O. Filtered before use. 
Homogenate TRIS Buffer, pH7.4 6.61g Tris-HCl, 0.97 TRIS base in 500ml Milli-Q H2O 
stock. Add 0.5% Triton X100 and 1% Protease 
inhibitor cocktail (Thermofisher; Halt Protease + 
Phosphatase Inhibitor cocktail) before use. 
Magnesium chloride buffer pH7.0 25mM Magnesium Chloride, 9mM Citric acid, 82mM 
Potassium phosphate in Milli-Q H2O 
Maleic acid buffer pH7.5 100 mM Maleic acid, 150 mM NaCl in Milli-Q H2O 
Modified Artificial Cerbrospinal Fluid 10mM Glucose, 252mM Sucrose, 24mM NaHCO3, 
3mM KCl, 2mM CaCl2, 2mM MgSO4, 1.25mM 
NaH2PO4 
Roche Blocking re-agent Dissolved in maleic acid buffer to 10% (w/v). Stored 
at 4°C for use. Long-term storage at -20°C. 
FISH Wash Buffer 70ml Formamide, 30ml 2xSSC 
2xSSC pH7.0 0.3M NaCl, 0.03M Sodium Citrate, in Milli-Q H2O 
TRIS Buffer pH7.0 1M Tris base in Milli-Q H2O 
 
Table 2.2.1: Buffers and solutions used during this research 
 
2.3 - Animals 
 
Experiments in Chapter 4 were performed on male nfkb1-/- mice on a C57Bl/6 background and pure 
C57Bl/6 wild-type controls. Pure background C57Bl/6 mice were a gift from Jorge Caamano, 
(Birmingham University, UK). Mice were housed at the pathogen-fee barrier area of the Newcastle 
Animal House (Centre for Comparative Biology). Mice were observed regularly and euthanized when 
they showed tumours or morbidity, in accordance with the Guidelines for Humane Endpoints for 
Animals Used in Biomedical Research. Nfkb1-/- mice were genotyped by our collaborators according 
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the Jackson laboratory protocol for nfkb1-/- mice. Each mouse was weighed and measured once a 
week. Mice were housed in cages (56x38x18 cm, North Kent Plastics, Kent, UK) of groups of 4–6 that 
did not change from weaning. Mice were provided with saw dust and paper bedding and had adlib 
access to water.  Mice were housed at 20±2 C under a 12 h light/12 h dark photoperiod with lights on 
at 07:00 hours.  
For 8 month time-point mice, mice received Ibuprofen via pump (mini-osmotic pump, Alzet, model 
2004) for a period of 2 months starting at 6 months of age. Ibuprofen was dissolved in PEG and DMSO 
(50:50) to a daily dosage of 50mg per kg. A small incision was made on the right flank and a mini-pump 
was inserted subcutaneously and the wound was repaired with 7mm clips. After 28 days a 
replacement was implanted. Under general anaesthesia, pumps were surgically removed and a wound 
repair was performed. A small incision was made on the left flank and a new mini-pump was inserted 
subcutaneously and the wound was repaired with 7mm clips. Mice were given Ibuprofen mixed in 
their food to a daily dosage of 50mg per kg (mouse) per day. For 18 month time-point mice, treatment 
was started at 9 months of age. 
For the mice in the clearance of senescent cells on ageing and cognition study, INK-ATTAC transgenic 
mice were generated and genotyped, as previously described by Baker et al. [123]. INK-ATTAC mice 
were housed in groups of 2-5 at Mayo Clinic, Rochester, Minnesota. Mice were housed at 22±0.5C 
under a 12 h light/12 h dark photoperiod. INK-ATTAC transgenic mice were genotyped by our 
collaborators at Mayo clinic. Mice at 25-30 months of age were randomly assigned to vehicle, AP20187 
and D&Q treated groups. These drugs are administered by different vectors. DQ (Dasatinib 5mg/kg, 
Quercetin (10mg/kg)) is given via oral gavage, while AP20187 (10mg/kg) is administered by intra-
perineal injection. As such, all mice were given oral gavage and intra-perineal injection, and the 
appropriate treatment or vehicle (60% Phosal, 10% ethanol, and 30% PEG-400). Vehicle mice were 
treated with vehicle by both oral gavage and IP. DQ treated mice were given DQ by oral gavage, and 
vehicle by intra-perineal injection. AP20187 mice were treated with vehicle by oral gavage, and 
AP20187 by intra-perineal injection. Mice were treated intermittently, with 3 treatments in 1 week, 
every 2 weeks, for 2 months.Ethical approval was granted by the LERC Newcastle University, UK and 
IACUC at Mayo Clinic (Protocols A26415, A26713, A40312). All experiments were undertaken in 
compliance with UK Home Office legislation under the Animals (Scientific Procedures) Act 1986. 
Organs were either fixed in 4% paraformaldehyde or frozen in liquid nitrogen. Fixed tissues were 
processed and embedded in paraffin. All sections were cut at a thickness of 3 μm or 10μm. 
48 
 
2.4 – Mouse Cytokine/Chemokine array MD31 
 
Brain tissue was frozen in liquid nitrogen at the time of harvest, and stored at -80°C was ground 
manually to a fine powder using a steel mortar and pestle. This was wiped clean between samples 
with 70% EtOH and cooled in liquid nitrogen. Powdered sample was stored at -80°C till homogenate 
preparation. 0.5ml Homogenate TRIS Buffer was added to powdered sample in a ceramic mortar and 
pestle, cooled in liquid nitrogen. They were manually ground together, and mixed until they formed a 
paste, then liquid. This was spun for 30 minutes at 16100 rpm. Supernatent was taken and stored at -
80°C. This was adjusted to 5μg/ml and shipped to Eve Technologies Corporation, Calgary, Canada for 
mouse cytokine/chemokine array MD31 using a Multiplexing LASER Bead Assay. 
 
2.5 - Behavioural Testing 
 
2.5.1 - Y-Maze, Forced Alternation Protocol 
 
A forced alternation Y-Maze set up was used. I built a symmetrical Y-maze using white plastic cut to 
measure. Each arm was 40 cm long, 8 cm wide, and 15 cm high with a curved lip to make it more 
difficult for the mouse to climb out. The end of each arm was marked with a black icon (+,▪, o). The 
home cage was moved into the room for one hour prior to testing to allow mice to acclimatise.  
In acquisition, one of the arms (▪ or o) was blocked off by a white barrier. The mouse is placed in the 
home arm (+) and given 10 minutes to explore the two open arms of the maze (home and familiar). 
After this, the mouse was returned to the home cage for a 1 hour inter-trial period. Between runs, the 
maze was cleaned thoroughly with 70% EtOH between trials to remove odors. Up to 5 mice could be 
tested at a time.  
After 1 hour, the mouse was placed in the home arm, with all 3 arms open and allowed to explore for 
2 minutes. If the mouse climbs out of the maze, it was returned to the abandoned spot. Latency to 
novel arm, primary arm choice and time spent in each arm were recorded. Arm Discrimination Index 
was scored as the time spent in the novel arm, divided by the total time spent in both the familiar and 
novel arms. 
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2.5.2 - Barnes Maze 
The maze consists of an open circular surface (diameter = 92cm), with a series of 20 holes (diameter 
= 5 cm) along the border and four visual markers at 0, 90, 180 and 270° positions (Square, Cross, 
Triangle or Circle) (Figure 2.5.2.1A). Theses visual markers are placed on the walls around the maze 
and the maze is elevated so that mice cannot exit via the sides (Figure 2.5.2.1B). Under one of these 
holes is attached the ‘target box’, which the mouse can enter and provides refuge from the bright and 
exposed open surface top (Figure 2.5.2.1C). The experiment requires the subject to learn the spatial 
position of this escape box relative to a number of visual cues positioned on the surrounding walls 
[361] (Figure 2.5.2.1D).  
The mouse is placed in an opaque pipe (diameter = 11cm, height = 15 cm), in the centre of the maze 
and allowed 10 seconds to calm. The pipe is removed and the timer started. An over-head camera, 
linked to a DVD recorder and monitor, allows the performance of the mouse to be observed and 
recorded. 
Each mouse is assigned one to one the four visual markers, under which the escape box will be placed 
during training (Figure 2.5.2.1E). In initial run, naïve mice are guided to the escape hole and allowed 
to rest inside for 2 minutes to acclimatise. The ‘Acquisition phase’ follows this, with mice running 4 
trials per day, for 4 days. In each trial, the mouse is given 3 minutes to find and enter the escape hole. 
If the mouse does not find the hole in the allotted time then it is again guided to the escape hole. The 
mouse is allowed to rest in the target box for 1 minute. Between trials the board and escape box are 
wiped with 70% EtOH to remove odour trails. 
As reported elsewhere [362], mice do not always enter the target hole after finding it and may proceed 
to either further explore the maze or sit at the entrance hole. To account for this, measurements were 
taken of the strategy, time and number of errors till first finding the target hole as suggested by 
Harrison et al. [361], these are referred to as the ‘primary’ parameters. 
Primary errors, total errors, primary latency to find hole, total latency to enter hole, and search 
strategy were recorded. Errors were defined as head deflection and nose-pokes into ‘false holes’. 
Search strategy was defined as 1) Direct – Moving directly to the target hole, or an adjacent hole prior 
to entry. 2) Serial – Finding the target hole after visiting at least two adjacent holes moving round the 
maze in a clockwise or counter-clockwise fashion. 3) Mixed – Search pattern involved moving across 
the centre of the board or seemingly random selection of search areas. 
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Short-term memory was tested on the fifth day in a 90s trial, without the target box present (Figure 
2.5.2.1E). Long-term retention is tested in the same fashion on the twelfth day with no training 
between these trials (Figure 2.5.2.1E). Location and frequency of visited holes, site of initial visit and 
time spent in target quadrant were additionally recorded in short and long-term tests. 
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Figure 2.5.2.1 : Barnes Maze set-up and training parameters. 
A) Graphical representation of the Barnes maze, showing the positions of visual reference points. B) 
Dimensions of the Barnes maze, walls are 120cm long and 60 cm high and the maze is 92cm in 
diameter and raised 15cm from the ground. The two closet walls are not rendered to show inside the 
maze. C) Positioning of escape box under target hole, and placement tube in centre of maze. D) Still 
capture from video of mouse in maze. E) Training and testing regime as divided by day. Training trials 
consist of 180 seconds to find and enter the target hole. Once entered, the box is closed and the 
mouse allowed to rest 2 minutes, it is re-trialled 1 hour late. During memory trials, the target box is 
removed and the mouse given 90 seconds to explore. 
A B 
C D 
E 
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2.6 - Immunohistochemistry  
 
2.6.1 – Immunohistochemistry protocol 
Tissues were de-paraffinated and hydrated using two washes of Histoclear, followed by step-down 
series of ethanol (100%, 90%, 70%) and then twice in distilled H2O, each step being 5 minutes per 
wash. Antigen retrieval was performed by incubation in 0.01M Citrate Buffer, microwaved for 4 
minutes at 800W, then 10 at 450W, and allowed to cool to room temperature, before being washed 
in water.  
Endogenous Peroxidase activity was blocked with 0.9% H2O2 for 30 minutes at RT. Samples were 
transferred to Phosphate-Buffered Saline (PBS) and drawn around with an immunopen. Blocking of 
non-specific binding was performed with 70μl per section of freshly prepared Normal Goat Serum 
(NGS) 1:60 in 0.1% Bovine Serum Albumin (BSA)/ PBS, for 30 minutes at room temperature in a 
humidified chamber (used for all subsequent incubations). This was followed by Avidin, Biotin blocking 
(each for 15 minutes, followed by PBS wash). Sections were then incubated over-night with primary 
antibody diluted in NGS/BSA/PBS at 4°C.  
Sections were washed in PBS 3 times and incubated with biotinylated secondary anti-mouse goat 
antibody in NGS/BSA/PBS for 30 minutes, then washed 3 times in PBS. ABC complex was prepared to 
manufacturer’s instructions 30 minutes prior to use. Sections were washed 3 times in PBS and 
incubated in freshly prepared NovaRed solution prepared to manufacturer’s instructions.  
Sections were then rinsed in distilled H2O, placed in Haematoxylin to counterstain, rinsed thrice in 
distilled H2O, placed in hot non-distilled H2O for 30 seconds, then washed in distilled H2O. Sections 
were dehydrated in 2x30 second 95% Ethanol, 2x30 second 100% Ethanol, 2x5min Histoclear and 
mounted with DPX. 
2.6.1.1 - Staining specific modifications 
For Iba1 and DCX stainings the following alterations were made. 10μm sections Paraffin embedded 
sections were used, rather than 3μm sections. Antigen retrieval was performed by incubation in 0.01M 
Citrate Buffer heated by 4 minutes at 800W, then 6 minutes at 450W, and allowed to cool to room 
temperature. This reduced separation of sample from the slide while preserving good signal to noise 
ratio. For goat primary antibodies locking solution used for blocking, primary and secondary antibody 
was freshly prepared 5% normal serum (of the secondary biotinylated antibody species) in PBS, for 30 
53 
 
minutes at room temperature. For Iba1 this was 5% Normal Horse Serum in PBS. For p21 staining, 
antigen retrieval time at 800W was increased to 30 minutes to increase antigen unmasking. 
2.6.5 - Microscopy 
Microscopy for Immunohistochemistry was performed with a Nikon Eclipse E-800 Brightfield Camera. 
Tile-scan images from the E-800 were stitched using Microsoft Image Composite editor, if required. 
For analysis of iba1+ cells a Leica DMi-8 in Brightfield mode was used for a x40 tile-scan of the 
hippocampus. This was split into CA3, CA1 and DG. The number of iba1+ in each area was recorded, 
and the area of each area. The final count was expressed as number of iba1+ cells per mm2 in a 10μm 
slice. DCX+ cells were counted along the DG blade, and the length of the DG blade at the sub-granular 
zone recorded in mm. Final count was expressed as number of DCX+ cells per mm. For the wild-type 
and nfkb1-/- study, p21 immunohistochemistry  was counted as positive for strong nuclear staining, or 
moderate to no staining. HMGB1 cells were quantified as positive or negative. These were expressed 
as a percentage of cells counted. 
2.7 – Immunofluorescence 
 
2.7.1 - γH2A.X Immuno-Fluorescence in situ Hybridisation  
Tissues were de-paraffinated and hydrated using two washes of Histoclear, followed by step-down 
series of ethanol (100%, 90%, 70%) and then twice in distilled H2O, each step being 5 minutes per 
wash. Antigen retrieval was performed by incubation in 0.01M Citrate Buffer, microwaved for 4 
minutes at 800W, then 10 at 450W, and allowed to cool to room temperature, before being washed 
in water and transferred to Phosphate-Buffered Saline (PBS).  
Blocking of non-specific binding was performed with 70μl per section of freshly prepared Normal Goat 
Serum (NGS) 1:60 in 0.1% Bovine Serum Albumin (BSA)/ PBS, for 30 minutes at room temperature. 
Sections were then incubated over-night with 1:500 mouse neural antibody NeuN (Abcam) in 
NGS/BSA/PBS at 4°C. From here all steps were performed in dark conditions to minimise sample 
bleaching. Sections were washed in PBS and incubated with secondary anti-mouse goat antibody 
(Alexa, 647nm) at 1:1000 in NGS/BSA/PBS for 30 minutes. Following PBS washes, non-specific blocking 
was performed for 30 minutes at room temperature with NGS/BSA/PBS, and Avidin, Biotin blocking 
(each for 15 minutes, followed by PBS wash). Sections were incubated in 1:250 primary rabbit γ-H2A.X 
antibody (Cell Signalling), NGS/BSA/PBS overnight at 4°C.  
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Sections were washed with PBS 3 times, and incubated in 1:200 biotinylated secondary goat anti-
rabbit antibody (Vector laboratories) in NGS/BSA/PBS for 30 minutes at room temperature. Following 
PBS wash, Avidin DCS (Vector laboratories, 1:500 in PBS) was applied to the sections for 30 minutes 
then washed again in PBS. Cross-linking was performed using 4% Para-Formaldehyde/PBS for 20 
minutes. Sections were washed in PBS and dehydrated using sequential 3 minute ice cold EtOH 
ethanol washes (70%, 90%, 100%) and then allowed to air-dry. 10μl of Hybridisation mix (2.5μl 1M 
Tris pH 7.2, 21.4μl Magnesium chloride buffer, 175μl De-ionised Formamide, 1μl PNA probe (Applied 
Biosystems), 12.5μl Blocking Buffer 1:9 Roche Blocking re-agent in Autoclaved Malic Acid and 33.6μl 
deionised H2O) was applied and a cover-slip placed upon the slide, after which DNA denaturation was 
performed by placing sections in an 80°C oven for 10 minutes. Sections were placed in humidified 
chamber for 2 hours at room temperature. Sections were then washed in 70% Formamide/2xSSC for 
10 minutes, 2xSSC 10 minutes, PBS 10 minutes on a mixing tray. Sections were mounted using 
VectorShield with DAPI (Vector laboratories). 
2.7.1.1 - γH2A.X quantification 
Microscopy for Immuno-fluorescent stainings was performed with a wide-field fluorescent 
microscope; a Leica DM-5500-B, fitted with a Leica DFC-360-FX camera, and attached to a desktop 
running Leica LASAF-2.1.0. Focal plane selection in fluorescence was selected using the DAPI channel, 
with z-stack bounds based on telomere probe focus. Images were stored as unaltered .lif for later 
measurement. Measurement of number of γH2A.X foci per cell, and number co-localising with 
telomeres was conducted under blinded conditions, with both the age and genotype of the animal 
masked. Neurons in the hippocampus were differentiated from glial cells based on location, 
morphology in the DAPI channel and by positive staining for the neuronal Abcam NeuN antibody, and 
Purkinje neurons by location, morphology and low intensity in the DAPI channel within the Cerebellum 
(as these cells do not express NeuN). 
2.7.2 - Paraffin-Fixed Tissue Auto-fluorescence 
Auto-fluorescence measurement was performed on paraffin-embedded slides from the brains of wild-
type versus nfkb1-/- knockout mice. Slides were selected, where possible, based on the presence of 
the areas of interest, namely the Cerebellum, Hippocampus and Cortex. Unprocessed slides were used 
for Purkinje cells, due to their large soma. The smaller size of Hippocampal neurons necessitated the 
use of de-waxed and mounted slides to discern individual foci. Microscopy imaging of the slides was 
performed, using identical settings for lamp intensity, gain, lens aperture and f-stop between slides, 
with single image capture, at x20 magnification for Purkinje neurons and A4 filter cube (Band Pass 
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360/40nm, Barrier Filter Band Pass 470/40nm), and x40 for Hippocampal neurons. Imaging was 
performed in equivalent morphological locations within the areas of interest between slides. 
Measurement was performed blinded of age and genotype; In hippocampal neurons, mean number 
of auto-fluorescent foci was counted per cell. In Purkinje neurons average image fluorescence was 
measured using a ‘Region of Interest’ tool to select cells of interest in Fiji (Image J derivative).  Signal 
increases linearly with slide and wax thickness, small differences between sittings can occur due to 
differing lamp intensity even if exposure is kept standard. To account for this, the signal:noise ratio is 
used. Noise, or ‘Background’, correction is performed by taking multiple readings from the edge of 
the tissue, where only paraffin is present and dividing the signal by this value to obtain the ratio.  
2.8 - RNA In situ hybridization (RNAISH) 
 
RNAISH performed to specification using Formalin-Fixed Paraffin-Embedded Sample Preparation Pre-
treatment Guide User Manual, Part 1 (Catalog No. 322452-USM) and RNAscope® 2.5 HD Detection Kit 
(RED) User Manual, Part 2 (Catalog No. 322360-USM). HybEZ Oven, with all required ACD reagents 
were used, with the following alteration. Slides were deparaffinised and hydrated using two washes 
of Histoclear, followed by step-down series of ethanol (100%, 90%, 70%) and then twice in distilled 
H2O, each step being 5 minutes per wash. This was performed by Dr. Diana Jurk. Imaged and quantified 
by myself. 
Sections were imaged at x40 using a Nikon Eclipse E-800 Brightfield Camera. Tile-scan images from 
the E-800 were stitched using Microsoft Image Composite Editor. The number of cells with positive 
foci, and total number of cells in each area (CA3 pyramidale, CA1 pyramidale and DG granular layer) 
was recorded. Cells with a glial morphology and dark neurons were excluded. 
 
2.9 - Electrophysiology 
2.9.1 - Isolated Hippocampus Slice Preparation 
On the day of procedure a single mouse was separated from cage-mates and was transported by car 
to the preparation area. Animals were given 30 minutes to recover and anesthetised with inhaled 
isoflurane prior to intramuscular injection of Ketamine (≥100 mg kg-1) and xylazine (≥10 mg kg-1). 
When all responses to noxious stimuli had ceased, the mice were intra-cardially perfused with ~25ml 
Modified Artifical CerbroSpinal Fluid (ACSF) [10mM Glucose, 252mM Sucrose, 24mM NAHCO3, 3mM 
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KCl, 2mM CaCl2, 2mM MgSO4, 1.25mM NaH2PO4]. Once perfused, the brain was removed and 
Cerebellum and Brainstem separated and stored in 4%PFA. The brain was sectioned using a Leica 
VT1000s into 450μM sections. These sections were trimmed to isolate the Hippocampus and 
transferred to a holding chamber were they rested for 1 hour at ~33°C, supplied by ACSF and 
humidified 95% O2/5% CO2. Brain removal and slice preparation was performed by Clare Tweedy, with 
assistance from myself. 
2.9.2 - Oscillation Recording and analysis 
For extra-cellular recordings, electrodes are filled with modified ACSF (resistance 2-5 MΩ). Recordings 
for gamma-frequency oscillation build up were taken in CA3 in the stratum radiatum (Figure 2.9.2.1A), 
with up to two electrodes per recording rig (Figure 2.9.2.1B). These were inserted by Clare Tweedy, 
while I monitored the rigs and recorded data. Administrating Carbachol, a cholinergic agonist, to 
isolated hippocampal slices stimulates synchronous low gamma-frequency neuronal oscillations 
originating primarily in CA3 and propagating to CA1 stratum radiatum [363, 364]. These oscillations 
persist for a number of hours, and in healthy slices will build in power and amplitude before stabilising 
at approximately 3-4 hours post-Carbachol administration. Carbachol was administered into the bath 
solution, and 60 second recordings were taken at set intervals for 3 hours (Figure 2.9.2.1C), and then 
until gamma oscillations stabilised (defined as 3 recordings in succession within 10% of each other, at 
or after 3 hours post-Carbachol administration). 1 second extract from Figure 2.9.2.1C can be seen in 
Figure 2.9.2.1D, showing oscillation). After the oscillations were stable, simultaneous measurements 
were taken between CA3 in CA1 of the same slice, in both stratum radiatum and stratum lacunosum 
moleculare. Propagation of the signal to CA1 was recorded 
Recordings were taken with an Axoclamp-2B amplifier (AxonInstruments Inc., Union City, CA, USA). 
Extracellular recordings were filtered at 0.001–0.4 kHz using Bessel filters. Noise from the mains 
electricity was subtracted from the signal using a Humbug (Digitimer, Welwyn Garden City, Herts, UK). 
Data were re-digitized at 10 kHz using an ITC-16 interface (Digitimer, Welwyn Garden City, UK). Data 
were recorded and analysed using Axograph software (Axon Instruments Inc., Union City, CA, USA). 
60 second recordings of activity were passed through a Fast Fourier transformation in Axograph to 
provide power spectra (Figure 2.9.2.1E). Area power for slow gamma oscillations was defined as area 
under the curve between 15 and 45Hz. Frequency was defined at the peak of the oscillation. 
Oscillations were determined as stable at or after 3 hours, when within ±10% for three consecutive 
measurements of 10-15 minute intervals. Once slices stabilised, further measurements were taken in 
radiatum and pyramidal layer of CA3 and CA1. The rhythmicity of the oscillation was measured by 
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correlating the generated gamma frequency oscillations to a time-lagged version of itself, which shows 
how consistent the repeated oscillation is. Oscillation rhythmicity was measured from auto-
correlations performed in MATLAB 2012, with the peak was normalised to 1. Cross-correlations 
compared simultaneously recorded oscillations in CA3 and CA1, recorded by moving two electrodes 
to the same slice, and placing one in each area. 
Data were analysed in Sigmaplot v12.5. P of <0.05 is taken as significant. Build-up data was assessed 
with 2-way repeated measures analysis of variance, with time and group (wild-type, nfkb1-/- untreated, 
nfkb1-/- treated) as factors. Differences between genotype and treatment were assessed by 2-way 
ANOVA without interactions. If the P-value indicated a significant difference, a Holm-Sidak post-hoc 
test was used to determine which parameters likely varied. 
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Figure 2.9.2.1: Recording of traces and power spectra from isolated hippocampal slices.  
A) Diagram of placement of electrode into stratum radiatum of CA3 in an isolated slice. B) Image of 
set-up electrophysiology rig C) Example 60 second epoch from stable-time point. D) Example extract 
of 1 second epoch from trace shown in C). E) Representative power spectra following fast-fourier 
transformation of 60 second epoch trace recordings extracted from stable time-points in CA3 stratum 
radiatum wild-type, nfkb1 knockout and nfkb1 knockout treated with Ibuprofen. Area power is 
measured as the area under curve between 15-45Hz and provides a measure of the strength of the 
gamma-frequency oscillation. Amplitude in the power of the maximum point of the power-spectra. 
Frequency is the frequency of the maximum amplitude. 
A 
C 
D 
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3.0 – Neuro-inflammation, cognitive deficits and senescent-like 
neurons in a model of chronic inflammation 
3.1 - Introduction 
 
Neuro-inflammation is linked to the onset of cognitive impairments and neurodegenerative diseases. 
Senescence is known to have an important role in inflammation through the release of SASP factors 
and IL-6 production has been observed in senescent-like neurons. However, the association between 
senescence-like neurons, inflammation and cognitive deficits has not yet been assessed. 
3.1.1- NF-κB in the brain and inflammation 
NF-κB is made up from a family of sub-units, as discussed in the introduction. Inducible and active NF-
κB family complexes are expressed in the cytoplasm of nearly all cells [365]. NF-κB transcription factors 
control the expression of over 500 genes, with both physiological and pathogenic roles [366]. 
Constitutively active NF-κB activity can be seen in glutamatergic neurons, such as granule and 
pyramidal cells of the hippocampus, and in the cortex [365, 367]. Inducible complexes are also found 
localised at synapses [368], and respond to synaptic transmission to alter gene expression through 
retrograde transport to the nucleus after glutamatergic stimuli, leading to activation [369]. It also has 
a neuro-protective role; blocking NF-κB using recombinant adenovirus induces cell-death [370], and it 
can be activated by insults such as cerebral ischæmia and excitotoxicity, altering the expression of 
apoptotic proteins and reducing the amount of neurons that die [371, 372]. However, NF-κB activity 
is also strongly associated with inflammation and age-dependent changes in gene expression [373, 
374].  
Chronic activation of NF-κB can drive ageing through increased inflammation, and increased levels of 
senescent cells [127]. Activity of the NF-κB transcription cassette is induced by a wide-range of insults, 
these can be immune challenges, such as viruses, LPS and cytokines, as well as from oxidative stress 
and DNA damage [375, 376]. NF-κB itself regulates a broad-range of genes, inducing the expression of 
pro-inflammatory cyto- and chemokines, and enzymes such as COX-2 [366, 377]. Many of these factors 
are key parts of the SASP, and NF-κB activation has a central role in senescence [232, 234]. Evidence 
of constitutive activation of NF-κB can be seen in a number of chronic inflammatory and immune 
diseases, including in the CNS in conditions such as AD [378-381]. 
There is evidence of increased NF-κB activity in the brains of aging mice, where it is associated with 
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increased release of cytokines such as IL-6 from glial cells [382]. Increased translocation to the nucleus 
and activity of NF-κB is seen in vulnerable neurons in neurodegenerative diseases, such as 
dopaminergic neurons in PD [383]. Increased NF-κB activation has been seen to increase alongside 
COX-2 in the brain of ageing humans and in sporadic AD [380].  NF-κB has low basal activity in glia, and 
remains largely in an inducible state in unchallenged glia cells [384]; however, it is activated in disease 
conditions such as AD and ischemia, where it regulates inflammation [384]. NF-κB activity in astrocytes 
following injury induces CCL2 expression and the infiltration of circulating leukocytes [385]. In 
microglia, NF-κB regulates the release of pro-inflammatory and pro-oxidative bio-reactive molecules, 
with over-activation causing and exacerbating degeneration [386].  
3.1.2 - Nfkb1-/- knockout mice 
Nfkb1-/- mice have constituently active NF-κB through the loss of the p50 subunit [387]. The subunits 
in the nfkb1 gene (p50/p105) lack transactivation domains and can act as active repressors of NF-κB’s 
pro-inflammatory action [388]. p50:p50 homo-dimers actively repress the transcription of many pro-
inflammatory genes [389]. p50 mediates the recruitment of the transcriptional repressor histone 
deacetylase 1 (HDAC1) to various inflammatory genes containing κB binding motifs, and its loss 
promotes dysregulation of inflammatory gene transcription [376, 390]. Knockout of this subunit leads 
to the wide-spread constitutive activation of the pro-inflammatory NF-κB gene cassette, and sterile 
peripheral inflammation in ageing [127].  
The mice appear to develop properly, but show accelerated ageing after development and a 
significantly shortened lifespan [127, 387]. Nfkb1-/- mice show accelerated accumulation of senescent 
cells in mitotic tissues, which is understood to further contribute to the chronic sterile inflammation 
and promote the premature ageing seen in the model [127]. The nfkb1-/- mouse model shows 
increased oxidative stress, mitochondrial H2O2 production, DNA damage associated telomere 
dysfunction and increased numbers of senescent cells in mitotic tissues at 9 months of age compared 
to age-match wild-type controls. In fact, the changes appear indicative of an accelerated ageing 
phenotype, with the 9 month nfkb1-/- mice presenting a similar phenotype to 24 months old wild-types 
[127]. This results in a much reduced life- and health-span compared to C57Bl/6 wild-type mice. 
It has also been reported that these animals show less neuronal apoptosis following ischæmia than 
wild-type mice [391]. However, after exposure to the neurotoxin Trimethlytin they show increased 
neuronal degeneration and mortality [392].  Nfkb1-/- mice appear more vulnerable to excitotoxic 
damage from kainite, and in culture show increased oxidative stress after glutamate exposure [393]. 
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Degeneration has also been reported in the optic nerve following axonal injury in the retina [394]. 
There is some evidence that nfkb1-/- mice undergo age-related neurodegeneration [395]. At 6-10 
months of age there is a trend towards reduced brain-volume and weight in nfkb1-/- mice, a slight 
reduction in NeuN positive cells in the hippocampus and cortex [395]. Increased lipofuscin was 
reported in electron microscopy images, as well as increased TUNEL positive cells, caspase-3 immuno-
staining and ‘dark neurons’, in the hippocampus.  
There are several papers describing cognitive function in nfkb1-/- mice, however, they have been 
performed on young animals at ages between 1.5-4 months. Reduced anxiety related behaviours such 
as defecation and increased exploratory activity has been reported at 2 months (B6,129 background) 
in novel environment tests [396]. However, in 2-3 month old mice on a C57Bl/6 background increased 
anxiety in open-field and light/dark tests has been reported, mediated by corticosterone [397]. 
Further, nfkb1-/- mice showed improved acquisition and memory in the Morris Water Maze; however, 
this is a stressful experiment and nfkb1-/- showed significantly higher corticosterone levels after the 
test which may lead to an increased drive to find the platform [397]. The use of the lower-stress Barnes 
maze in the same paper showed no difference in acquisition or memory at 2-3 months in nfkb1-/- mice 
compared to wild-type controls [397]. Other experiments using the Morris Water Maze have shown a 
slight trend for improved acquisition at 2 months, but reduced memory of the platform location in 
subsequent trials [398], and no differences at 3-4 months [399]. So far these experiments have focused 
on the innate roles of p50 in areas such as neurogenesis [399] or showed links to altered LTP in the 
hippocampus [398], and have not looked in relation to the sterile inflammation and progeria 
phenotype of the mice. 
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3.2 - Overview of Study Plan 
 
To evaluate the effect of nfkb1 knockout and chronic sterile inflammation on cognitive function and 
the senescence-like phenotype, I used several cohorts of C57Bl/6 wild-type and nfkb1-/- mice at 
different time points, with short- and long-term Ibuprofen intervention (Figure 3.2.1A). Wild-type and 
nfkb1-/- (on a C57Bl/6 genetic background) mice were housed in a pathogen-free environment.  
Some wild-type and nfkb1-/- mice were harvested at 3 months of age for tissue analysis (Figure 3.2.1A 
I).  At 6 months of age, wild-type and nfkb1-/- mice had mini-pumps surgically implanted that supplied 
constantly either a vehicle or ibuprofen, replaced every 4 weeks, for 2 months. These mice were then 
harvested at 8 months of age (Figure 3.2.1A II). As mice that were treated with ibuprofen via 
minipumps showed difficulties in wound-closing after implantation and future treatments were 
instead administered by mixing ibuprofen in soaked food placed in the cage (Figure 3.2.1A III-IV). Mice 
were treated with this soaked diet (± ibuprofen) starting at 3 months of age, and used for 
electrophysiological characterisation at 8 months (Figure 3.2.1A III). Long-term ibuprofen in soaked 
food treatment begun at 9 months until the end of the experiment when they were harvested for 
tissues. At 17 months of age spatial memory was tested using the Barnes Maze and mice were then 
harvested after, at 18 months of age (Figure 3.2.1A IV).  
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Figure 3.2.1: Study plan  
A) Shows overview of timelines for treatments and harvest points. AI) Wild-type and nfkb1-/- 
mice were harvested for post-mortem analysis at 3 of age. AII) Wild-type and nfkb1-/- mice 
were surgically implanted with a mini-pump that administered ±ibuprofen at 6 months of age. 
This delivered either vehicle, or Ibuprofen, at a constant rate into the mouse for 2 months 
before the mice were harvested. AIII) Wild-type and nfkb1-/- mice, and nfkb1-/- mice fed with 
±ibuprofen for 5 months, were used for electrophysiology at the age of 8 months. AIV) Wild-
type and nfkb1-/- were treated with soaked diet for 9 months starting at 9 months of age 
containing ±ibuprofen. B) Mice are colour coded (for easy tracking in the following Figures) by 
genotype and treatment, with blue used for untreated wild-type mice and red for nfkb1-/- mice, and 
green for ibuprofen treated wild-types and yellow for ibuprofen treated nfkb1-/- mice. 
A 
B 
II 
I 
III 
IV 
64 
 
3.3 - Ageing nfkb1-/- mice have increased neuro-inflammation  
3.3.1 - Increased inflammatory cytokines in nfkb1-/- brains at 18 months of age, and rescue 
with Ibuprofen 
Neuro-inflammation can be observed in neurodegenerative conditions and has been associated with 
cognitive impairment [400]. However, there appears to be a requirement for ‘priming’ or vulnerability 
and an additional inflammatory insult. In humans aged people experience greater cognitive declines 
than the young following inflammatory insults [94-96]. Systemic and ventricular administration of LPS 
in aged mice leads to deficits in working memory [401][94] and increased expression of pro-
inflammatory genes, such as IL-1B and IL-6 [93]. However, these effects are reduced, or absent, in 
animals that are not already ‘primed’ by either ageing [93] or prion disease [401]. Chronic NF-κB 
activation is known to drive systemic sterile inflammation and ageing [127], but the effects on the 
brain and, if there is a link between this inflammation and cognitive performance, is not entirely 
understood. 
To test whether inflammation also affected the brain of nfkb1-/- mice a cytokine array was performed 
on whole brain homogenate for 5 mice per group at the ages of 8 and 18 months (Figure 3.3.1.1A). 
At 8 months of age, nfkb1-/-  mice did not show significantly elevated levels of cytokines in the brain 
compared to young wild-type mice. Ageing nfkb1-/- mice showed up-regulation across a broad-
spectrum of inflammatory factors in the brain (Figure 3.3.1.1A).  
IL-6 was significantly upregulated in aged nfkb1-/- mice, compared to wild-type controls (Figure 
3.3.1.1B). Ageing nfkb1-/- mice also showed a significant up-regulation of IL-6 between 8 and 18 
months of age, while wild-type mice only showed a trend. Ibuprofen treatment at 18, but not 8 
months, showed a trend for reduced levels, but was still significantly higher than age matched wild-
type controls (Figure 3.3.1.1B). 
RANTES (also known as chemokine C-C motif ligand (CCL) 5, CCL5) was significantly up-regulated in 
ageing nfkb1-/- mice compared to wild-type mice. Again, this also showed a significant up-regulation 
with age in nfkb1-/- mice, but not wild-type mice (Figure 3.3.1.1C). Here there was a significant 
reduction with Ibuprofen treatment in aged nfkb1-/- mice, but not at 8 months. However, the levels 
were still significantly higher than age matched wild-types controls. 
Eotaxin (also known as CCL11) was also significantly higher in ageing nfkb1-/- mice than wild-type 
controls (Figure 3.3.1.1D). Here there was a significant reduction with Ibuprofen treatment in aged 
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nfkb1-/- mice, but only a trend for an increase at 8 months. No change with age was observed in wild-
type mice. 
Monocyte chemoattractant protein-1 (MCP-1), also called CCL2, was significantly higher in ageing 
nfkb1-/- mice than wild-type controls (Figure 3.3.1.1E). Ageing nfkb1-/- mice also showed a significant 
up-regulation of IL-6 between 8 and 18 months of age, while wild-type mice only showed a trend. 
There was a significant increase in 8 month nfkb1 knockout mice treated with ibuprofen compared to 
their untreated litter mates, but a significant reduction at 18 months.  
Macrophage colony-stimulating factor (M-CSF) was significantly upregulated in ageing nfkb1-/- mice, 
compared to age matched wild-type controls and 8 month nfkb1-/- mice (Figure 3.3.1.1F). Ibuprofen 
significantly reduced the levels of M-CSF at 18 months in nfkb1 knockout mice, but had no effect at 8 
months. 
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Figure 3.3.1.1: Nfkb1-/- mice show increased neuro-inflammation with age, ameliorated by 
long-term dietary Ibuprofen treatment 
A) Secreted protein array of inflammatory and SASP related factors obtained from brain 
homogenates at 8 and 18 months of age in wild-type, nfkb1-/- and nfkb1-/- treated with 
Ibuprofen for 2 and 9 months. Extract of data for B) IL-6; C) RANTES; D) Eotaxin; E) MCP-1; F) 
M-CSF. Data are mean of 5 animals per group. Significant differences from One Way Analysis 
of Variance (Holm-Sidak Post-hoc) shown by * <0.05, ** <0.005, *** <0.001. Difference 
between ages within genotypes <0.05 shown by #. 
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3.3.2 - Nfkb1-/- mice show increased density of microglia as well, as 
activation, with age in the hippocampus. 
Given the central role of the hippocampus in spatial learning and memory, and the results of the 
cytokine array, characterisation of microglia was performed in the hippocampus of wild-type and 
nfkb1-/- at 3, 8 and 18 months of age. Microglia were marked using Iba1, a membrane bound calcium 
binding protein that is expressed specifically in microglia in the CNS [402]. 
Microglial are extremely motile and adaptable cells, switching not only their expression of secreted 
factors, but also their morphology and role in response to differing stimuli [103]. Microglia 
continuously monitor their environment, extending and retracting their processes, and physically 
sensing surrounding neurons, glial and vascular cells [403, 404]. Microglia in this state are termed 
‘ramified’ or ‘resting’ microglia and possess a small, oval-shaped, soma and long, branching processes. 
Ramified microglia have direct effects on the cells they contact, such as pruning synapses to aid in 
synaptic plasticity and learning [405]. However, when challenged they shift towards primed and 
activated states. When activated microglia undergo morphological changes, with a swelling of the 
soma and retraction of cellular processes. Microglial processes quickly converge on injured lesions 
[404], and this is accompanied by proliferation towards the site [406]. Normally this should shield the 
injured site and microglia will phagocytose debris, while secreting factors to promote repair of 
damaged cells. However, chronic, or excessive, activation can be harmful, leading to secretion of pro-
inflammatory factors and neuronal damage [406]. Proliferation of microglia can be seen in models of 
neurodegeneration, and when blocked slows disease progression [407]. With age microglia become 
increasingly primed, or ‘reactive’, and shift towards a more inflammatory phenotype [109]. Microglia 
isolated from ageing brains express higher levels of pro-inflammatory cytokines such as IL-6 and IL-1β, 
leading to an amplified response when activated [104].  
Microglia were assessed using Ionised calcium binding adapter molecule, Iba1 (Figure 3.3.2.1A). 
Microglial density differs across the brain, and even in specific sub-structures of the hippocampus, 
with differences in density between areas suggested as a contributor to differential dysfunction 
between areas [408]. As such, the hippocampus was subdivided into 3 areas, with the area and 
number of microglia recorded and used to calculate density. These areas were CA3+CA2 (referred 
henceforth in this chapter as CA3), CA1 and DG, as all have unique roles in memory function and spatial 
processing [409]. For CA3 and CA1, the pyramidal layer and associated stratum were included, and for 
DG, granular, molecular and polymorph layers were included. 
An age dependent increase in microglial density could be observed in nfkb1-/- mice (Figure 3.3.2.1B-
D). At 8 and 18 months the density of microglia in CA3 (Figure 3.3.2.1B) and CA1 (Figure 3.3.2.1D) 
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areas in nfkb1-/- mice was significantly higher than in wild-type mice. In the DG there was again an 
effect with age, but nfkb1-/- mice did not show significantly higher levels until 18 months (Figure 
3.3.2.1D). Long term treatment until 18 months did have a significant effect on microglial density in 
the CA3 and DG, but not CA1, in nfkb1-/- mice, but not wild-type mice.  
Whether this increased density of microglia is accompanied by increased activation of microglia was 
assessed next (Figure 3.3.2.1D). The size of microglial soma can be used as a measure of microglial 
activation, and increases significantly during microglial activation [410]. Due to the high density of Iba1 
positive cells within the CA3+CA2 in nfkb1-/- animals, and its role in encoding spatial memory and 
pattern recognition [52, 55], analysis of soma size was performed here. While significantly increased 
density of microglia had been observed in the CA3 at 8 months of age onwards, there was no 
significant change in microglial activation until 18 months of age (Figure 3.3.2.1D). Untreated nfkb1-/- 
mice showed a significant increase in soma-size, which was ameliorated by treatment with Ibuprofen. 
This suggests that by 18 months, there is activation of microglia that might, at least in part, contribute 
to the observed increased release of inflammatory factors. However, that there is no shift towards 
activation until 18 months in the nfkb1-/- mouse does suggest that there may be another factor that 
accumulates prior to this, and activates microglia. 
70 
 
 
 
A 
C 
D E 
B 
71 
 
Figure 3.3.2.1: Nfkb1-/- mice show increased density of microglia with age and microglial 
activation in the hippocampus. 
A) Representative images of Iba1 staining using NovaRed (Brown) and Haematoxylin (blue) to 
counterstain in wild-type and nfkb1-/- mice at 3, 8 and 18 months, with and without ibuprofen. 
Quantification of iba1 positive cells in wild-type and nfkb1-/- mice at 3, 8 and 18 months, with and 
without Ibuprofen, in the B) CA3m C) CA1 and D) DG. E) Quantification of mean soma size of Iba1 
positive cells in the CA3. 2-way ANOVA (Holm-Sidak) for age and genotype. Treatments are compared 
by two-tailed Mann-Whintey U. Significant differences between genotype, as well as treatments, at 
each age point are displayed by (* p<0.05, ** p<0.005, *** p<0.001), significant difference with age 
by (# p<0.05).  
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3.3.3 - Nfkb1-/- mice show reduced neurogenesis, but no significant differences after 
Ibuprofen treatment 
It has been suggested that adult neurogenesis reinforces the Dentate Gyrus’s role in spatial pattern 
separation between similar stimuli, as required in the Barnes Maze, to effectively differentiate and 
recall the correct information [411]. Additionally, there has been an observed link between 
neurogenesis and factors seen up regulated here, e.g. Eotaxin and MCP-1 (Figure 3.3.1.1), as well as 
in parabiosis experiments between young and old mice [412]. In those experiments the increases in 
cytokines, including Eotaxin and MCP-1, was associated with declining neurogenesis and impairments 
in cognitive function [412]. Injections of Eotaxin were sufficient inhibit neurogenesis and radial arm 
maze performance [412]. 
Doublecortin was used as a marker for neurogenesis, and its modulation by experimental procedure 
[413]. Doublecortin is a microtubule associated protein that marks precursor and immature neurons 
in the dentate gyrus (Figure 3.3.3.1A). It is expressed by dividing neuronal precursors and in neurons 
early in their maturation, with levels declining 7-30 days after neurogenesis, while mature neuronal 
markers such as NeuN become increasing expressed in the same period [414].  
An age dependent decline was found in both wild-type and nfkb1-/- mice (Figure 3.3.3.1B). However, 
nfkb1-/- mice showed decreased levels of neurogenesis compared to wild-type mice. Ibuprofen 
treatment by mini-pump for 2 months had no significant effect at 8 months of age in either wild-type 
or nfkb1-/- mice. At 18 months, 9 months of treatment with Ibuprofen showed a trend for 
improvement, but this was not significant. A negative correlation between density of microglia in the 
dentate gyrus and DCX positive cells was observed (Figure 3.3.3.1C).  
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Figure 3.3.3.1: Assessment of neurogenesis in the brains of wild-type and nfkb1-/- mice at 
3, 8 and 18m, with and without NSAID Ibuprofen treatment 
A) DCX marks immature and precursor neuronal cells, here shown in the Dentate Gyrus stained by 
NovaRed (brown) and counterstained by Haematoxylin in blue. B) Representative images of DCX 
staining in the Dentate Gyrus of wild-type and nfkb1-/- mice at 3, 8 and 18 months, with and without 
ibuprofen. C) Quantification of DCX positive cells per mm of DG blade of wild-type and nfkb1-/- mice 
at 3, 8 and 18 months, with and without Ibuprofen. 2-way ANOVA (Holm-Sidak) for age and genotype. 
Treatments are compared by two-tailed Mann-Whintey U. Significant differences between genotype, 
as well as treatments, at each age point are displayed by (* p<0.05, ** p<0.005, *** p<0.001), 
significant difference with age by (# p<0.05).  D) Correlation between microglial density in the DG and 
DCX positive cells. Significance tested by two-tailed Spearman correlation coefficient (** p<0.005, by 
Gaussian approximation). 
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3.3.4 - Discussion  
Previous work by the lab has shown increased chronic sterile inflammation in the periphery of nfkb1-
/- knockout mice, and that this drives tissue ageing and the onset of age-associated pathologies [127]. 
However, how well this inflammation extends to the CNS with age is not well characterised. We 
hypothesised that increasing neuroinflammation may occur with age in nfkb1-/- mice, and this could 
drive dysfunction in the brain.  
As discussed previously, the loss of the p50 subunit in these mice leads to low-level elevation of 
inflammation from lack of p50:p50 homodimers and loss of the ability to recruit HDAC1 to genes 
containing the κB motif, reducing competition for activating p65 containing dimers [376]. This leads 
to dysregulation of multiple pro-inflammatory genes, including CCL2/MCP-1 and GM-CSF [376]. 
Significant up-regulation of IL-6 can be seen with age in blood plasma in nfkb1-/- mice, compared to 
wild-type mice [127]. While this initially matches wild-type mice at 4.5 months, by 9 months of age 
levels are significantly increased. In the liver at 9 months of age, this is accompanied by increased 
infiltration of immune cells and significant upregulation of mRNA, as well as proteins, in a range of 
inflammatory cytokines, including IL-6, MCP-1, Eotaxin (CCL11) and RANTES (CCL5). In contrast, in the 
whole-brain homogenate at this age-point, only a trend for a mild increase in pro-inflammatory 
cytokines was observed in untreated nfkb1-/- mice. This could be due to protection of the brain from 
passive diffusion of circulating cytokines by the blood-brain barrier (BBB). However, peripheral 
cytokines can stimulate BBB vascular endothelial cells, leading to expression of prostaglandin E 
synthase and COX-2 and promoting pro-inflammatory cytokine release [415]. Many cytokines, 
including IL-1α and IL-1β, IL-6, can be actively transported across the blood brain barrier by a variety 
of transporters [416]. It may be that while circulating plasma levels increase, local production of 
cytokines in these brains is not significantly up-regulated at this time-point. Yet by 18 months, 
upregulation of in a wide-range of pro-inflammatory factors could be seen in the brains of nfkb1-/- 
mice. Many of these cytokines point towards the involvement of microglia.  
Microglia are the resident immune cells in the brain, and they respond to challenge from both the 
periphery and CNS in a variety of ways, releasing bioactive molecules, and promoting both repair and 
degeneration [105]. MCP-1, for example, mediates microglial activation, and a decline in 
neurogenesis, following cranial irradiation [417]. Microglial proliferation and activation was assessed 
primarily in the hippocampus, with differentiation between different sub-fields. The counts in the 
dorsal hippocampus are comparable to those previously published on Iba1 positive cells in young 
mice, once differences in sectioning and counting techniques are considered [408]. Here I found a 
small, but significant increase in the CA3 and CA1 sub-regions of the hippocampus in normally ageing 
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wild-type mice. I found mixed results when searching for existing literature on microglial density in 
C57Bl/6 mice with ageing. Previous reports in C57Bl/6 mice showed a slight trend for increase by 13-
14 months in the CA1, which is similar to what I observed [106]. The trend in the DG here was also not 
significant, which does match their results, and those reported by Mouton et al. in male C57Bl/6 mice 
[107]. It should be noted that both of these studies stained for complement receptor 3, while I used 
Iba1, and different stereological methods were used.  
Nfkb1-/- mice showed an increased density in microglia number compared to wild-type mice, first in 
the CA3 at 3 months, followed by the CA1 at 8 months, and in the DG by 18 months. This could be 
explained by increased proliferation of microglia. Progressive increases in Iba1 positive microglial 
density in the CA1 can be seen in C57Bl/6 mice injected with brain homogenate from two models of 
prion disease (ME7 and 22L) [407]. This increased density likely comes from increased proliferation of 
microglia, as treatment with the cell-cycle inhibitor cytosine arabinoside reduced the number of 
proliferating cells and prevented an increase in the number of microglia. Interestingly, this promoted 
activation of these microglia and increased neuro-degeneration in the CA1 of ME7 treated mice [407]. 
This could reflect the changes seen in nfkb1-/- mice, with microglia proliferating in response to damage 
and inflammatory signals at earlier ages, but not becoming activated at this stage. The increased 
density in the prion model mice above was regulated by colony-stimulating factor-1 receptor, 
activating the transcription factors PU.1 and C/EBPa [407]. This receptor is activated by M-CSF/CSF1, 
which contains an NF-κB consensus element in its promotor. M-CSF was significantly upregulated in 
nfkb1-/- mice, and like microglia levels, downregulated with ibuprofen treatment. Altered nfkb1-/- 
signalling could promote the transcription of this and promote the microglial proliferation.  
However, this was also not upregulated till 18 months and increased density was seen prior to this. In 
line with the inflammatory cytokine arrays, microglia in CA3 of nfkb1-/- mice showed a significant 
increase in activation or priming, as measured by soma hypertrophy, at 18 months of age, but not 
before. While in normal ageing, as discussed above, the total number of microglia does not appear to 
increase, priming and inflammatory cytokine release does [109]. This is accompanied by expression of 
major histocompatibility complex class II molecules and receptors such as complement receptor 3 and 
retraction of dentritic processes as measured by Iba1 [109]; with ~25% of microglia from ageing 
BALB/c mice (18-20 months) being MHC II positive, compared to <3% in young adult BALB/c mice as 
measured by flow-cytometry (3-4 months) [418]. The increased priming or activation seen in nfkb1-/- 
mice could represent an acceleration of age-associated changes, and may explain the increased 
release of cytokines seen at this point; as microglia from aged mice brains exhibit greater basal levels 
of cytokine release, and while the fold change in expression in response to stimuli such as LPS remains 
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the same, this leads to a sum increase in pro-inflammatory cytokine release, together with difficulty 
switching to a less inflammatory state [104, 109]. 
nfkb1-/- microglia also appear to have an altered response to inflammatory insult to nfkb1+/+ microglia, 
but this regulation is complex. Work from Rolova et al. suggests that in vitro microglia cultured from 
nfkb1-/- knockout mice show an altered response to LPS, with reduced levels of IL-6, MCP-1 and IL-10 
[419]. This is surprising, given that loss of p50 can be thought of in relation to the loss of NF-κB 
inhibition by the p50:p50 homo-dimer, and since p50 mediates the binding of transcriptional repressor 
histone deacetylase-1 to MCP-1 [376]. Instead, the loss of the ability to form the p65:p50 dimer 
appears to result in a loss in the capacity to respond directly to LPS via canonical NF-κB signalling, and 
decreased production of IL-6 and MCP-1 is seen compared to nfkb1+/+ microglia [419]. Yet, in vivo, 
injection of LPS in the periphery induces a pro-inflammatory microglial phenotype in nkfb1-/- mice, 
with an increase in inflammatory cytokine production [419].  
Rolova et al. suggest that while loss of p50 in microglia naturally shifts their phenotype from M1 to 
M2 in response to LPS due to alterations of canonical NF-κB signalling, a secondary pro-oxidative or 
pro-inflammatory stimuli from another source triggers an increased pro-inflammatory response in 
vivo. This can be seen in the case of LPS injection, where it was attributed to the increased infiltration 
of neutrophils, and their production of ROS, triggering the release of TNFα and IL-6 via the JNK 
pathway and preventing the shift to an M2 state [419]. However, the same increase in pro-
inflammatory response was reported when nfkb1-/- mice were crossed with APP-transgenic AD mice, 
but no increased neutrophil infiltration was reported, leaving the interacting cell that promotes pro-
inflammatory activation of microglia in nfkb1-/- unknown [419]. 
Work from Taetzsch et al.provides additional evidence [420]. They also reported an increased and 
longer lasting pro-inflammatory cytokine response following (this time peripheral, not central) LPS 
injection, together with increased M1 microglial morphology. This was reduced with treatment with 
the radical scavenger 5,5-Dimethyl-1-Pyrroline-N-Oxide, supporting the role of ROS in mediating 
microglial activation in nfkb1-/- mice. In contrast to Rolova et al., using cultured microglia from nfkb1-
/- mice, they reported an increased and longer lasting pro-inflammatory cytokine release compared to 
nfkb1+/+ microglia. The main difference that I can find here is that when harvested, these are actually 
mixed astrocyte/microglia cultures, and while Rolova et al. separated microglia from this culture, 
Taetzsch et al. does not. Increased astrocytosis has been observed in nfkb1-/- mice by 11 months of 
age [421], and this additionally implicates astrocytes as a potential source of ROS that trigger 
prolonged M1 activation in nfkb1-/- microglia. 
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Given that the increases in microglial density in nfkb1-/- mice occurred first in the CA3, and were then 
followed by other areas of the hippocampus at later time-points, it is possible that there is localised 
cytokine signalling that cannot be detected at the whole brain level. Neurons in the CA3 are vulnerable 
to age-related changes such as hyper-excitability [39, 68], and this could trigger, possibly initially 
protective, localised microglial proliferation. Neurons can provide an activating stimuli to microglia 
through factors such as M-CSF and MCP-1, following focal brain injury [422] and impaired oxidative 
metabolism [423], these are initially produced by neurons and trigger the initial microglial activation 
and proliferation. Additionally, localised increased microglial proliferation and priming can be seen 
due to DNA damage accumulation from DNA damage repair deficiencies in specific populations of 
neurons [424]. As such, there are multiple potential initial triggers that might lead to sustained in vivo 
activation of microglia in nfkb1-/- mice. 
I observed a decrease in both pro-inflammatory cytokines, microglia proliferation and hypertrophy, 
with long-term dietary ibuprofen (a COX inhibitor) treatment at 18 months in nfkb1-/- mice. Which 
could suggest that these increases in nfkb1-/- mice occur, at least partially, through COX mediated 
pathways. There are a number of potential explanations for how COX-2 activity and inhibition could 
mediate the observed changes. The decreased microglia activation could be accounted for by reduced 
systemic inflammation, infiltration of immune cells and inflammatory cytokines, as decreased 
infiltration of CD3+ cells has been observed in the liver of 8 month nfkb1-/- mice with 2 months 
Ibuprofen treatment [127]. Additionally, inhibition of COX (1 and/or 2) by ibuprofen in BBB vascular 
endothelial cells, may reduce the generation of prostaglandins stimulated by systemic inflammation, 
that stimulates inflammatory signalling in the brain [415].  
Ibuprofen also appears to be blood brain barrier permeable [425], and could have a direct effect on 
microglia, as well as cells that may trigger their activation, such as astrocytes and neurons. Activated 
microglia show increased COX-2 expression through NF-κB signalling [426]. However, Taetzsch et al. 
reported (although did not show the data) no effect on COX-2 expression in nfkb1-/- mixed glia culture 
compared to nfkb1+/+ mixed glia culture, or in BV2 microglia treated with nfkb1 siRNA [420]. This could 
suggest that the effects are not mediated by an intrinsic effect of altered NF-κB signalling on COX-2 
levels in microglia in nfkb1-/- mice. However, ibuprofen could still directly target microglia, as ibuprofen 
can induce S-phase cell-cycle arrest and apoptosis of microglia in vitro in BV2 microglia [427]. Which 
would explain the reduced cytokine release, and proliferation and activation of microglia in 18 month 
ibuprofen treated nfkb1-/- mice. 
Increased COX-2 activity has also been reported in astrocytic gliosis [428]. Ibuprofen treatment has 
shown reduced astrocyte activation in Dementia with Lewy-bodies transgenic mice [428]. Reduced 
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astrocyte activation could reduce the triggering of microglial activation, given that their presence, and 
the production of ROS, was required for activation of nfkb1-/- microglia in culture [419, 420]. 
Additionally, there may be changes in COX-2 expression in neurons as a result of altered NF-κB 
signalling. While COX-2 has a physiological role in neurons [429], increased COX-2 activity has 
neurotoxic effects and can be seen early in neurodegenerative diseases, such as Alzheimer’s [333, 
380] and in normal ageing [380], and is associated with NF-κB DNA binding to the COX-2 promotor 
[380]. Neuronal COX-2 is an NF-κB target gene, and p65 and COX-2 can be seen in vivo in neurons, 
with suppression of both by aspirin [377]. COX-2 promotor activity in in vitro neuroblastoma cell lines 
is dependent on NF-κB, and COX-2 is strongly upregulated by NF-κB inducing stimuli [377]. Loss of p50 
could potentially lead to persistent upregulation of COX-2 activity in neurons, which ibuprofen may 
reduce. However, it should be noted that p50 was also active together with p65, and it is uncertain 
how the loss of this sub-unit would affect COX-2 activity in neurons. In mitotic cells nfkb1-/- knockdown 
appears to promote NF-κB activation of COX-2 and the production of ROS [127]. The same could be 
happening in neuronal and astrocyte cells here with COX-2 activity promoting ROS generation and 
triggering microglial activation in untreated nfkb1-/- mice, and with a reduction in ibuprofen treated 
nfkb1-/- mice. 
However, in the brains of 8 month mice, nfkb1-/- treated with Ibuprofen for 2 months by mini-pump 
there was an trend for increase in levels of IL-6, Eotaxin, IL-2, IL-9, and a significant increase in MCP-
1, with but no significant effect on microglial parameters. The exact cause for this is unclear; however, 
Ibuprofen treatment in the mini-pump treated animals (both wild-type and nfkb1-/-) did lead to 
problems with surgical wound healing, and re-opening of the wounds. In mice infected with Vibrio 
vulnificus, ibuprofen treatment has been reported to lead to increased levels of IL-6, IL1β, TNF-α and 
MIP-2 [430]. While the mice are in low pathogen conditions, it was not quarantine level, and an open 
wound around the pump may have contributed to infection or increased sterile inflammation. 
Analysis of neurogenesis was also performed in these mice. Upregulation of Eotaxin and MCP-1  has 
been reported by Wyss-Coray’s research group in their parabiosis studies of young and old mice [412]. 
They identified a number of factors, including Eotaxin and MCP-1, that were elevated in normal old 
mice, and young mice that had been joined to an old-mouse via parabiosis surgery. Eotaxin was the 
most strongly upregulated of these factors and was also found to increase with age in the 
cerebrospinal fluid of humans. Young mice show impairments in learning during radial arm water maze 
testing after injection with eotaxin [412]. This was linked to altered neurogenesis and as such I 
measured the numbers of DCX positive cells in the DG.  
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In nfkb1-/- mice I found a down-regulation of DCX positive cells compared to wild-type mice. There was 
also an association between DCX and microglia numbers in the DG, when all groups were pooled, as 
has previously been observed in ageing wild-type mice [431]. However, although there were trends, 
the number of DCX positive cells in the DG was not significantly ameliorated by long-term ibuprofen 
treatment in nfkb1-/- mice, despite reduced levels of MCP-1 and Eotaxin. This may be explained by 
intrinsic effects of nfkb1-/- on neurogenesis that are not related to inflammation [399]; it has previously 
been observed in young nfkb1-/- mice that while there is no change in the net rate of neural precursor 
cell proliferation in the hippocampus sub-granular zone, there is a reduction in the number of 
immature neurons that survive to maturity [399]. Further, experiments on IkB/tTA NF-κB repressor 
mice (a neuron-specific ablation of all NF-κB subunits through increased IκB-α attached to a neuronal 
promotor), showed a decrease in successful integration of the immature neurons [432]. As DCX marks 
both immature neurons and precursor cells; the numbers may come primarily from reduced survival 
of immature cells, due to an intrinsic increase in vulnerability.  
Together this suggests that nfkb1-/- do show an increasing neuro-inflammatory profile with ageing. 
Increased proliferation of microglia can be seen in the hippocampus, but it is worth bearing in mind 
that microglia can also be protective and this may reflect a response to damage. However, by 18 
months microglial hypertrophy and a significant upregulation of numerous pro-inflammatory 
cytokines can be seen. This was ameliorated by long-term dietary treatment with ibuprofen. This may 
not come directly from the effects of nfkb1-/- and altered NF-κB signalling on microglia, as these appear 
to show a decreased basal response, but through a secondary ROS or inflammation mediated insult 
and a defect in microglia switching from M1 to M2 activation states. Neurogenesis was significantly 
lower than in wild-type mice. These alterations may be due to microglia and inflammation, but since 
this was not significantly ameliorated by ibuprofen, may also reflect an intrinsic vulnerability of newly 
generate neurons in nfkb1-/- mice. Both neuroinflammation, and neurogenesis have been linked to the 
onset of age-associated cognitive deficits, and as such, these were assessed in the next sub-chapter.  
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3.4 - Nfkb1-/- mice show deficits in spatial discrimination and memory 
3.4.1 - Nfkb1-/- mice show significant deficits in novel arm discrimination in Y-maze, 
rescued by Ibuprofen at 6 months of age 
Alternation tasks, such as the Y-maze, use the propensity of rodents to explore novel environments, 
and allow the testing of their working memory [433]. Here a forced-alternation testing paradigm was 
used, with the mouse placed in the home arm of the Y-maze, with one arm blocked and one arm open 
(Figure 3.4.1.1A). The mouse was allowed to explore for 10 minutes and then returned to the home 
cage. One hour later, the mouse was placed into the home arm of the Y-maze again for 2 minutes 
(Figure 3.4.1.1A). If mice remember the maze properly, they should choose the novel arm to enter, 
and show a preference for exploration of this arm. 
Wild-type mice at 6 and 10 months of age showed a strong preference for the novel arm (forced 
alternation), with 89% and 80% of mice entering it as they’re first choice, respectively (Figure 
3.4.1.1B). Nfkb1-/- mice showed no clear preference for the novel arm during the trial, with mice 
entering the novel arm first only 50% of the time (Figure 3.4.1.1B). Nfkb1-/- mice treated with 
ibuprofen in soaked food for 2 months entered the novel arm more, at 80% of choices. Nfkb1-/- mice 
also showed significantly increased latency to enter the novel arm compared to wild-type controls, 
with no change seen between 6 and 10 months in wild-type mice (Figure 3.4.1.1C). Ibuprofen treated 
nfkb1-/- mice showed a trend for reduced primary latency, being closer to wild-type values (Figure 
3.4.1.1C). 
The arm discrimination index is the time spent in the novel arm, divided by time spent in both novel 
and familiar arms (Figure 3.4.1.1D). Nfkb1-/- mice scored a significantly lower discrimination index 
score than age-matched wild-type control mice. Nfkb1-/- mice treated with Ibuprofen had a 
significantly higher arm discrimination index score than their untreated litter-mates. 
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Figure 3.4.1.1: Nfkb1-/- mice show reduced spatial discrimination and memory in forced 
alternation Y-maze 
A) Mice were given a training session in Y-maze with one arm-closed, and one- open. 60 minutes later, 
a retrieval trial was conducted and multiple parameters recorded: B) Pie chart showing the choice of 
arm first entered by each genotype. C) Time taken to reach novel arm. D) Arm Discrimination Index 
for the first 2 minutes. E) Arm Discrimination index after 5 minutes. Graphs are mean+/-SEM (n = 4-
18 mice). Significant differences from One Way Analysis of Variance (Holm-Sidak Post-hoc) shown by 
*<0.05; ** <0.005; *** <0.001. 
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3.4.2 – Nfkb1-/- mice show deficits in long-term spatial memory in the Barnes Maze at 7 
months 
3.4.2.1 - At 7 months Nfkb1-/- mice show no significant deficits in spatial learning in the 
Barnes Maze 
 
The Barnes maze [36] is a dry-land test for the assessment of spatial learning and memory. While 
initially designed for use in rat models, the small size of mice and their ability to fit through smaller 
holes make the test well suited for the use in mice [361, 434-436]. Spatial memory in the Barnes Maze 
is dependent on hippocampal functioning and mice with damage to this region perform worse [434, 
437]. As a dry-land test, and unlike water-based mazes, it does not involve the strong aversive stimuli 
to water and constant exertion from paddling. It instead relies on an aversion to bright light and open 
spaces, and is considered to be a lower stress alternative to the Morris water maze [438, 439]. While 
mice may be more inclined to further exploration or passive behaviour, here the Barnes Maze was 
considered a better choice due to the potential confounding effects of differing stress and anxiety 
response of nfkb1-/- mice compared to wild-types that has been observed in the MWM [397]. 
Additionally, given the age and frailty of the mice tested, with nfbk1-/- mice near the end of their typical 
life-span, the use of a dry-land test should minimise stress and suffering to the animals while reducing 
confounding factors from muscle-strength.  
The method mice use to locate the target hole can be categorised into 3 different groups. The mouse 
can move directly to the target hole or adjacent hole and this is termed a ‘Direct’ search pattern. When 
mice reach the holes or edge of the maze, they will frequently check a hole, then the next, and repeat 
this search until they reach the target hole. This is termed a ‘Serial’ search. Additionally the mouse 
may employ a random search pattern, employing a mix of serial searches and crossing the centre of 
the board and this is termed a ‘Mixed’ search pattern (Figure 3.4.2.1A). 
 
Wild-type and nfkb1-/- mice showed a decline in the use of mixed search strategies across training, in 
favour of direct or serial search patterns (Figure 3.4.2.1B). Nfkb1-/- mice employed less mixed search 
strategies on the first day, but after this there was little difference. Wild-type and nfkb1-/- mice both 
showed a corresponding increase in the use of direct searches across training. Treatment of nfkb1-/-
mice with ibuprofen showed a similar use of strategies to un-treated mice on days 1, 2 and 4, but large 
use of direct searches on day 3.  
 
By day 4, there was no significant difference between wild-type and nfkb1-/-  mice in the number of 
incorrect searches prior to finding the target hole (Figure 3.4.2.1C), or in the time taken to find the 
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target hole (Figure 3.4.2.1D). nfkb1-/- mice showed a trend for finding the target hole quicker during 
the first day than wild-types. nfkb1-/- mice treated with ibuprofen did not show a significantly altered 
primary latency on days 2-4 compared to untreated littermates, but showed a trend for reduced errors 
on day one, and increased errors on day 4.  
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Figure 3.4.2.1: Performance during training days in 7 month old wild-type and nfkb1-/- mice 
A) Visual depictions of search strategies, showing an example mouse’s path for each search strategy. 
Direct (Black) search pattern is classified as the mouse having moved either directly to the target hole, 
or an adjacent hole. Serial (Green) is classified as having searched two or more holes in a serial pattern 
before finding the target hole. Mixed (Yellow) employs seemingly random searching, with serial and 
direct searches and having crossed the centre of the maze one or more times. B) Shows the average 
percentage of each strategy used across the training batteries (4 tests per day) on the 4 training days 
for nfkb1-/- (± ibuprofen) and wild-type C57Bl/6. The average number of incorrect holes searched (C) 
and time taken (D) before finding the target (escape) hole. 
A 
B 
C D 
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3.4.2.2 - At 7 months nfkb1-/- mice show deficits in long-term memory in the Barnes Maze 
 
After 4 days of training had been completed with the escape box in place, two further 90 second trials 
were conducted without the escape box, one on day 5, and another a week later on day 12. More 
detailed analysis of the search was performed on these trials. Errors, time taken and search strategy 
to initially find the target hole are still recorded (Figure 3.4.2.2.1). No significant difference was found 
in the number of primary errors, or latency (Figure 3.4.2.2.1A-B). A decreased frequency of direct 
searches was used by untreated nfkb1-/- mice during the long-term memory trial, this was rescued 
with Ibuprofen treatment (Figure 3.4.2.2.1C). 
During the short-term memory test (Figure 3.4.2.2.2A), wild-type mice directed their search primarily 
at the target hole and the adjacent holes, with some further exploration of the board. nfkb1-/- mice’s 
search was not significantly lower at the target and adjacent hole compared to wild-type mice, but did 
show more searches at off-target markers (present at -5, +5 and ±10 positions) (Figure 3.4.2.2.2A). 
nfkb1-/- mice treated with Ibuprofen showed no significant differences to untreated nfkb1-/- mice 
(Figure 3.4.2.2.2A). 
Only wild-type mice showed no significant decrease in preference for the target and adjacent hole in 
the long-term memory tests (Figure 3.4.2.2.2A); however, nfkb1-/- mice performed significantly worse 
than wild-types, although the decrease compared to the short-term test was not significant. Ibuprofen 
treated nfkb1-/- mice did not perform significantly better than untreated mice. 
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Figure 3.4.2.2.1: Performance during of short- and long-term memory tests in 7 month old 
wild-type and nfkb1-/- mice 
Graphs are showing A) the average number of errors prior to finding the target hole, B) the average 
time taken to find the target hole and C) the choice of search strategy employed by each group. 
Graphs are mean+/-SEM (n = 4-6 mice). No significant differences found by 2-way RM ANOVA for 
primary errors or latency.  
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Figure 3.4.2.2.2: Search distribution during short and long-term memory tests in the 
Barnes Maze at 7 months in wild-type and nfkb1-/- mice  
The head-pokes into each hole of the Barnes maze were recorded during the short- and long-term 
memory retention tests for each mouse. From this the percentage of the total head-pokes in each 
hole was determined to give the search distribution (Bars and whiskers show average mean + SEM). 
A-B) The graphs show number of searches per hole for wild-type and nfkb1-/- mice, un-treated and 
treated with Ibuprofen. The target hole is located at position 0, with each of the additional 19 holes 
around the board marked numerically relative to the target hole. As such positions -10 and +10 are 
the same hole, being opposite to position 0. Dotted line shows the expected 5% for each hole if the 
search was random. A) Shows search distribution during short-term memory and B) shows the search 
distribution during long-term memory testing. Graphs are mean+/-SEM (n = 8-24 mice) 2-way RM 
ANOVA. * p<0.05 between genotype in vehicle treated, or treatment within genotype. 
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3.4.3 – Nfkb1-/- mice show deficits in short- and long-term spatial memory in the Barnes 
Maze at 18 months 
3.4.3.1 - Chronic inflammation alters use of spatial search strategy, but had no effect on 
errors made in 18 month old nfkb1-/- mice during training days 
 
Wild-type and nfkb1-/- mice showed a decline in the use of mixed search strategies across training, in 
favour of direct or serial search patterns (Figure 3.4.3.1.1A). This decrease was more pronounced in 
the wild-type mice, and mixed searching remained more common in the nfkb1-/-mice, still at 
approximately 30% of searches by the end of the training period. Wild-type mice showed a 
corresponding increase in the use of direct searches across training, while nfkb1-/- mice showed no 
improvement in this regard, with the change instead being due to increased use of serial searches. 
Treatment of nfkb1-/- mice with the NSAID Ibuprofen lead to a closer phenocopying of the wild-type 
mice in the use of mixed searches, and a greater incidence of direct search patterns. In this cohort, an 
additional wild-type treated with Ibuprofen was used. In wild-type mice, treatment with Ibuprofen did 
not effect the decline in mixed searches, but lead to a seeming decline in the use of direct searches, 
with none observed at all on day 3. 
 
However, while trends in the search pattern could be observed, there was little difference in the 
number of incorrect searches prior to finding the target hole (Figure 3.4.3.1.1B), or in the time taken 
to find the target hole (Figure 3.4.3.1.1C). nfkb1-/- mice were significantly faster in finding the target 
hole during the first day than wild-types, while those that were treated with Ibuprofen were not 
significantly different to untreated wild-type mice.  
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Figure 3.4.3.1.1: Performance during training days in 18 months old wild-type and nfkb1-/- 
mice, with and without ibuprofen 
A) Visual depictions of search strategies, showing an example mouse’s path for each search strategy. 
Direct (Black) search pattern is classified as the mouse having moved either directly to the target hole, 
or an adjacent hole. Serial (Green) is classified as having searched two or more holes in a serial pattern 
before finding the target hole. Mixed (Yellow) employs seemingly random searching, with serial and 
direct searches and having crossed the centre of the maze one or more times. B) Average percentage 
of each strategy used across the training batteries (4 tests per day) on the 4 training days for nfkb1-/- 
and wild-type C57Bl/6, with and without Ibuprofen treatment. The average number of incorrect holes 
searched (C) and time taken (D) before finding the target (escape) hole. Graphs are mean+/-SEM (n = 
8-24 mice) 2-way RM ANOVA. p-values shown by # (p<0.05) between short- and long-term memory, 
(** p<0.01) between genotype in vehicle treated, or treatment within genotype. 
A 
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3.4.3.2 - Chronic inflammation impacts short- and long-term spatial memory in 18 month 
nfkb1-/- mice 
 
During the short-term memory test on day 5 nfkb1-/- mice made significantly more errors prior (Figure 
3.4.3.2.1A) and took significantly longer to find the target hole compared to wild-type mice (Figure 
3.4.3.2.1B). Ibuprofen treatment appeared to worsen the performance of the wild-type mice making 
more errors and taking significantly longer to find the target. Ibuprofen treated nfkb1-/- mice were not 
significantly different in the short-term test in these parameters to un-treated mice. During the long-
term memory test untreated wild-type mice made significantly more errors and took longer to find 
the target hole than they did in the short-term memory test (Figure 3.4.3.2.1A-B). Ibuprofen treated 
nfkb1-/- mice made fewer errors than untreated nfkb1-/- mice during the long-term search. 
In choice of strategy, 50% of wild-type mice employed a direct search strategy, with only 12.5% using 
mixed search strategies (Figure 3.4.3.2.1C). nfkb1-/- employed less direct spatial searches and an 
increased use of mixed searches. Ibuprofen treatment seemed to have opposite effects depending on 
genotype, with treated wild-type mice making fewer direct, and more mixed searches. Treated nfkb1-
/- mice employed more direct searches and less mixed searches than their untreated littermates. 
During the long-term test, use of search strategy was similar amongst untreated nfkb1-/- and treated 
and untreated wild-types. In the long-term test, ibuprofen treated nfkb1-/- used predominantly direct 
searches, and no mixed searches. 
Since the escape box is removed after the initial training days, mice cannot exit the maze, they 
continue to search, frequently coming back to the target hole. One can track the distribution of this 
search around the maze to give further indication of how well the mice remember the position of the 
target hole (Figure 3.4.3.2.2). This is performed by recording how many times the mouse poked its 
head into, or deflected its head over, each hole. To account for the seemingly altered locomotive 
speed, anxiety of the nfkb1-/- mice, the percentage of total searches around the board is displayed, 
rather than the raw number. If the search pattern was random, each hole would be expected to be 
visited 5% of the time. 
During the short-term memory test (Figure 3.4.3.2.2A), wild-type mice directed their search primarily 
at the target hole and the adjacent holes, with some further exploration of the board. nfkb1-/- mice’s 
search pattern was more evenly distributed, with less head pokes at the target hole or adjacent holes 
than wild-type mice, indicating a decreased recall of the location of the target hole. nfkb1-/- mice 
treated with Ibuprofen showed significant improvement in recall for the target hole, with a search 
pattern close to wild-type mice. Ibuprofen treatment in wild-type mice, however, decreased the 
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number of head-pokes in the target hole and they showed a search pattern resembling those of nfkb1-
/- mice.  
Only wild-type mice showed a significant decrease in percentage of search at the target hole during 
the long-term memory tests (Figure 3.4.3.2.2B), but still performed significantly better than nfkb1-/- 
mice. Wild-type mice treated with Ibuprofen, interestingly, were not significantly different to the un-
treated wild-type mice. Additionally, Ibuprofen treated nfkb1-/- mice again performed better than 
untreated males, with a profile closer to wild-type mice.  
A visual comparison, showing the results in Figure 3.4.2.2.2 and Figure 3.4.3.2.2 super-imposed onto 
the Barnes maze, is shown in Figure 3.4.3.2.3. Wild-type mice showed no change in short-term 
memory (Figure 3.4.3.2.3A) between these ages, but a reduction in preference for the target and 
adjacent hole in long-term memory trial by 18 months (Figure 3.4.3.2.3B). Nfkb1-/- had reduced, but 
still somewhat intact short-term memory at this age, but this was reduced by 18 months (Figure 
3.4.3.2.3A). Long-term memory preference was close to random (5% of search at each hole) in both 
ages in untreated nfkb1-/- mice (Figure 3.4.3.2.3B). 
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Figure 3.4.3.2.1: Performance during of short- and long-term memory tests in 18 months 
old wild-type and nfkb1-/- mice, with and without ibuprofen 
Graphs are showing A) the average number of errors prior to finding the target hole, B) the average 
time taken to find the target hole and C) the choice of search strategy employed by each group. Graphs 
are mean+/-SEM (n = 8-24 mice) 2-way RM ANOVA. p-values shown by # (p<0.05) between short- and 
long-term memory, (* p<0.05, ** p<0.01, ***<0.001) between genotype in vehicle treated, or 
treatment within genotype.  
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Figure 3.4.3.2.2: Search distribution during short and long-term memory tests in the Barnes 
maze in 18 month old wild-type and nfkb1-/- mice, with and without ibuprofen 
The head-pokes into each hole were recorded during the short- and long-term memory retention tests 
for each mouse. From this the percentage of the total head-pokes in each hole was determined to give 
the search distribution (Bars and whiskers show average mean + SEM). A-B) The graphs show number 
of searches per hole for wild-type and nfkb1-/- mice, un-treated and treated with Ibuprofen. The target 
hole is located at position 0, with each of the additional 19 holes around the board marked numerically 
relative to this. As such positions -10 and +10 are the same hole, being opposite to position 0. Dotted 
line shows the expected 5% for each hole if the search was random. A) The graph shows the search 
distribution during short-term memory and B) the search distribution during long-term memory. 
Graphs are mean+/-SEM (n = 8-24 mice) 2-way RM ANOVA. p-values shown by # (p<0.05) between 
short- and long-term memory, (* p<0.05, ** p<0.01) between genotype in vehicle treated, or 
treatment within genotype. 
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Figure 3.4.3.2.3: Visual comparison of Barnes Maze search distribution at 7 and 18 months 
of age in wild-type and nfkb1-/- mice 
Visual representation of distribution of search around Barnes Maze in short- and long-term memory 
proves in 7 and 18 month mice (A and B, respectively). Target hole is displayed at top of each 
distribution graph and coloured green. Dotted line around centre represents 5% demarcation, which 
would be expected for a completely random search. Since there is a visual marker at 0, 90, 180 and 
270° positions, mis-targeted searches can be seen, especially in nfkb1-/- mice. Significance or error 
bars are omitted for clarity, but available in previous representations. 
A 
B 
99 
 
3.4.4 - Discussion 
We hypothesized that increased neuro-inflammation with age would lead to cognitive deficits in the 
nfkb1-/- mouse. To test spatial memory, I used two different tests of spatial memory, the Y-maze and 
the Barnes Maze. The Y-maze was used at 6 months, and the Barnes maze at 7 and 18 months. 
Previous research on nfkb1-/- mice has been performed at young ages, between 1.5 and 4 months of 
age, with contradicting results for in vivo cognitive function and memory [392, 396-399]. These studies 
have so far focused on the intrinsic roles of the loss of p50 in NF-κB activity, but and have not focused 
on the potential role of inflammation and ageing.  
I found reduced memory function in the Y-maze in nfkb1-/- mice at 6 months of age compared to wild-
type mice. The Y-maze (Forced alternation) has been previously used by Denis-Donini et al. to assess 
cognitive function in younger 3-4 month nfkb1-/- mice [399]. However, they used multiple memory 
tests, at 20, 30 and 40 minutes after acquisition. In Denis-Donini et al.’s study, nfkb1-/- mice initially 
showed no difference to wild-type mice when tested 20 minutes after the acquisition phase, with both 
showing increased entry into the novel arm compared to the other two arms. At 30 minutes, wild-
type mice still showed a preference for the novel arm, but nfkb1-/- did not. Neither group showed a 
preference at the 40 minute time point. I tested 6 month nfkb1-/- mice 1 hour after acquisition, and 
found a reduced discrimination index scoring for the novel arm and increased primary latency in nfkb1-
/- mice compared to wild-type mice. This suggests that nfkb1-/- mice show a significant deficit in 
retention of spatial memory compared to wild-type mice at an early age.  
However, it appears that Denis-Donini et al. tested the same mice at 20, 30 and 40 minutes [399]. This 
is perhaps closer to a re-training paradigm, given that wild-type mice also showed no preference in 
the 40 minute trial, while I found a distinct preference when tested 1 hour after. This could be affected 
by alterations in exploratory activity and learning rather than purely memory. Increased exploratory 
behaviour has been reported in 2 month old nfkb1-/- mice compared to wild-types by Kassed et al. 
[396]. Additionally, nfkb1-/- mice have shown some indication of improvements in the acquisition 
phase of the Morris water maze at 2-3 months [397, 398] that might lead to earlier switch to an 
alternating search pattern. Due to the different protocols, additional testing would be required to 
determine from what age nfkb1-/- start to show a deficit.  
I found improvements during training in untreated nfkb1-/- mice during the Barnes Maze at 7 months 
of age. Nfkb1-/- mice showed increased use of direct searches and took less time to find the target hole 
compared to wild-type mice. At 18 months, nfkb1-/- mice still showed reduced latency on the first day 
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of training compared not only to wild-type mice, but also ibuprofen treated nfkb1-/- mice. A possible 
explanation could be increased anxiety leading to the mouse to want to exit the maze faster. While 
Lehmann et al. showed increased anxiety in open field and light/dark tests in in 2-3 month nfkb1-/- 
mice, they found no difference during the acquisition phase of the Barnes Maze, in contrast to my 
results here [397]. Additionally, work by Kassed et al. showed decreased defecation and freezing 
during novel environment tests, and increased exploratory behaviour, which would suggest reduced 
anxiety [396]. Yet, during the Y- and Barnes maze, I noted a trend for increased solid defecation in 
nfkb1-/- mice compared to wild-type mice and urination, which was rarely seen with wild-type mice. 
This could represent an age-related change in anxiety, but may also be due to different genetic 
backgrounds, housing conditions and experimental conditions such as light intensity. 
Despite decreases in primary latency in untreated nfkb1-/- mice at 18 months, I found a decreased use 
of direct searches. This suggests that they do have difficulty in remembering the exact location of the 
target hole. A possible explanation for the decreased latency would be that they move faster. This 
could be a product of their mass. By 18 months nfkb1-/- mice had significantly lower body weights 
compared to wild-type mice (data not shown). nfkb1-/- mice treated with ibuprofen showed a trend 
for increased body weight and did not show the same decreased primary latency. Velocity has 
previously been reported in the Morris water maze in nfkb1-/- mice, but with contradictory results, 
with 2 month mice showing a generally slower speed [398], but 11 month mice showing an increased 
swim speed [421]. However, this is in water, which may counter obesity driven changes.  
Retention of spatial memory in the Barnes maze was tested 24 hours after acquisition (short-term) 
and 7 days after acquisition (long-term). Lehmann et al. have previously reported no differences 
between wild-type and nfkb1-/- mice in short-term memory at 2-3 months of age [397]. At 7 months, I 
observed a trend for reduced short-term memory and observed a significant deficit in long-term 
memory (which had not been tested in the protocol used by Lehmann et al.). By 18 months, nfkb1-/- 
mice showed a significant deficit in both short- and long-term spatial memory. In contrast, wild-type 
mice showed no age-related deterioration in short-term memory performance with age, but did show 
a decline in long-term memory. Together, this suggests that nfkb1-/- mice undergo an age-dependent 
decline in short-term spatial memory.  
It should be noted that there were differences in the maze used here and by Lehmann et al.  (100cm 
diameter compared to 92cm here; 21 holes, compared to 20 here; 5 minute trial and 2 minutes in the 
target box, compared to 3 minutes and 1 minute here) [397]. Training protocol in their experiments 
was 4 trials per day for 5 days, compared to 4 trials per day for 4 days here. Additionally, their short-
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term probe was conducted 3 hours after the final training trial, while I conducted it 24 hours after the 
final training trial. As such, the protocol I used may be somewhat more sensitive to detecting changes 
in spatial memory as it provided less training, with a longer delay. 
Spatial memory 24 hours after acquisition has also been reported in nfkb1-/- mice using the Morris 
water maze, by Denis-Donini et al. [399] and Oikawa et al. [398] (although this was termed ‘long-term’ 
in the papers). Denis-Donini et al.’s protocol used 1 training task per day, across 10 days, in 3-4 month 
nfkb1-/- mice [399]. This is a less vigorous training pattern than employed in the Barnes Maze, but the 
target platform can be located visually and no difference was seen between wild-type and nfkb1-/- 
mice. This suggests that both visual acuity and target-cued memory was not affected at this age. When 
the platform was removed and mice were tested, both nfkb1-/- and wild-type mice showed a 
preference for previous platform location and there was no difference between genotypes. This would 
lend support for this type of spatial memory being unaltered at this age, as observed in the Barnes 
Maze at 2-3 months by Lehmann et al. [397].  
Oikawa et al. used younger 2 month old nfkb1-/- mice and in contrast showed decreased retention of 
spatial memory [398]. In Oikawa et al.’s Morris water maze protocol, mice were tested for 4 trials a 
day, for 7 days, the retention of this spatial memory was again tested by removing the platform and 
recording the search. However, this was not a single memory trial 24 hours after, but instead a block 
of 3 days (24, 48 and 72 hours after acquisition), with 4 no-platform trials per day. In this block trial 
approach, nfkb1-/- mice performed significantly worse than wild-type mice on the first day of testing 
without the platform. Yet, they showed no difference on the next two days. This could represent that 
both strains are capable of recognising that the platform is no longer there, and an attempt to find a 
new position, as searches at the target location on the last two days were below the time that would 
be expected by chance. 
Long-term spatial memory (tested 7 days after acquisition) has not, to my knowledge, been previously 
assessed using the Barnes maze in nfkb1-/- mice. Interestingly, preference for the target hole was 
significantly impaired in nfkb1-/- mice at both 7 and 18 months of age. Two possible explanations would 
be; that there is an age-dependent change affecting spatial memory before 7 months of age; or, that 
there is an intrinsic deficit in nfkb1-/- mice. Testing wild-type and nfkb1-/- mice at an earlier age would 
be required to determine if the deficit observed in the Barnes maze long-term memory test was age-
dependent effect, or an intrinsic feature of the model. 
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One possible explanation for the observed deficits in spatial memory would be a deficit in LTP. Oikawa 
et al. investigated LTP in isolated hippocampal slices from young 2 month nfkb1-/- mice [398]. They 
found that while LTP can be reliably induced in both nfkb1-/- and wild-type mice by high frequency 
stimulation; 3 hours post-stimulation there is significantly reduced late-LTP in nfkb1-/- slices. This could 
explain the decreased performance in the long-term memory test I performed in the Barnes Maze, 
with nfkb1-/- mice having difficulty properly reinforcing or retrieving spatial memory over long periods. 
This defect may be due to an intrinsic effect of the loss of p50 and p65:p50 dimers. Inhibition of NF-κ 
B’s DNA binding capacity, with kB decoy DNA, has previously been shown to reduce LTP magnitude 
[440]. Additionally, blockade of IKK/NF-κB signalling reduces levels of post-synaptic proteins and 
mature spine numbers and appears to rely on p65 [441]. p65 is densely located at dendritic spines  
[442] and the loss of p50 could reduce the ability of neurons to respond appropriately to stimulation 
via p65:p50 signalling, reducing the ability to alter gene expression and protein synthesis required to 
reinforce late-LTP [368] 
The reductions in neurogenesis reported in the last chapter may have an effect, as these were reduced 
already by 3 months of age. A relationship between decreased neurogenesis, and reduced spatial 
memory and pattern separation has previously been suggested [411]. However, at 18 months while 
performance in the Barnes Maze was improved with ibuprofen in nfkb1-/-, there was not a significant 
change in DCX positive cell numbers. Clelland et al. found a significant deficit in spatial discrimination 
with complete ablation of neurogenesis [411]. However, here the reduction in neurogenesis measured 
by DCX is less severe, at a 24-33% reduction in median values in nfkb1-/- mice compared to wild-type 
mice, depending on age. Additionally, there is still disagreement over the exact contribution of adult 
neurogenesis in rodent brains [411, 412, 443], and how much adult neurogenesis contributes towards 
spatial pattern separation has been brought into doubt in recent years [443]. Groves et al. prevented 
neurogenesis through Ganciclovir treatment, but found that this did not lead to any significant 
differences in pattern separation, or fear conditioning [443]. Meta-analysis by the same group failed 
to find a significant relation between adult neurogenesis, and spatial memory, or anxiety [443]. As 
such, the reductions in DCX positive cells in the DG observed in nfkb1-/- mice do not appear to fully 
explain the observed deficits in spatial memory. 
The increasing neuroinflammation observed earlier in the chapter may account for the observed 
decreases in spatial memory with age. Neuroinflammation can have a significant effect on memory 
function [92, 93], and even transient inflammatory events can induce long-term defects in spatial 
memory performance, with even more pronounced effects in AD transgenic mouse models [444]. Arm 
discrimination was restored to wild-type levels by a 3 month dietary ibuprofen treatment at 6 months 
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of age in nfkb1-/- mice. While there was no significant effect in Barnes maze performance at this age, 
long term dietary treatment with ibuprofen at 18 months did show an improvement compared to 
untreated nfkb1-/- mice. This treatment also ameliorated the levels of inflammatory cytokines, and 
microglial proliferation and activation. IL-6 was one of the cytokines that showed upregulation by 18 
months in untreated nfkb1-/- mice, and was reduced in ibuprofen treated nfkb1-/- mice. IL-6 appears 
important in mediating changes within spatial memory and LTP, even in basal conditions [445]. IL-6 
also appears to be required to trigger the increased production of cytokines in the hippocampus and 
deficits in spatial memory induced by peripheral inflammation [446]. Chronic activation of microglia 
may also damage neurons and could contribute to hippocampal damage [447].  
One point of interest was a decrease in short-term memory in 18 month wild-type mice treated with 
Ibuprofen. While NSAID use has been associated with a reduced risk of developing neurodegenerative 
conditions, untreated wild-type mice showed little age-associated change in spatial memory by this 
point. COX-2 has additional and direct roles in normal cognitive function that may explain the observed 
deficit in wild-type mice treated with Ibuprofen. COX-2 is expressed in the cell-bodies and dendrites 
of neuronal populations (both typically post-synaptic areas), including pyramidal and dentate gyrus 
cells in the hippocampus and Purkinje cells in the cerebellum [448, 449]. This activity is dependent on 
excitatory activity and has been linked to a role in the modulation of synaptic plasticity and spatial 
learning, through the release of brain-derived neurotrophic factor [331, 450]. In rats, treatment with 
Ibuprofen does not appear to affect non-hippocampal learning tasks, such as the visible target tests, 
or properties of baseline synaptic transmission, but does have an effect on hippocampus dependent 
tasks and the induction of LTP [450]. This appears to be specific to COX-2, as specific inhibitors, such 
as NS-398 and celecoxib, increase latency to target and impair the consolidation and retention of 
spatial memory in the Morris Water Maze [429, 451]. This is consistent with the deficits in 
performance in the Barnes maze observed in ibuprofen treated wild-type mice. 
Together, this data suggests that nfkb1-/- mice show deficits in spatial memory that can be rescued by 
ibuprofen treatment, as tested by the Y-maze at 7 months and Barnes maze at 18 months. Untreated 
nfkb1-/- mice show increasing deficits in spatial memory with age, compared to wild-type mice, as 
assessed by Barnes maze. The observed differences in spatial memory following ibuprofen treatment 
in nfkb1-/- mice would imply that inflammation, or a NF-κB-COX-2 mediated pathway, is contributing 
to the observed cognitive deficits. 
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3.5 - Nfkb1-/- mice show deficits in the power and synchronicity of gamma 
frequency neuronal oscillations in isolated hippocampus. 
3.5.1 - Gamma frequency oscillations in the hippocampus 
Neuronal oscillations are rhythmic changes in neuronal activity and occur at the level of individual 
neurons and in the synchronous firing of arrays of neurons [452]. Neuronal network oscillations are 
seen throughout the entire mammalian brain and can bind the activity of arrays of neurons, often 
between multiple brain areas and hemispheres [453, 454].  This allows the coordination of activity in 
a manner dependent on network connectivity, rather than physical proximity, and enables proper 
cognitive function [453, 454].  
Oscillations can be divided into broad categories by frequency, varying substantially from the slower 
delta (<4Hz), theta (4-12Hz) ranges into the higher gamma frequencies (20-80Hz). While these are 
found across much of the brain, including the hippocampus, their exact frequencies, mechanism and 
behavioural correlates vary [455]. Due to their differing frequencies, oscillations can be nested within 
each other, allowing for the handling of multiple neuronal arrays and the control of input from 
different brain areas [456].  
In the hippocampus there are multiple oscillations present, with theta frequency (5-12Hz) and gamma 
frequency oscillations (20-80Hz) being particularly prominent [457, 458]. Multiple aspects of spatial 
information can be represented by a specific code of gamma-frequency sub-cycles, created by the 
firing of different neurons depending on the phase of the overall theta cycle [457]. These gamma-
frequency oscillations contribute to memory formation, with an increase seen dependent on memory 
load [454, 459].  
Gamma oscillations can be generated in the DG, and CA1-3 regions of the hippocampus. The CA3 can 
act internally as a slow gamma (~40Hz in vivo) oscillation generator [460]. Oscillations in CA3 can be 
generated through the interaction of the two main populations of neurons in the hippocampus [460]. 
Principal neurons are slow-firing (1-3Hz) excitatory glutamatergic pyramidal cells and form the 
majority of cells in the hippocampus. In the CA3 region, pyramidal cells receive input from the mossy-
fibres of the DG and project into CA1 and sub-cortical regions. Faster-firing (~40Hz) inhibitory 
GABAergic interneurons form another population of neurons. These have a widespread axonal plexus 
and can inhibit multiple neurons in synchrony. These neurons are heavily interconnected through 
synapses and gap junctions, which allows for synchronous excitatory and inhibitory bursts throughout 
the local circuit [364, 461].  A cycle of excitation and inhibition between these pyramidal cells and the 
interneurons helps to generate gamma-frequency oscillations [462]. The gamma-cycle begins with the 
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pyramidal cells firing, exciting GABAergic interneurons which act by feed-forward inhibition to inhibit 
the pyramidal cells. No longer stimulated by the pyramidal cells, the inhibitory input from the 
interneurons declines and a fresh cycle can begin, this leads to a phase-locked firing pattern in the 
gamma frequency [463].  
Gamma frequency firing of CA3 pyramidal neurons projecting to the CA1 can excite inhibitory 
interneurons in this region [460, 464]. These interneurons then control the firing of CA1 pyramidal 
neurons through feed-forward inhibition [464]. This entrains the firing of the CA1 subfield to the CA3, 
propagating a synchronous gamma-frequency oscillation to the CA1 [464]. The firing of the CA3 assists 
in the rapid acquisition of novel spatial information, pattern separation of similar spatial information, 
and the retrieval of information from place cells [54] [55] [52]. In ‘normal’ ageing the CA3, unlike the 
CA1, undergoes a number of changes in excitatory properties and their ability to adjust firing to novel 
environments [39, 68]. Similarly, in ageing C57Bl/6 mice reductions in gamma oscillations can be 
observed in the in vitro hippocampus by 16 months of age [465, 466]. Further, alterations to gamma 
oscillations can be seen in multiple neurological disorders, reductions in neurodegenerative conditions 
such as Alzheimer’s disease, and is believed to play a significant role in the characteristics of these 
diseases [465, 467]. 
3.5.2 - Nfkb1-/- mice show significant deficits in the generation of Carbachol-induced 
gamma frequency oscillations in CA3 of the hippocampus 
Neuronal oscillations can be measured by monitoring changes in the electrical field potential in the 
brain. When neuro-transmitters, such as glutamate, are released at a synapse, positive ions can move 
into the dendrite leaving a negative extracellular space (Sink). These currents can move along the 
dendrite, and the ions exit again creating a positive extra-cellular space (Source), creating an electrical 
field between the sink and source. These were originally recorded via electroencephalogram, with 
electrodes attached to a subject’s head that can detect this electrical potential through the scalp. 
However, this will only be seen if enough neurons are firing in together in phase as individual impulses 
would otherwise cancel each other out when summed together. More direct and sensitive 
measurements can be performed by inserting electrodes directly into brain tissue and measuring the 
local field-potential in specific areas.  
During the first hour after bath administration of Carbachol to the slices, a gradual increase in the 
power of the oscillations can be observed and after 75 minutes, the slices begin to approach their 
eventual stable values (Figure 3.5.2.1A). Nfkb1-/- slices do not show the same degree of increase 
compared to slices from wild-type animals, and the area power of these oscillations diverged 
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significantly by 75 minutes and remained significantly different until the stable time-point. There was 
a large degree of variability in power between slices, which increased with the oscillation power after 
Carbachol administration. nfkb1-/- mice treated with Ibuprofen showed a trend for stronger gamma 
oscillations, with gamma power typically falling between the values for wild-type and untreated nfkb1-
/- slices, and were not significantly different to wild-type slices until 120 minutes after Carbachol 
administration, where variability decreased as oscillations stabilised. Once slices had stabilised, wild-
type slices had significantly higher median area powers than slices from untreated nfkb1-/- (Figure 
3.5.2.1B). Slices from wild-type mice showed higher variability, with some area powers up to 8µV2. 
The area power of slices from ibuprofen treated nfkb1-/- mice fell between wild-type and untreated 
nfkb1-/- slices, but was still significantly lower than wild-type values. 
The maximum amplitude of the oscillations followed the same pattern as area power, but with more 
variability. A significant deficit became apparent after 120 minutes in nfkb1-/- mice (Figure 3.5.2.2A). 
nfkb1-/- mice treated with Ibuprofen showed a trend for a rescue in oscillation amplitude and area-
power, with values falling between wild-type and untreated nfkb1-/- mice, although it was not 
significantly different to either during the 180 minutes after Carbachol administration. However, given 
the number of animals and range of potential values (between untreated nfkb1-/- mice and the wild-
type level they might be restored to) this is not surprising. At the stable time-point, slices from 
untreated nfkb1-/- mice had significantly lower amplitude values than wild-type mice (Figure 3.5.2.2B). 
Slices from ibuprofen treated nfkb1-/- mice showed a trend for increased oscillation amplitude, but 
was still significantly lower than slices from wild-type mice. 
However, in contrast, the frequency of oscillations (once they could be observed) started in the 
gamma frequency range (15-45Hz), and remained stable across 180 minutes post-Carbachol 
administration, with most values falling between 20 to 30 Hz (Figure 3.5.2.3A). There was no 
significant differences between genotype or in Ibuprofen treated animals during the 180 minutes post-
Carbachol administration, or at the stable time-point (Figure 3.5.2.3B).  
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Figure 3.5.2.1: Nfkb1-/- mice show significantly reduced gamma-frequency oscillation area 
power in extracellular field recordings from CA3 stratum radiatum in isolated 
hippocampal slices  
A) Oscillation area power at baseline, after rest for 1 hour, then for 3 hours post-Carbachol bath 
administration for wild-type, nfkb1-/- mice, and nfkb1-/- mice with Ibuprofen. B) Oscillation area power 
at stable time-point in wild-type, nfkb1-/- mice, and nfkb1-/- mice with Ibuprofen. n is hippocampal 
slices, with 4-5 animals per group and 3-6 slices per animal. Outliers are shown. 2-way Repeated 
Measures ANOVA without interactions was performed on the build-up, p-values shown by * <0.05, ** 
<0.005, *** <0.001. Performed with Clare Tweedy, performing brain removal and electrode 
placement, and advice from Fiona LeBeau. 
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Figure 3.5.2.2: Nfkb1-/- mice show significantly reduced gamma-frequency oscillation 
maximum amplitude from extracellular field recordings from CA3 stratum radiatum in 
isolated hippocampal slices 
A) Oscillation area power at baseline, after rest for 1 hour, then for 3 hours post-Carbachol bath 
administration for wild-type, nfkb1-/- mice, and nfkb1-/- mice with Ibuprofen. B) Oscillation area power 
at stable time-point in wild-type, nfkb1-/- mice, and nfkb1-/- mice with Ibuprofen. n is hippocampal 
slices, with 4-5 animals per group and 3-6 slices per animal. Outliers are shown. 2-way Repeated 
Measures ANOVA without interactions was performed on the build-up, p-values shown by * <0.05, ** 
<0.005, *** <0.001.  
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Figure 3.5.2.3: No significant differences between wild-type and nfkb1-/- mice in gamma-
frequency oscillation frequency from extracellular field recordings from CA3 stratum 
radiatum in isolated hippocampal slices 
A) Oscillation frequency at baseline, after rest for 1 hour, then for 3 hours post-Carbachol bath 
administration. B) Oscillation frequency at stable time-point. n is hippocampal slices, with 4-5 animals 
per group and 3-6 slices per animal. Outliers are shown. 2-way Repeated Measures ANOVA without 
interactions was performed on the build-up, no significant differences found.  
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3.5.3 - Nfkb1-/- show significant deficits in the rhythmicity of Carbachol-induced gamma 
frequency oscillations in the hippocampus 
 
The generation of gamma frequency oscillations relies on a delicate circuit between pyramidal and 
interneurons and requires the precise timing of firing to generate a cohesive and stable oscillation. As 
the data suggests that there are impairments in the generation of gamma frequency oscillations in the 
CA3 stratum radiatum of nfkb1-/- mice, the rhythmicity of these oscillations was also recorded. This 
should provide a measure of how stable the gamma frequency oscillation generated by the circuit is, 
and how well it communicates these oscillations to the CA1. 
Auto-correlations of recordings from stable-time point recordings in CA3 stratum radiatum were taken 
in wild-type, nfkb1-/- mice and ibuprofen treated nfkb1-/- mice (Figure 3.5.3.1A). A visual 
representation of representative normalised auto-correlations from wild-type, untreated nfkb1-/- and 
ibuprofen treated nfkb1-/- slices can be seen in (Figure 3.5.3.1A), with a greater degree of correlation 
in wild-type slices than nfkb1-/- slices, shown by the size of the peaks. These were recorded and 
analysed from traces taken from both the stratum radiatum (Figure 3.5.3.1B) and stratum pyramidale 
(Figure 3.5.3.1C). 
Gamma frequency oscillations in the stratum radiatum of wild-type slices showed high rhythmicity 
index scores, indicating a stable gamma frequency oscillation is being generated (Figure 3.5.3.1D). 
Nfkb1-/- slices show a significant reduction in the rhythmicity of gamma frequency oscillations 
compared to wild-type slices, while there was a trend for improvement in ibuprofen treated nfkb1-/- 
slices, with the median rhythmicity index falling between the median of wild-type and nfkb1-/- slice 
values. 
In contrast, the rhythmicity of recordings taken from the pyramidal layer showed no differences in the 
median rhythmicity index between wild-type or nfkb1-/- slices, and no significant effect with ibuprofen 
treatment, although an increase in variability can be observed in nfkb1-/- slices (Figure 3.5.3.1E).  
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Figure 3.5.2.1: Nfkb1-/- show reduced gamma oscillation synchronicity in CA3 stratum 
radiatum 
A) Representative auto-correlations of gamma oscillations recorded CA3 stratum radiatum of wild-
type, nfkb1-/- and nfkb1-/- mice treated with Ibuprofen. Schematic diagrams of electrode placement in 
slices for the recording of LFPs in B) the stratum radiatum and C) the statum pyramidale. Normalised 
rhythmicity of gamma frequency oscillations in D) CA3 stratum radiatum and E) CA3 stratum 
pyramidale of wild-type, nfkb1-/- and nfkb1-/- mice treated with Ibuprofen. n is hippocampal slices, 13-
24 slices per group. Outliers are shown. 2-way ANOVA without interactions. Significant differences 
between genotype, as well as treatments, are displayed by (* p<0.05).   
A 
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3.5.4 - Nfkb1-/- mice show significant deficits in the propagation of synchronous signal 
between CA3 and CA1 
 
As previously described, gamma oscillations generated in the CA3 propagate the oscillation to the CA1 
stratum radiatum via the schaffer collateral [460, 464]. This entrains the firing of the CA1 subfield to 
the CA3; this communication is important for the rapid formation of spatial memories and especially 
the retrieval of  previously stored spatial information based on spatial cues  [52, 54, 55, 409]. 
To measure the propagation of gamma oscillations from CA3 to CA1, a second electrode was placed 
in the CA1 stratum radiatum distal to the CA3 once the slices had stabilised. If a gamma oscillation 
could be detected in this region, then slice was deemed to be propagating properly, if not the CA1 
electrode was moved to a medial position. If an oscillations was still not evident then the electrode 
was moved again to a more proximal position.  
In wild-type mice 92% of slices showed gamma frequency oscillations in the distal portion of the CA1 
stratum radiatum, with the remaining 8% showing an oscillation once the electrode was moved to the 
medial portion, demonstrating normal projection of gamma activity from the CA3 to the CA1 (Figure 
3.5.4.1A). However, only 75% of untreated nfkb1-/- slices showed oscillations in the distal region of 
CA1, a further 17% showed a gamma frequency oscillation in the medial proportion, and 8% showed 
no oscillations in any position of the CA1; demonstrating an impaired ability to project gamma activity 
from CA3 to CA1. In ibuprofen treated nfkb1-/- slices, 79% of slices showed an oscillation in the distal 
CA1, and 14% when moved to the medial position, and the remaining 7% only when moved to the 
proximal position. However, all slices propagated to at least one position in the CA1, showing an 
improvement in the propagation of gamma activity from CA3 to CA1. 
Cross-correlations compare two simultaneous recordings, one in CA3 against one in CA1, in the same 
way that at auto-correlation compares the rhythmicity of a recording against itself. This provides a 
measure of the synchronicity of the oscillations between CA3 and CA1 and provide insight into how 
well the CA3 entrains the firing of CA1. Wild-type slices showed a strong level of synchronicity between 
CA3 and CA1 in the stratum radiatum, signifying that the oscillation in CA1 is well entrained to CA3 
(Figure 3.5.4.1B). However, nfkb1-/- slices showed a significant reduction in rhythmicity between the 
oscillations in CA3 and in CA1 stratum radiatum compared to wild-type controls. Ibuprofen treated 
nfkb1-/- slices showed a significant improvement compared to untreated nfkb1-/- slices, and were not 
significantly different to wild-type controls. However, when the electrodes were moved to stratum 
pyramidale of these respective areas, no significant differences were between the groups could be 
observed (Figure 3.5.4.1C). Seven of the nfkb1-/- mice used in the Y-maze were used in the 
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electrophysiology experiments, a correlation could be observed between their arm discrimination 
index in the first two minutes of the trial and the average CA3-CA1 cross correlation rhythmicity index 
from slices taken from that animal (Figure 3.5.4.1D). A trend for decreased latency to the primary arm 
with increasing CA3-CA1 cross-correlation , and a higher values in animals that made the correct 
primary arm choice could also be observed, but were not significant (Figure 3.5.4.1E-F, respectively).   
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Figure 3.5.4.1:  Nfkb1-/- mice show reduced propagation of gamma oscillations to CA1 
stratum radiatum  
A) Placement of electrodes to measure presence of gamma oscillations in distal, medial and proximal 
portions of CA1 stratum radiatum of wild-type, nfkb1-/-, and nfkb1-/- mice treated with ibuprofen. Pie 
charts show proportion of slices propagating into CA1, with distal recorded, then if there is no 
oscillation, medial and then for proximal if still no oscillation. A lower proportion of nfkb1-/- mice had 
oscillations present in the distal portion, with some showing no oscillation in CA1. B) Cross-correlations 
of oscillations recorded in CA3, and distal CA1 stratum radiatum, if the slice is oscillating at this point. 
C) Measurements of cross-correlations in CA3 and distal CA1 stratum pyramidale. 2-way ANOVA 
without interactions, p-values shown by * <0.05. D-F) Mice were tracked and their performance in the 
Y-maze correlated with the average cross-correlation of slices taken from the animal between CA3 
and CA1. Spearman correlation, significance is shown by *<0.05.  
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3.5.5 - Nfkb1-/- mice show spontaneous hyper-excitable bursting in CA3 of the 
hippocampus 
Network hyper-excitablity can be observed in seizure and neurodegenerative disease such as AD. 
These are bursts of activity from sharp-wave ripples and burst discharges that cause a sudden 
depolarisation in the LFP. Sharp wave and burst discharges (henceforth termed ‘Hyper-excitable 
events’) were recorded from 60s epochs as events which exceeded 5x the Standard Deviation of the 
entire 60s epoch (Figure 3.5.3.1A-B). They were recorded at Baseline+1 hour time point, where the 
slices had been allowed to rest in the rigs, 15 minutes post-Carbachol administration when gamma 
oscillations were beginning to occur in some slices and once oscillations had stabilised (Figure 
3.5.3.1C). 
Spontaneous hyper-excitable events could be observed in slices from both wild-type and nfkb1-/- mice 
prior to Carbachol administration (Figure 3.5.5.1C). Nfkb1-/- mice showed significantly more hyper-
excitable events prior to Carbachol administration compared to wild-type controls. In slices from 
ibuprofen treated nfkb1-/- mice, there was a trend for a decrease in the median number of events per 
slice, with the value closer to wild-type slices and this was not significantly different to either group. 
Carbachol administration should reduce the number of hyper-excitable events was reduced following 
Carbachol administration in all groups as gamma oscillations formed, but showed a trend for increased 
number of events in slices from untreated nfkb1-/- mice. 
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Figure 3.5.3.1: Nfkb1-/- slices show increased number of hyperexcitable events 
Example A) 5 seconds and B) 200ms extracts taken from representative 60s epochs at Base-line + 1 
hour time-point. C) show number of spontaneous discharges at baseline+1 hour recording (pre-
Carbacohol administration), 15 minutes after Carbachol and at stable timepoint. Box-plots showing 
number of hyper-exictable discharges from 16-24 slices per group, pooled from 4-5 animals. Outliers 
are shown. 2-way Repeated Measures ANOVA without interactions was performed on base-line +1, 
15 min post-Carbachol and stable time-point, p-values shown by * <0.05.  
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3.5.6 – Discussion 
I had previously observed increased microglial presence and activation in the hippocampus region, 
reduced neurogenesis, as well as alterations in the neuro-inflammatory profile of cytokines associated 
with hippocampal dysfunction. Additionally, I observed deficits in performance in the Y-maze and 
Barnes Maze of nfkb1-/- mice, measures of spatial learning and memory [433]. To investigate if there 
was an alteration in hippocampal function in nfkb1-/- mice that would explain the observed deficits in 
spatial memory, I tested gamma frequency oscillations in isolated hippocampal slices. Deficits in 
gamma-frequency oscillations can be observed with normal ageing, as well as multiple neurological 
disorders, such as Alzheimer’s disease, where it is believed to underlie some of the cognitive deficits 
observed [465-467]. 
The data here show that there is an impairment in the build-up, power and amplitude of Carbachol-
induced gamma-frequency oscillations generated in the CA3 of nfkb1-/- mice, compared to age-
matched wild-type controls. In ageing C57Bl/6 mice reductions in the power of gamma oscillations can 
be observed in the in vitro hippocampus by 16 months of age, compared to younger wild-type animals 
[465, 466]. The defects in the build-up of the oscillation after Carbachol are similar to what is observed 
in older wild-type mice, as well as neurodegenerative models [465]. I also observed a small, but 
significant decrease in the rhythmicity of gamma-frequency oscillations within the stratum radiatum 
of CA3 in nfkb1-/- mice, with a trend for a partial rescue of activity in ibuprofen treated mice. Decreases 
in neuronal synchrony, especially in the gamma frequency range, can be observed in brain disorders 
and diseases such as Alzheimer’s [468]. In normal ageing, only slight reductions in the cross-correlation 
within CA3 can be observed [466], and, while significant, the decrease in auto-correlation in CA3 
observed here was not large in nfkb1-/- mice.  
The gamma oscillation deficits in nfkb1-/- mice may reflect the premature ageing phenotype observed 
in the mouse as a whole occurring in the neuronal circuit, or neurodegenerative changes. Since the 
generation of gamma oscillations requires the precise timing of synchronous firing from arrays of 
pyramidal neurons and interneurons, it is vulnerable to disruptions within this circuit. The percentage 
decrease observed in Carbachol-induced gamma frequency power, in nfkb1-/- mice compared to wild-
type control mice, is similar to that previously observed between 5 month and 22 month wild-type 
mice [466]. Which suggests that if this is acceleration of an age-related decline, then nfkb1-/- mice are 
match wild-type mice at this age-range [466]. Additionally, this is backed up by the lack of a significant 
change in the peak frequency of the gamma oscillations was observed, which is in line with results 
from normally ageing mice [466].  
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However, since these readings were taken at a single time-point it cannot be totally ruled out that 
these are deficits specific to the model and not an accelerated age-dependent change. Slices from 
nfk1b-/- mice treated with ibuprofen showed a trend for improved oscillation build up, with no 
significant difference to slices from wild-type control mice in the build-up of gamma oscillations until 
later in the build-up. However, these trends were not significant compared to their untreated nfkb1-/- 
littermates. The lack of significance may be explained by the large variability in results, and a 
comparatively narrow window between nfkb1-/- and wild-type mice, as it would likely not be a 
complete rescue of the phenotype. 
Nfkb1-/- mice showed a significant deficit in propagation of gamma activity from CA3 to CA1 compared 
to wild-type mice, which was ameliorated with ibuprofen treatment. This may reflect an impairment 
in the Schaffer collaterals, which run from CA3 to CA1. Computational models and hippocampal lesions 
have shown that CA3-CA1 communication is important for the retrieval of memory in hippocampal-
dependent tasks [469]([470]. These studies propose CA3 pyramidal neurons act as an auto-associative 
network to store new memories, and retrieve memories from CA1, when presented with limited cue 
information [469]([54, 470]. Increased CA3-CA1 gamma synchrony in local field potentials can be seen 
at the point of arm-choice in delayed alternation continuous T-maze [52], which suggests that CA3-
CA1 gamma synchrony is involved in the retrieval of information about the previous trial. Gamma 
synchrony between areas appears to also be necessary across the circuit, high synchrony can be 
observed in the CA3, CA3 to CA1 and a burst of high CA1-entorhinal cortex synchrony can be observed 
in various T-maze setups, just prior to the correct choice of arm, but not before an incorrect arm choice 
[52, 471, 472].  
The defects observed here, especially in CA3-CA1 gamma synchrony, in nfkb1-/- mice would explain 
their reduced preference for the novel-arm in the Y-maze, and might represent CA3 dysfunction and 
a failure to entrain CA1 firing to recall the correct arm. Furthermore, ibuprofen treatment improved 
both of these parameters in nfkb1-/- mice, more closely matching wild-type mice. When compared to 
the performance of nfkb1-/- mice in the Y-maze, there was a degree of correlation between average 
CA3-CA1 stratum radiatum cross-correlation and arm discrimination index, additionally the mice who 
made failed to enter the Y-maze arm correctly the first time showed a trend for lower average cross-
correlation, which observation is in line with the existing evidence and models. There was no 
observable correlation with auto-correlative capacity. This would suggest that, at least in this model, 
chronic inflammation is linked to decreased CA3-CA1 communication. This could be due to deficits in 
the Schaffer collateral and its ability to entrain CA1 firing, such as reduced synapse or collateral 
density, which may explain deficits in the retrieval of previous learnt spatial information. 
123 
 
The deficits in oscillation power, and reduced rhythmicity of oscillations in nfkb1-/- slices suggests that 
there are abnormalities within the circuit that generates slow-gamma oscillations. There are number 
of possible explanations for the observed defects in gamma oscillations. Phenotypic changes to 
constituent cells within the circuit, as well as loss of cells, could explain the observed deficits. As 
gamma frequency oscillations require the precise firing of excitatory pyramidal cells and inhibitory 
interneurons, disruptions to this balance can result in deficits in gamma oscillations. 
Gamma oscillations are driven by the firing of parvalbumin positive GABAergic interneurons, which 
inhibit the soma of excitatory pyramidal cells [473]. Parvalbumin is a calcium binding protein 
expressed on a sub-population of GABAergic interneuron [474]; these calcium proteins are vital for 
calcium buffering, the correct firing of these neurons [475] and the generation of gamma oscillations 
[473]. There are reductions in the number of cells positive for these interneuron markers, including 
parvalbumin, in the hippocampus with age and disease (although the relative decreases vary between 
region and the CA3 sees only mild decreases in positive cells) [476-478]. However, normally ageing 
wild-type mice show well preserved neuron numbers in the hippocampus, even in mice with cognitive 
impairment, and little change in pyramidal cell number [31, 58, 59]. Instead the decline in parvalbumin 
positive neurons appears to be driven by phenotypic change rather than cell loss, with reductions in 
the expression of parvalbumin, leading to a reduction in pre-synaptic calcium buffering capacity and 
reduced GABA release, which may directly contribute to the observed changes in gamma oscillations 
[479-481].  
The death of neurons in the circuit could also contribute to the decreased area power. Loss of neurons 
in the CA3 can be seen in neurodegenerative diseases such as AD [482], although deficits in gamma 
oscillations appear to occur earlier in disease pathology [465]. Within the nfkb1-/- mouse some 
alterations in hippocampal number have been previously reported. Lu et al. reported with no 
differences at 6 months, and an approximately 10% reduction hippocampal NeuN positive cells at 10 
months, and activated caspase-3 at both ages [395] However, these numbers were reported from the 
whole hippocampus, with randomly selected fields within the hippocampus, so it is not clear if this is 
region specific degeneration or not. Additionally, a 20% reduction in CA2 neurons has been reported 
in male nfkb1-/- mice at 11 months [421]. A reduced number of neurons contributing to the gamma 
oscillation could explain the reduced area power of the oscillations. Future experiments on the 
number of parvalbumin positive cells and expression, along with other neuronal markers, would help 
ascertain if there is a specific vulnerabilities that would disrupt the gamma generating circuit. 
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Interestingly, I observed network hyper-excitability in 8 month nfkb1-/- mice, which could be due to 
reduced inhibitory input from interneurons. CA3 neurons show increased basal rates of firing with 
normal ageing [39, 68], and deficits in their capacity to respond to novel environments [39]. Hyper-
excitability has also been linked to a decrease in pattern separation [69], and treatment with anti-
epileptic drugs (which reduce hyper-excitability) help improve cognition [71]. This could also 
contribute to the observed deficits in spatial memory. Hippocampal neurons from nfkb1-/- mice show 
increased vulnerability to excitotoxic injury following glutamate exposure, and show increased 
oxidative stress, which could promote loss of neurons [393]. However, the ‘hyper-excitable events’ I 
recorded here were in the local field potential, and can be generated by defects in both interneurons 
and pyramidal cells. Intracellular recordings of inhibitory and excitatory post-synaptic potentials 
would be required to ascertain the relative contributions of these cell types. 
The firing of neurons and the generation of a network gamma frequency oscillations is also a highly 
energy intensive task [483]. It is associated with high rates oxygen consumption and alterations in 
redox state, and oscillations are vulnerable to disruption if there is a loss of energy supply or 
mitochondrial dysfunction [483]. Deficits in gamma oscillations can be seen with mitochondrial 
dysfunction, redox dysregulation and oxidative stress [484-486]. In mice with decreased glutathione 
expression, increased oxidative stress can be seen selectively in the CA3 and DG of the hippocampus, 
accompanied by impairment of Parvalbumin interneurons and deficits in gamma oscillations [485]. 
However, work I performed in my Master’s thesis on whole brain homogenate from nfkb1-/- mice aged 
9 to 10 months did not show a significant change in mitochondrial metabolism, however, although 
there was a slight trend for superoxide production from complex I. However, this was from whole 
brain homogenate and does not rule out the possibility that there could be changes in mitochondrial 
function at an individual cell level, or in specific areas, that would contribute towards the observed 
deficits in gamma oscillation.  
The observed deficits in gamma oscillations in nfkb1-/-mice outlined above could be due to the 
increased neuro-inflammation. Nfkb1-/- treated with ibuprofen showed a trend for improved 
performance in gamma oscillation generation and significant improvements in CA3-CA1 synchrony. 
Chronic inflammation has been shown to impair long-term potentiation in CA1 pyramidal neurons 
induced by input to the schaffer collaterals [102], which could explain the deficits in propagation of 
the gamma frequency oscillation in nfkb1-/- mice. As discussed previously, increased IL-6 levels are 
associated with cognitive dysfunction in a number of conditions. A trend for increased IL-6 at 8 months 
could be seen in whole brain homogenate from nfkb1-/- mice, and a significant increase can be seen in 
aged nfkb1-/-mice; additionally, significantly increased circulating levels of IL-6 have been reported in 
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nfkb1-/- mice at this age [127].  IL-6 can modulate glutamatergic neuro-transmission [487] and appears 
to mediate age-related loss of parvalbumin GABAergic interneurons in the hippocampus, through 
increased NADPH oxidase super-oxide production [484].  Studies have shown that reductions in 
parvalbumin positive cells were especially pronounced in the CA3 region in 22-26 month wild-type 
mice, but attenuated in IL-6 knockout and mice treated with anti-oxidants, which showed improved 
spatial memory in the Morris Water Maze [484]. Increased p65 binding could be seen in aged mice 
extracts and was decreased in IL-6 knockout mice; in vivo, application of IL-6 induced oxidative stress 
and a reduction in the expression of parvalbumin – these were both blocked through the inhibition of 
NF-κB activity [484]. This could underlie the early defects in gamma oscillations seen in the nfkb1-/- 
model. Although, whether p65 nuclear localisation would be disrupted by the loss of p50, or mediated 
by additional NF-κB dimer types is not clear. 
Together, these data suggest nfkb1-/- mice show a significant deficit in the generation of Carbachol 
induced gamma frequency oscillations in CA3 of the hippocampus. Further, there is a loss of 
propagation of the oscillation to the CA1. These may explain the deficits seen in hippocampal 
dependent spatial memory observed earlier in the chapter. The trends for improvement in oscillation 
build up, and significant rescue of CA3-CA1 oscillation synchrony with ibuprofen treatment suggests 
that this may be mediated through a COX-2 dependent pathway. A previously unexplored contributor 
to the observed deficits in spatial memory and gamma oscillations - and the phenotypic changes which 
can contribute to these deficits - could be the senescent-like neuronal phenotype. Senescence-
associated markers have been observed with ageing in the hippocampus, and other neuronal 
populations [112], but little is currently known about the phenotype; Dysregulation and shifts in gene 
expression can be seen in senescent cells, and could contribute to changes in factors such as 
Parvalbumin, neurotransmission and altered receptor densities [121]. Alterations in morphology are 
also observed, that could affect axonal, dendritic and synapse formation, and projection to other areas 
[86]. Alterations in calcium handling and signalling have now been observed in cellular senescence, 
and there is an emerging link between increased intracellular free calcium levels, mitochondrial 
dysfunction and the cell-cycle arrest, and the secretory phenotype of senescence [488]. Further, 
mitochondrial dysfunction and the generation of ROS is seen downstream of DNA damage signalling 
and promotes, then stabilises, the senescent phenotype [177]. As such, in the next sub-chapter, I 
investigated DDR and senescence-associated markers in neurons in wild-type and nfkb1-/- mice. 
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3.6 - Ageing and chronic inflammation lead to increased DDR signalling and 
senescence-associated markers in neurons. 
 
3.6.1 - Introduction 
 
Microglial proliferation, cytokine levels increase and cognitive deficits increase with age in nfkb1-/- 
mice and are ameliorated by long-term ibuprofen treatment.  Microglia in nfkb1-/- mice show 
prolonged and elevated pro-inflammatory release once activated, but appear to require a secondary 
ROS driven stimuli. Work by the team has previously established the role of cellular senescence in 
mitotic cells in the premature ageing phenotype of nfkb1-/- mice [127]. In mitotic tissues, increased 
sterile inflammation in nfkb1-/- mice accelerates the accumulation of senescent cells, which further 
exacerbates inflammation and leads to the accumulation of further senescent cells, through the 
release of pro-inflammatory and pro-oxidative molecules [127]. Further, the team has shown the 
presence, and increasing frequency, of senescence-like neurons in multiple brain areas of normally 
ageing wild-type mice [112]. Whether these neurons are associated with inflammation in the brain 
and the activation of glial cells has not been previously shown, nor has if these cells are associated 
with cognitive deficits. Senescent-like neurons have previously been established as being positive for 
inflammatory cytokines such as IL-6 and markers of oxidative damage, which may increase tissue 
levels of the cytokine and prime microglia. 
Increased inflammation can trigger the accumulation of senescent cells through activation of the DDR 
[127, 489]. Circulating and resident immune cells can release ROS and RNS species [490]. In chronic 
inflammation, these radical species can react with DNA, either directly or indirectly, to form oxidative 
adducts and breaks [490]. This has been linked to the propagation of inflammation, through activation 
of the DDR and the release of SASP factors through downstream pathways such as NF-κB [119, 232]. 
The release of these factors can further induce cellular senescence in bystander cells [122]. The direct 
transfer of ROS is mediated through cell to cell transfer through gap junctions [122], and inflammatory 
chemo- and cytokines through secretion [86]. 
Two main neuronal cell types were chosen for analysis in these brains. Purkinje cells in the cerebellum 
were chosen due to the previously observed increase of senescent-like neurons in mice with telomere 
dysfunction [112] and the deficits in neuro-muscular coordination in nfkb1-/- mice [127]. Pyramidal 
layer neurons of the hippocampus were chosen for their roles in spatial learning and memory, and the 
observed deficits in gamma frequency oscillation generation. Multiple senescence markers were used, 
as a single marker is insufficient to approximate the rate of senescent cells [121]. Markers of the DDR, 
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such as DNA damage and the activation of downstream pathways were assessed through 
measurement of yH2A.X foci and activation of p21. Exclusion of High Mobility Group Box 1 from the 
nucleus was used as an additional marker [121, 491]; together with the accumulation of auto-
fluorescent lipofuscin aggregates [492]. 
3.6.2 - Telomere-associated foci (TAF) increase in purkinje and pyramidal neurons with 
age and chronic inflammation. 
Both total number of γH2A.X foci, and number of foci co-localising with telomeres were counted per 
neuron, and then mean number of γH2A.X foci, TAF and frequency of neurons with multiple TAFs were 
recorded (Figure 3.6.2.1A). Telomere associated γH2A.X foci were distinguished from regular foci by 
their co-localisation with PNA telomere probe (Figure 3.6.2.1B).  
In Purkinje neurons no significant difference in the total number of foci between untreated wild-type 
and nfkb1-/- mice, or treated animals, was observed (Figure 3.6.2.1C). By 18 months significantly higher 
rates of yH2A.X foci in CA1 neurons could be observed in nfkb1-/- compared to wild-type animals 
(Figure 3.6.2.1D). Ibuprofen treated wild-type animals also exhibited higher number of foci (Figure 
3.6.2.1D). Increasing heterogeneity between animals in each group could be observed with age.  
A significant increase in the number of TAFs could be observed with age in both purkinje neurons 
(Figure 3.6.2.1E) and pyramidal neurons (Figure 3.6.2.1F). This occurred first in Purkinje neurons of 
nfkb1-/- mice, which showed significantly elevated levels by 8 months of age (Figure 3.6.2.1E), and in 
both purkinje and CA1 pyramidal neurons in both genotypes by 18 months of age (Figure 3.6.2.1F). 
Nfkb1-/- mice showed significantly higher levels of TAFs, and cells positive for multiple TAFs, at all ages 
and in both Purkinje and pyramidal cells compared to wild-type mice (Figure 3.6.2.1G-H). Long-term 
Ibuprofen treatment reduced these levels towards wild-type levels, and there was a slight trend for 
reduction with the short-term mini-pump Ibuprofen treatment at 8 months of age (Figure 3.6.2.1E-H). 
The mean number of TAFs, and the frequency of neurons with multiple TAFs, remained comparatively 
stable between 3 and 8 months of age in wild-type mice, while nfkb1-/- showed an earlier age-related 
increase.  
In the pyramidal neurons of wild-type mice, the number of non-TAF yH2A.X foci (n.b. this is not total 
yH2A.X foci, which includes all foci types) did not increase linearly with age, with no change between 
3 and 8 months, and a small increase at 18 months in (Figure 3.6.2.2A). However, the ratio of TAFs did 
increase linearly with age (Figure 3.6.2.2B). The same was true in nfkb1-/- mice, but with higher rates 
of foci (Figure 3.6.2.2C-D).  
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To test whether these TAF were Telomere-induced foci (TIF) in ageing mice, the telomere intensity of 
each telomere associated with yH2A.X was measured in CA3 hippocampal neurons from 18month old 
wild-type mice (Figure 3.6.2.3). TIFs are yH2A.X foci induced by the loss of T- and D-loop conformation 
due to telomere shortening, leading to the unfolding of the telomere complex and exposure of the 
chromosome end, which is recognised as a double-stranded break. I found longer telomeres were 
significantly enriched for yH2A.X foci, compared to short-telomeres in 3 different animals (Figure 
3.6.2.3A-C). This suggests that it is not the un-capping of shorter telomeres that is responsible for the 
presence of TAFs, but rather the increased likelihood of a longer telomere being damaged. 
One factor that became apparent during the analysis of pyramidal neurons in the hippocampus was a 
difference in damage levels between different sub-regions (Figure 3.6.2.4A). Initially images were 
taken at intervals along the pyramidal structure, starting in CA1, but with some images taken in CA2 
to CA3. During quantification it appeared that neurons in CA2 and CA3 displayed higher levels of DNA 
damage. Following this observation I removed the counts of data from CA3 regions, leaving the 
pyramidal counts as solely as CA1 pyramidal neurons. There was a trend for higher numbers of yH2AX 
foci in nfkb1-/- mice (Figure 3.6.2.4B). Nfkb1-/- mice showed a significant increase in the mean number 
of TAFs in CA3 neurons (Figure 3.6.2.4C), as well as the number of cells bearing multiple TAFs (Figure 
3.6.2.4D). Further, a large proportion of neurons was found to have much higher numbers of TAFs 
than previously observed, with 10-15% of CA3 neurons in nfkb1-/- mice having 5 or more TAFs (Figure 
3.6.2.4E) – where as in CA1 pyramidal neurons it was unusual to see more than 3 . A comparison 
between levels of DNA damage and TAFs in neurons from CA1 and CA3 found that nfkb1-/- mice had 
increased levels of TAFs in CA3, compared to CA1, while wild-type mice showed no significant 
difference (Figure 3.6.2.4F-J). There was significantly higher frequency of the cell-cycle inhibitor p21 
in CA3 neurons (Figure 3.6.2.4I). 
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Figure 3.4.2.1: Telomere associated DNA damage increases with age in Purkinje neurons 
and CA1 hippocampal cells, and is elevated in nfkb1-/- mice 
A) Representative image of yH2A.X (green), Telomere probe (Red) and nuclear stained using DAPI 
(blue) in CA1 neurons from wild-type and nfkb1-/- mice, treated and untreated at 3 and 18 months. B) 
Several TAFs in A) are highlighted and co-localisation between yH2A.X and telomere probe shown by 
normalised intensity plot. C) Quantification of mean yH2A.X foci in Purkinje neurons and D) CA1 
pyramidal neurons. E) Quantification of mean TAF foci in Purkinje neurons and F) CA1 pyramidal 
neurons. G) Quantification of percentage of neurons with 2 or more TAF foci in Purkinje neurons and 
H) CA1 pyramidal neurons. 2-way ANOVA (Holm-Sidak) for age and genotype. Treatments are 
compared by two-tailed Mann-Whintey U. Significant differences between genotype, as well as 
treatments, at each age point are displayed by (* p<0.05, ** p<0.005, *** p<0.001), significant 
difference with age by (# p<0.05). 
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Figure 3.6.2.2:  TAF accumulate linearly with age in pyramidal neurons, with no significant 
linear increase in non-telomere associated foci 
A) Linear regression of mean yH2A.X foci in untreated wild-type mice at 3, 8 and 18 months. B) Linear 
regression of mean yH2A.X foci in untreated wild-type mice at 3, 8 and 18 months. C) Linear regression 
of mean yH2A.X foci in untreated nfkb1-/- mice at 3, 8 and 18 months. B) Linear regression of mean 
yH2A.X foci in untreated nfkb1-/- animals at 3, 8 and 18 months. Significance tested by two-tailed 
Spearman correlation coefficient (* p<0.05, ** p<0.005, *** p<0.001 by Gaussian approximation). 
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Figure 3.6.2.3: Telomere-Associated Foci accumulate preferentially in longer telomeres in 
neurons 
Histograms showing telomere-intensities of telomeres co-localising (yellow) and not co-localising (red) 
with γH2A.X foci in hippocampal neurons of 3 wild-type mice (A-C). Black dotted-line shows median 
intensity for telomeres not associated with γH2A.X foci with each histogram. Orange dotted-line 
shows median intensity for telomeres that are associated with γH2A.X foci with each histogram.  An 
average of 1058 telomeres were analysed per animal. Tested by Mann-Whitney U for each animal, 
significance shown by *** = p<0.0001. 
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Figure 3.6.2.4: Increased telomere associated DNA Damage in CA3 pyramidal neurons in 
nfkb1-/- mice 
A) Representative image of γH2A.X Immuno-FISH in CA3 Hippocampus Neuron 18 month old animals 
γH2A.X in Green, PNA probe (Telomeres) in Red, DAPI in Blue. B) Mean γH2A.X foci and C) mean TAF 
in CA3 neurons of wild-type, nfkb1-/- and nfkb1-/- treated with Ibuprofen D) Percentage of CA3 neurons 
positive for multiple telomere-associated DNA damage foci TAF). E) Percentage of CA3 neurons 
positive for 5 or more telomere-associated DNA damage foci (TAF). Comparison between CA1 and CA3 
in wild-type and nfkb1-/- mice for F) γH2A.X foci G) mean TAF and H) percentage of neurons with 2 or 
more TAFs. One Way ANOVA, Bonferoni Post-hoc, n=5-6 animals for DNA Damage markers, n=3-4 for 
p21.I) Comparison of DNA damage in CA1 and CA3. Two Way ANOVA, Holm-Šidák Post-hoc. 
Significance marked as (* = p<0.05, ** = p<0.05, *** p<0.001). All bars are mean +SEM.  
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3.6.3 - p21 expression increases in parallel with DDR foci in neurons with ageing and 
chronic inflammation. 
The activation of cyclin kinase inhibitor p21, a downstream factor in the DDR pathway, is associated 
with arrest of the cell-cycle and is elevated in senescence in mitotic cells [177, 222]. It appears to be a 
requirement for the development of the senescence-like phenotype, as mice with short-telomeres 
and p21 knockout show greatly reduced rates of senescence-associated markers such as Senescence-
associated Beta Galactosidase activity, phospho-p38 MAPK, IL-6 and markers of oxidative and DNA 
damage [112]. It is likely that this is either due to p21 signalling being required for the development 
of senescence-associated features, or due to a lack of cell-cycle inhibition leading to increased re-entry 
and cell-death in damaged neurons. 
The levels of nuclear p21 in Purkinje neurons of ageing wild-type and nfkb1-/- mice were investigated 
(Figure 3.6.3.1A). Nfkb1-/- mice showed increased p21 levels with age at 8 and 18 months, and 
significantly higher levels than wild-type mice at these ages (Figure 3.6.3.1B). Long-term Ibuprofen 
treatment was able to reduce these levels in nfkb1-/- mice, but did not have a significant effect in wild-
type mice. Considering all animals and ages there was a significant correlation between γH2AX foci 
and TAFs (Figure 3.6.3.1C-E). Both nfkb1-/- and wild-type mice showed a linear increase in p21 positive 
neurons with age (Figure 3.6.3.2A-B); moreover, there was a significantly increased rate of 
accumulation in nfkb1-/- compared to wild-type mice (Figure 3.6.3.2C).  
p21 can be activated by the DDR, and forms a positive feedback loop through ROS creating further 
DNA damage [177]. As such, I tested for an association with DNA damage levels and p21. A significant 
correlation between p21 levels and DNA damage could be observed when looking at individual 
animals between 3 and 18 months. I was concerned that age might be the driving factor in these 
associations, so I additionally tested only animals at 18 months (Figure 3.6.3.3). At 18 months I found 
no association between total γH2A.X foci and p21 activity (Figure 3.6.3.3A), but found an association 
with mean number of TAFs and frequency of cells with 2 or more TAFs (Figure 3.6.3.3B-C). Additionally 
p21 correlated with additional senescence markers such as autofluorescent aggregates and loss of 
nuclear HMGB1 (Figure 3.6.3.3D-E). 
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Figure 3.6.3.1: Increasing p21 positive Purkinje neurons in the Cerebellum with age, and in 
nfkb1-/- mice 
A) Representative images of p21 staining in the cerebellum of 3, 8 and 18 month old mice. p21 stained 
with NovaRed (Brown), counterstained with Haematoxylin (Blue) B) Graph showing percentage of 
neurons positive for p21 staining at each age group. Samples were available for wild-type mice aged 
24 and 32 months, and were included for reference. Box and whiskers show the median of the means. 
2-way ANOVA (Holm-Sidak) for age and genotype. Treatments are compared by two-tailed Mann-
Whintey U, as are 24 and 36 month wild-type mice to retain interactions in 2-way ANOVA. Significant 
differences between genotype, as well as treatments, at each age point are displayed by (* p<0.05, ** 
p<0.005, *** p<0.001), significant difference with age by (# p<0.05). C-E) Correlation between 
numbers of neurons positive for nuclear p21 staining and mean yH2A.X foci, mean TAF and percentage 
of cells positive for multiple TAFs, respectively, per animal in 3 to 18 months old wild-type and nfkb1-
/- mice. Significance tested by two-tailed Spearman correlation coefficient (** p<0.005, *** p<0.001 
by Gaussian approximation).  
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Figure 3.6.3.2: Correlations between p21 and age in Purkinje cells of wild-type and nfkb1-/- 
mice  
A-B) Correlation between numbers of neurons positive for nuclear p21 staining and age in wild-type 
and nfkb1-/- purkinje neurons. Red line shows linear regression, dotted blue lines show 95% confidence 
intervals. C) Comparison of rate of increase in nfkb1-/- and wild-type mice with ageing. Significance 
tested by two-tailed Spearman correlation coefficient (* p<0.05, ** p<0.005, *** p<0.001 by Gaussian 
approximation).  
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Figure 3.6.3.3: Correlations between p21 and other senescence-associated markers in 
Purkinje cells in 18 month animals  
A-E) Correlation between numbers of neurons positive for nuclear p21 staining and markers of 
senescence A) gH2AX, B) mean TAF, C) 2≥ TAF, D) autofluorescence and E) HMGB1, per animal, in 18 
month old wild-type and nfkb1-/- mice, with and without ibuprofen. Red line shows linear regression, 
dotted blue lines show 95% confidence intervals. Significance tested by two-tailed Spearman 
correlation coefficient (* p<0.05, ** p<0.005, *** p<0.001 by Gaussian approximation).  
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3.6.4 - High Mobility Group Box 1 translocates from the nucleus in nfkb1-/- neurons 
 
High Mobility Group Box 1 (HMGB1) is a highly conserved non-histone chromatin binding protein that, 
when localised to the nucleus, regulates chromatin architecture [493]. It can bend DNA to allow access 
for other proteins, such as transcription factors [493]. However, the protein leads a double life and is 
also a pro-inflammatory cytokine and Alarmin [494]. In undamaged cells HMGB1 is primarily located 
in the nucleus; however, following hyper-acetylation on lysine groups HMGB1 is transported from the 
nucleus to the cytoplasm [494]. From here it can be secreted into the extra-cellular milieu where it 
takes the role of a pro-inflammatory cytokine, activating receptor for advanced glycation end products 
and Toll-like receptors, leading to activation of NF-κB and COX-2 [494]. In tissues it mediates 
inflammation related tissue damage, for example in brain ischæmia [494, 495]. It is released passively 
by necrotic cells and actively secreted by immune cells [496]. HMGB1 is also a key regulator of 
senescence and is actively exported from the nuclei of senescent cells into the extra-cellular milieu 
through p53-mediated pathway [491]. Relocation of HMGB1 in senescent cells is required for 
stimulation of NF-κB activity and secretion of IL-6 [491]. This was assessed by immunohistochemical 
staining for HMGB1 for positive and negative nuclei (Figure 3.6.4.1A) 
Nfkb1-/- mice showed a significant increase in HMGB1 translocation in Purkinje neurons with age 
(Figure 3.6.4.1B). While wild-type mice showed a trend, this was not significant. Nfkb1-/- mice had 
significantly higher frequencies of neurons with no nuclear HMGB1 than wild-type mice at 8 and 18 
months, while long-term Ibuprofen treatment ameliorated this. Whether HMGB1 has been excluded 
from the nucleus was also measured in granule cells immediately adjacent to HMGB1 nuclear positive, 
and negative, Purkinje neurons (Figure 3.6.4.1C). Granule cells surrounding HMGB1 negative neurons 
were significantly more likely have also have no HMGB1 in their nucleus, suggesting a manner of 
bystander effect or localised damage.  
CA3 pyramidal layer cells in nfkb1-/- mice showed an age-dependent increase in HMGB1 translocation, 
and were significantly elevated compared to wild-type controls (Figure 3.6.4.1D). There was a trend 
for reduced HMGB1 translocation at 18 months with Ibuprofen treatment, and it was significantly 
rescued by long-term ibuprofen treatment at 18 months. 
 
 
 
141 
 
 
 
 
A 
B C 
D 
142 
 
Figure 3.6.4.1: Nfkb1-/- show age dependent loss of nuclear HMGB1 in neurons  
A) Representative images of HMGB1 staining in the cerebellum of 3 and 18 month old mice. HMGB1 
stained with NovaRed (Brown) counterstained with Haematoxylin (Blue) B) Quantification of purkinje 
neurons with no nuclear HMGB1 at 3, 8 and 18 months in wild-type and nfkb1-/- mice, with and without 
ibuprofen treatment. C) Increased frequency of HMGB1 nuclear negative granule cells surrounding 
HMGB1 nuclear negative Purkinje neurons. Graph shows mean of 100 purkinje neurons in each group, 
in 3 18 month wild-type animals. D) Quantification of CA3 pyramidal layer cells with no nuclear HMGB1 
at 3, 8 and 18 months in wild-type and nfkb1-/- mice, with and without ibuprofen treatment. 2-way 
ANOVA (Holm-Sidak) for age and genotype. Treatments are compared by two-tailed Mann-Whintey 
U. Significant differences between genotype, as well as treatments, at each age point are displayed by 
(* p<0.05, ** p<0.005, *** p<0.001), significant difference with age by (# p<0.05). HMGB1 bystander 
assessed by paired two-tailed t-test, significance shown by * p<0.05 
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3.6.5 – Nfkb1-/- mice show increased autofluorescent lipofuscin accumulation in neurons 
Lipofuscin is an electron-rich lysosomally accumulated aggregate that increases with age in many cell 
types [497] and accumulates in senescent cells [492, 498]. The aggregates are complex and 
multifaceted, including oxidatively damaged lipids and proteins. As such, Lipofuscin is often used as a 
marker of oxidative damage, and increases in parallel with markers of oxidative damage, such as 8-
oxo-dG [177]. Many trapped proteins contain metal ions, and aggregates can account for up to 16% 
of metals within a cell [499]. The presence of these ions contribute significantly to the electron-rich 
nature of the aggregate and leads to a bright autofluorescence excitement across a broad spectrum 
during fluorescence microscopy [500, 501]. While this autofluorescence is often problematic for 
fluorescent image analysis, it can be analysed in its own-right to assess lipofuscin accumulation. Due 
to the size of the Purkinje cell, this can be performed easily on un-processed paraffin-fixed sections 
(Figure 3.6.5.1); however, for cells with a smaller soma such as pyramidal neurons it is necessary to 
process the slide and instead count individual foci (Figure 3.6.5.2).  
Purkinje neurons in both wild-type and nfkb1-/- mice showed increased auto-fluorescence with age 
(Figure 3.6.5.1A). Nfkb1-/- mice had significantly higher levels at all 3 ages (Figure 3.6.5.1B). Ibuprofen 
treatment reduced the levels of autofluorescence at both 8 and 18 months of age in nfkb1-/- mice, but 
did not significantly effect wild-type mice. Pyramidal neurons also showed an increase with age. 
Pyramidal neurons from 18 month nfkb1-/- mice had significantly higher levels than wild-type mice. 
While there was a slight trend for decreased autofluorescent granules with long-term Ibuprofen 
treatment, it was not significant. 
Due to the small soma-size of hippocampal neurons, de-paraffinated slides were used instead, and 
the number of average number of autofluorescent granules per cell counted in pyramidal neurons 
(Figure 3.6.5.2A). Both wild-type and nfkb1-/- neurons showed a significant increase in the number of 
autofluorescent granules with age (Figure 3.6.5.2B). Ibuprofen treatment lead to a significantly 
increased average number of granules in wild-type mice at 18 months, and in nfkb1-/- mice at 18 
months showed a trend for decreased average number of granules (Figure 3.6.5.2B).  
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Figure 3.6.5.1: Nfkb1-/- mice show increased Purkinje cell autofluorescence 
A) Representative images of autofluorescence in the cerebellum of 3 and 18 month old wild-type and 
nfkb1-/- mice, with and without iburprofen B) Graph showing mean number of autofluorescent 
intensity per neuron, per mouse, in each age group. Box and whiskers show the median of the means. 
2-way ANOVA (Holm-Sidak) for age and genotype. Treatments are compared by two-tailed Mann-
Whintey U. Significant differences between genotype, as well as treatments, at each age point are 
displayed by (* p<0.05, ** p<0.005, *** p<0.001), significant difference with age by (# p<0.05). 
  
A 
B 
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Figure 3.6.5.2: Pyramidal neurons show increased autofluorescent granules with age, and 
in nfkb1-/- mice 
A) Representative images of autofluorescence in the CA3 hippocampus of 3 and 18 month old wild-
type and nfkb1-/- mice, with and without ibuprofen D) Graph showing mean number of 
autofluorescent granules per neuron, per mouse, in each age group. Box and whiskers show the 
median of the means. 2-way ANOVA (Holm-Sidak) for age and genotype. Treatments are compared 
by two-tailed Mann-Whintey U. Significant differences between genotype, as well as treatments, at 
each age point and correlations are displayed by (* p<0.05, ** p<0.005, *** p<0.001). Significant 
difference with age by (# p<0.05). 
A 
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3.6.6 - Discussion 
The presence of senescent cells is known to drive ageing and age-associated diseases in mice [124]. 
The frequency of senescent-like neurons has been observed to increase in ageing mice brain [112], 
but it is not yet known if it plays a role in age and disease associated cognitive decline. As discussed 
previously in the chapter, nfkb1-/- mice show increased glial activation, neuro-inflammation, deficits 
in gamma frequency oscillations and deficits in spatial memory compared to wild-type mice. These 
showed partial rescue with long-term dietary ibuprofen, suggesting that inflammation at least partially 
drives this dysfunction. We hypothesised that the presence of senescent-like neurons is involved with 
these chronic-inflammatory associated cognitive deficits. In neurons from nfkb1-/- mice I observed an 
increase in the frequency of senescence associated markers, such as DDR activation, p21 activation 
and HMGB1 release. There was a partial rescue in a number of these factors and cognitive function 
with long-term ibuprofen treatment, suggesting that the inflammation seen in nfkb1-/- mice is playing 
a role in senescence induction.  
Senescence can be initiated through activation of the DDR [174] and increasing ROS production and  
generating new damage [177]. In order to test this I investigated the presence of yH2A.X foci to assess 
double-stranded breaks in neurons. While there were trends, no significant changes could be seen in 
the total number of yH2A.X foci in Purkinje neurons with age, or genotype. This matches existing data 
on DNA damage markers in these neurons in terms of single-stranded damage, Purkinje cells have the 
highest level of DNA strand breaks, as measured by in situ nick translation, but do not show an age-
related increase between 11 and 28 months [502]. yH2A.X in neurons has been previously reported 
to increase with age in Purkinje neurons [112]. However, this was measured in terms of cell positive 
or negative by IHC, rather than the foci number by IF reported here and is likely less sensitive. Further, 
no increase was reported until 32 months of age, with no visible difference between 4 and 8 months 
of age. The oldest age tested here was 18 months in wild-types, and an increase may not be seen until 
later, or could be related to the loss of pyramidal neurons observed in late age [502]. No such age 
associated loss of neurons occurs in pyramidal cells despite an age-dependent increase in single-
strand damage [502] and double-strand breaks in old baboon hippocampal neurons [211] previously 
observed. Increased levels here could be observed in pyramidal neurons in nfkb1-/- mice at 18 months, 
but not before, which may indicate an acceleration of age-accumulated damage. 
The variability in total yH2A.X could be related to its physiological roles within neurons, which could 
mask the number of damage associated breaks. Increases in the number of yH2A.X  foci in 
hippocampal neurons can be seen after 2 hours of exposure to novel environments [208]. However, 
if returned to their home cage for 24 hours, the number of yH2A.X foci returns to the same level as 
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mice who never left the home cage. This could be linked to the increased neuronal activity, which 
could lead to increased ROS production and Ca2+ influx as a by-product. It would also indicate either 
a rapid repair of this transient damage. It is not yet known if these breaks contribute to DDR signalling. 
However, the location of these breaks appears more targeted, specifically to promotor regions of 
neuronal early-response genes. The rapid expression of these genes is important for synaptic 
plasticity, learning and memory. The yH2A.X positive foci in the promotor regions of these genes are 
physiologically generated by topoisomerase IIβ and allow physical access to the DNA for transcription 
factors [207]. Since post-mortem represents a single snap shot, factors such as rehousing prior to 
autopsy, or other exposure to novel environments may contribute to variation. 
yH2A.X and DDR induction by X-ray irradiation in neurons does not appear significantly related to 
apoptosis, but rather signals G0 to G1 cell-cycle transition through ATM-p53-p21 signalling [309]. This 
was tested in sensory ganglion neurons, but appears consistent with experiments involving irradiation 
of mouse brains, which showed an increase in damage in vivo in surviving hippocampal neurons even 
3 months after damage [211]. In both cases, DNA damage could be defined as being in one of two 
categories, transient repairable DDR foci, and persistent DDR foci [211, 309]. After X-ray irradiation 
induced double-stranded damage in ganglion neurons, yH2A.X foci can be observed, however, these 
are repaired within a day, while persistent yH2A.X foci can still be observed 15 days after [309]. These 
were both positive for DDR factors, such as pATM and 53BP1, that indicate downstream DDR 
signalling, but also epigenetic changes in chromatin condensation [309]. In irradiated mouse brains, 
hippocampal neurons, breaks can be seen immediately after IR, but a significant number were still 
present after 3 months [211]. However, this damage was preferentially located at telomeres, which 
comprise a mere 0.02% of the genome [211]. 
Telomere dysfunction appears to be an important driver in the generation of senescent-like neurons 
[112]. Late generation terc-/- mice, lack the catalytic subunit of telomerase, leading to generation 
dependent telomere shortening and an accelerated ageing phenotype. Telomeres in these mice, can 
become uncapped as they are unable to properly form a protective T-loop, which otherwise shelters 
the chromosome end, and its recognition as a double-strand break [197, 198, 202, 203]. In these mice, 
a substantial increase in the number of Purkinje and cortical neurons with an active DDR and 
senescent-like features can be observed [112]. This would be consistent with critically short telomeres 
within neurons resulting in telomere uncapping, triggering of the DDR signalling and the induction of 
the senescent-like phenotype.  
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To assess telomere dysfunction in nfkb1-/- mice neurons, I measured the number of yH2A.X foci co-
localising with telomeres (TAFs). Unlike yH2A.X located outside of the telomere region, the number of 
TAFs could be seen to increase with age in neurons in wild-type and nfkb1-/- mice. This is consistent 
with a study which showed an age-dependent increase in 53BP-1 foci co-localising with telomeres in 
baboon neurons [211], and increasing TAF numbers with age in other tissues such as the liver [127] 
and lung [503].  These levels were significantly higher in untreated nfkb1-/- mice; however, long-term 
dietary ibuprofen treatment reduced the average number of TAFs in nfkb1-/- mice, but had no effect 
on wild-type mice. This could suggest that chronic inflammation may be driving telomere dysfunction 
in these neurons, which is consistent with results previously observed in the livers of nfkb1-/- mice. 
Yet, in mitotic cells telomere shortening and uncapping is typically a function of DNA replication and 
the loss of the telomeric end-repeat sequence. Furthermore, unless genetically altered (as in the terc-
/- mice mentioned previously), mice constitutively express telomerase and maintain long-telomeres 
throughout life. However, DNA damage can occur at telomeres even in the absence of uncapping, and 
is sheltered from repair factors by the shelterin complex [209, 211]. 3 months after irradiation of 
mouse hippocampal neurons, 40% of DNA damage found was located at the telomeres and was not 
located preferentially at shortened telomeres [211]. With the data from Hewitt et al., this indicates 
that DNA damage can be located within telomeres independent of length, where it is sheltered from 
DNA repair by the shelterin complex [504] leading to persistent DDR foci [209, 211]. I confirmed this 
in ageing in wild-type mice CA3 neurons at 18 months, and found that not only TAF were not found 
preferentially in short telomeres, but were significantly weighted towards longer telomeres. This data, 
together with how common telomere damage was compared to non-telomeric damage (despite only 
being 0.02% of the genome), suggests that telomere regions are highly susceptible to damage and 
that longer telomeres may be more vulnerable to damage as they provide more space for the damage 
to occur.  
The increasing levels of damage located at the telomeres could provide a consistent level of DDR 
signalling that stabilises the expression of non-apoptotic ATM-p53-p21 signalling. Activation of this 
pathway can be seen increasing in the 3 days following X-ray irradiation induced DNA damage in 
neurons [309]. This persistent signalling of the DDR in mitotic cells leads to the induction of stress-
induced senescence [209, 211]. This occurs partially through the stabilisation of p21-p38 MAPK 
expression and the stimulation of ROS production [177] and leads to the production of inflammatory 
cytokines known as the SASP [210]. p21 activation appears to be important in driving the senescent-
like phenotype in ageing mice, as evidenced by the reduction in neurons bearing senescence-
associated markers in late generation terc-/- mice lacking p21 [112]. Increased levels of p21 positive 
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neurons could be observed with age in both wild-type and nfkb1-/- mice. By 8 months this was 
significantly higher than in wild-type mice and followed an accelerated trajectory with age compared 
to wild-types. This was significantly correlated with the numbers of TAFs and neurons positive for 2 or 
more TAFs in purkinje neurons when all groups were considered. However, as this could be a factor 
of age, I also looked at these parameters purely in 18 month mice. This showed no significant 
correlation with the number of yH2A.X foci, but was again correlated with TAF and cells positive for 2 
or more TAFs. Additionally, the frequency of p21 positive neurons was associated with other 
senescent-markers, including increases in oxidative damage associated autofluorescent intensity and 
nuclear release of HMGB1. 
One possible mechanism behind this DNA damage and telomere dysfunction in nfkb1-/- mice neurons 
could be the presence of inflammation, as the number of TAFs was reduced with long-term anti-
inflammatory treatment. Inflammation is capable of driving of cell-senescence through paracrine 
signalling pathways [323]. This can be induced by factors such as IL-1a, TGFB and MCP-1, through p15 
and p21 signalling [323]. Inflammatory signals are associated with the pathways that promote 
oxidative stress and telomere dysfunction [119, 127, 177, 213]. For example, CXCR2 binding pro-
inflammatory cytokines, such as IL-8, can promote the intracellular accumulation of ROS via CXCR2 
mediated signalling [213]. This can promote DDR signalling through the generation of DNA damage, 
and in turn promote further ROS generation [177] and inflammatory cytokine secretion [119]. 
Previous work in our  lab found elevated oxidative stress in nfkb1-/- mice, with treatment with the anti-
oxidant BHA reducing the frequency of telomere associated damage in the liver [127]. This generation 
of ROS, and subsequent telomere damage appears to be mediated through COX-2 activation, although 
the specific mechanism is not yet know. In vitro, work on mouse adult fibroblasts isolated from nfkb1-
/- mice suggested that the associated COX-2 expression, increased ROS production and secretion of 
cytokines was a consequence of the induction of senescence [127]. This may act to drive the 
accumulation of persistent DNA damage and the presence of senescence markers in neurons, as long-
term treatment with the COX-2 inhibitor ibuprofen reduced the levels of telomere associated damage. 
Inflammation in nfkb1-/- mice may come from either the periphery, or directly from cells in the brain. 
nfkb1-/- mice show an elevated response to peripheral pro-inflammatory insults, such as systemic LPS 
injection, in the midbrain [420]. Indeed, peripheral inflammation can cross the blood brain barrier, 
and is linked to the priming and activation of microglia and inflammatory responses in the brain, which 
can lead to delayed and progressive degeneration [505]. Nfkb1-/- mice show increased expression of 
numerous inflammatory factors in the periphery by 9 months of age [127], which could induce priming 
in microglia. Increased priming of microglia can be seen in normally ageing, with an increased and 
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exaggerated pro-inflammatory response, and decreased activation threshold of this response [87] and 
appears accelerated in nfkb1-/- mice. Additionally, nfkb1-/- microglia have previously been shown to 
have a deficit in in resolving the inflammatory M1 response, which can lead to prolonged inflammatory 
activation [420].  
However, microglia in nfkb1-/- require a secondary, ROS mediated stimuli, in order to trigger their pro-
inflammatory activation [419, 420]. The observed increase in DDR signalling in nfkb1-/- neurons could 
itself drive glial activation. This would match what has been observed in another accelerated ageing 
model, ercc1Δ/− mice [424, 506]. These mice show reduced DNA repair, glial activation and a similar 
loss of cognitive function to that observed here [424, 506]. A neuron specific ercc1 knockout was also 
generated, these are Ercc1f/−CaMKII-Cre+ mice [506]. These and have heterozygous ercc1 expression 
in the whole body (which is largely phenotype free), but homozygous ercc1 knockout in αCaMKII 
expressing cells (primarily excitatory pyramidal neurons in the forebrain). In the brains of these 
animals show increased in astrogliosis with age that was restricted to brain areas with αCaMKII 
expressing neurons, particularly the hippocampus and cortex [506]. Suggesting that DNA damage in 
neurons is capable of activating glial cells; this was accompanied by activation of p53 in neurons, 
suggesting DDR activation by the unrepaired damage. Further work from Raj et al. [424] shows 
increased microglial priming (marked by hypertrophy and Mac2 expression) specifically in the areas 
where Ercc1f/−CaMKII-Cre+ neurons are present [424]. This is similar to the observed increase in 
microglial density and soma hypertrophy, accompanied by persistent DDR signalling and elevated 
senescence-markers, which I observed in the hippocampus of nfkb1-/- mice. Interestingly, no such 
increase was observed in GFAP-Cre targeted Ercc1Δ/− mice [424], suggesting that DNA damage 
accumulation in astrocytes was not capable of inducing microglial priming or hypertrophy. This would 
be in line with the lack of a DDR, due to transcriptional repression of DDR factors, in mature astrocytes 
[507].  
Progressive age-associated deficits in LTP could be observed in isolated hippocampal slices from 
Ercc1f/−CaMKII-Cre+ mice, together with decreased performance in the Morris Water Maze [506], 
which is similar to the deficits in spatial memory I observed. While a mild loss of neurons could be 
observed in these mice, as previously suggested by type-II TUNEL staining in nfkb1-/- mice [395], the 
observed decrease in LTP could be better explained by altered or disrupted gene transcription from 
DNA damage, or DDR signalling. Unrepaired DNA damage in neurons is accumulated in 
transcriptionally silent chromatin domains, but still signals the DDR [508] and dysregulation of gene 
expression has been observed in senescence of mitotic cells [121]. These could contribute to defects 
in LTP and altered protein expression observed with age in neurons.  
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Thus, in nfkb1-/- mice increased inflammation and microglial activation could promote DDR activation 
through pro-inflammatory and pro-oxidative molecules; while a DDR driven senescence-like 
phenotype in neurons may further promote this, leading to a positive feedback loop. Although, it is 
difficult to establish causality in a whole body nfkb1-/- knockout, further testing in cell-specific nfkb1-/- 
could contribute evidence towards this.  
There are a number of mechanisms that may trigger the activation of microglia by neurons. Senescent 
cells release elevated levels of pro-oxidative and pro-inflammatory molecules, known as the SASP, 
which not only reinforce senescence [323], but also induce DDR activation and senescence in 
surrounding cells via gap junctions [122]. This senescence bystander effect is driven through the 
release of ROS from dysfunctional mitochondria and the activation NF-κB, triggering DNA damage in 
surrounding cells [509]. Persistent DDR signalling can then trigger the production of ROS [177], and 
SASP factors, such as IL-6, from senescent cells [119]. That this occurs in neurons is supported by the 
increased staining for IL-6 previously observed in senescent-like neurons, which was elevated in mice 
with telomere dysfunction [112].  
Additionally, here I observed an increase in the loss of nuclear HMGB1 from nfkb1-/- mice compared 
to wild-type mice. Here I found that the frequency of neurons without nuclear HMGB1 was associated 
with increased DDR signalling by p21 and TAFs. HMGB1 is actively transported from the nuclei of cells 
by p53 signalling, and stimulates the activation of NF-κB and IL-6 secretion through Toll-like Receptor 
4 [491]. However, it also acts as a pro-inflammatory cytokine, and oxidised HMGB1 is secreted from 
senescent fibroblasts, inducing secretion of cytokines in an auto- and para-crine fashion through Toll-
like Receptor 4 [491]. Here, I observed a possibly bystander effect between purkinje cells and 
surrounding granule cells, with HMGB1 negative purkinje cells being surrounded by relatively more 
HMGB1 negative granule cells, compared to positively stained Purkinje cells. 
HMGB1 can mediate microglial priming and potentiates the neuro-inflammatory response to 
inflammation, with increased NF-κB pathway activity, and production of cytokines such as IL-6 in 
response to inflammatory challenge [510]. Its release has previously been observed from neurons and 
activated microglial cells in the brain upon stress [495] and excitotoxic damage [511]. It appears to 
play an important role in mediating delayed neuro-inflammation following ischæmic damage, as 
suppression of expression with short-hairpin RNA substantially reduces microglial activation, the 
induction of pro-inflammatory markers and a reduced infarct size [511]. HMGB1 binds to macrophage 
antigen complex 1 on microglia, which leads to activation of NF-κB and localising cytosolic sub-units 
of NADPH oxidase to the cell-membrane [496]. This leads to the secretion of pro-inflammatory 
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cytokines and super-oxide [496]. As such its release from senescent-like neurons could indicate 
potential mechanism by microglia become primed with age. Recent research has shown that 
circulating levels of HMGB1, in the CSF, and total mRNA and protein levels, in the hippocampus, are 
known to increase in normally ageing rodents [512]. This could contribute to age-related priming of 
microglia and the subsequently increased inflammatory response and effects on cognition seen in the 
aged after inflammatory insult [94, 97, 98].  
It should be noted that HMGB1 is also released passively from necrotic neurons [513], and the release 
of HMGB1 by damaged neurons has been implicated in forming a positive inflammatory and 
degenerative feed-back loop in Parkinson’s models [496]. Although, I attempted to exclude necrotic 
cells here by not counting cells with a necrotic or shrunken morphology. It is possible that this partially 
underlies the changes in nfkb1-/- mice as cell death has been reported in the nfkb1-/- mouse brain [395].  
Additionally, I was also aware that these may well be ‘dark neurons’, a fixation artefact that 
complicates post-mortem analysis in the brain, and mimics a necrotic appearance closely but does not 
lead to cell death [514]. These are comparatively common in brains from animals not perfused with 
paraformaldehyde at dissection, as was the case in these mice, and if the brain is physically 
compressed in removal [514]. In this study the mice were not perfused to allow for the collection of 
frozen tissues, and the hearts were also needed, which would have been damaged by injection 
perfusion.  
In this chapter, I hypothesised that a DDR induced senescence-like phenotype is involved in the age-
associated increases in neuro-inflammation and associated cognitive deficits. My data show an 
increase in persistent DNA damage, DDR activation and senescence associated markers in purkinje 
and hippocampal pyramidal neurons in nfkb1-/- mice. Both of which are associated with aged-related 
changes in phenotype and cognitive function. This may be mediated through intrinsic effects of 
nfkb1/p50 knockdown, or through an associated increase in inflammation. It appears to partially 
mediated through a COX-2 dependent mechanism, although if this is inflammation or ROS generation 
is not clear. It is not currently clear if changes within neurons, systemic circulating factors, microglial 
activation, or a combination of all of these factors drives the observed dysfunction. 
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4.0 - Senolytic treatment reduces the number of senescent-like 
neurons in ageing wild-type mice 
 
 
4.1 - Introduction 
 
Senescent-like neurons have been observed to increase in the brain, with age (here and [112]). This 
occurs in areas associated with age-related changes, such as the cerebellum and hippocampus. In the 
previous chapter I demonstrated that the numbers of senescent-like neurons in these areas increases 
in a model of chronic inflammation, together with a decreased performance in hippocampal-
dependent memory tasks and a deficit in the generation of gamma-oscillations.  
From the existing body of literature, the existence of senescence-like neurons is likely linked to the 
reactivation, or prevention of reactivation, of the cell-cycle. The frequency of neurons with signs of 
partial G1 and S-phase cell-cycle reactivation increases in the brains of patients with cognitive 
impairment and Alzheimer’s disease, especially in the CA3-4 to CA1 of the hippocampus [292, 293]. 
This reactivation eventually leads to apoptosis of the cell [297, 298], while preventing this cell-cycle 
re-entry lowers the rates of neuronal apoptosis [289, 306, 307, 309]. Given the observed frequency of 
neurons in vivo and known rate of cell death, it is likely that these cells are persistent for long periods 
[293].  
It is unclear if senescence and senescent-like neurons actually contribute towards neuro-inflammation 
and cognitive impairment through the ‘bystander’ effect, or are simply innocent bystanders. 
Senescent cells can induce tissue dysfunction though the release of pro-inflammatory and pro-
oxidative factors that can promote further senescence in surrounding cells [86, 122, 509, 515]. Their 
presence in other tissues are associated with a number of, typically age-related, pathologies such as 
liver disease [139, 516], pulmonary disease, [355, 503], atherosclerosis [358], cardiac and kidney 
dysfunction [124]. Yet, senescence is beneficial in other circumstances, such as wound healing [517], 
tissue repair [518] tumour suppression [519] or embryonic development [118]. So far, it is still 
unknown whether a senescent-like phenotype in neurons serves a specific function and has evolved 
as such and if it is beneficial or detrimental to the organism.  
Polyploid neurons from young mice maintain distal connections, and show some signs of activity, such 
as early intermediate gene expression [311]. This suggests that there is still at least a degree of 
154 
 
functional integration. As such, there exists the possibility that this simply is a protective mechanism 
against cell death in vitro and in vivo [289, 306, 307, 309], and that these cells do not negatively 
contribute to overall network connectivity. Therefore, elimination of senescent cells in the whole body 
may counter ageing, but the killing of senescent-like neurons carries the risk of damaging brain 
function.  
4.1.2 - Treatment of chronologically aged mice with senolytic compounds 
To assess if clearance of senescent cells was linked to either an improvement in cognition, or a decline, 
our laboratory, in collaboration with the laboratory of James Kirkland at the Mayo Clinic, Rochester, 
Minnesota, assessed cognitive function in an aged cohort of mice using two different senolytic 
approaches. A cohort of aged INK-ATTAC mice (25-30 months at start of treatment) was used. Baseline 
measurements of cognition were taken prior to the administration of the 2 different senolytic 
approaches, pharmacological clearance by Dasatinib and Quercetin (DQ), and pharmacogenetic 
clearance by AP20187. Cognitive and behavioural analyses were performed in Mayo Clinic, by Mikołaj 
Ogrodnik, post-mortem the brain tissues were shipped to the UK where I performed the 
characterisation of senescent-like neurons in the brain. 
The pharmacogenetic INK-ATTAC approach [123, 124] involves replacing the promotor of dimerising 
caspase-8 with part of the promotor region of p16, which is activated in many senescent cells (Termed 
INK-ATTAC). When the drug AP20187 is added, it promotes the dimerization of caspase-8. This then 
promotes apoptosis in cells where this is expressed, namely p16 expressing cells. This approach has 
been shown to result in a reduction in the number of p16 positive senescent cells and in improvements 
in median lifespan and age-associated pathology in aged mice [124, 351]. Dasatinib and Quercetin 
(DQ) is a combination therapy of two drugs that have proven effective in killing senescent cells in vitro 
and in vivo. Recently, it has demonstrated that a single dose of DQ was sufficient to effectively clear a 
high percentage of p16 positive cells in the liver [346]. Pharmacogenetic clearance through AP20187 
has shown improvements in healthspan and median lifespan in wild-type mice at 18 months [124]. 
Both AP20187 and DQ show improvements in several parameters of healthspan in progeroid models, 
AP20187 in BubR1  mice [123], and DQ in ercc1-/- mice [356]. 
There was high mortality in this study, likely due to the advanced age of the mice (27-32 months by 
end of treatment). During the study the total mortality for male mice was 27%. The use of AP20187 
has previously been demonstrated to improve median life-span in INK-ATTAC C57Bl/6 and mixed 
background mice [124]. This was administered twice per week from 12 months till end of life, in 
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contrast to the intermittent treatment used her for 2 months. Mortality was highest in Vehicle treated 
mice at 40%, 30% in DQ treated mice, and 8% in AP20187 treated mice.  
4.1.3 - Intermittent treatment with the senolytic compounds Dasatinib and Quercetin, and 
AP20187, prevent age-associated memory decline in aged wild-type mice. 
Treatments with the senolytic compounds DQ and AP20187 have been shown by Mikołaj Ogrodnik to 
improve cognitive function in aged INK-ATTAC mice (Figure 4.1.3.1). Learning and memory impairment 
was assessed using a shallow-water motivated Stone T-Maze paradigm [520]. As a T-maze variant, it 
is a series of left-right turns, which the mouse must memorise, in order to navigate from the start 
point to a dry escape box [520]. Impaired learning in the Stone T-Maze can be seen with lesions to the 
striatum and septo-hippocampal system [521]. Performance in the maze decreases with age, with 
deficits in learning and retention [520]. 
The water-motivated T-maze [520] used here has the maze partially filled with water, which allows 
the mouse to maintain contact with the ground, while keeping their head above the water and 
motivating their escape. They were acclimatised and trained on the first day with a ‘straight run’ that 
presented no choices, but showed that advance means escape. Mice were defined as successful if they 
reached the goal box in under 10 seconds, in 6 of 9 training trials. If they failed they were excluded 
from further analysis. The next day the maze version was introduced, with mice having 9 trials within 
the day, with 5 to 12 minutes between trials in a heated holding box with a drying towel. Primary 
latency and wrong turns (errors) to the escape box were recorded. Mice were allowed a total of 5 
minutes in the maze before failure, and trial termination, 3 failures lead to exclusion from further 
analysis. 
In the cognitive data from the Stone T-Maze, aged 27-32 month INK-ATTAC male mice, compared to 
5 month control mice, make significantly more errors (Figure 4.1.3.1a,c), and take longer to complete 
the maze than young control mice (Figure 4.1.3.1b,d). In young mice, two months of intermittent 
treatment with the senolytics DQ and AP20187 did not significantly affect the number of errors, or 
time taken to complete the maze (Figure 4.1.3.1a,b). In contrast, in aged INK-ATTAC mice, treatment 
with DQ and AP20187 significantly improved performance in the maze, with fewer errors made and a 
significant decrease in latency (Figure 4.1.3.1c,d).  
To account for the possibility of survivor bias and to track if there are changes in cognition, the data 
was also normalised to percentage change compared to base-line testing, which was performed prior 
to the start of treatment (Figure 4.1.3.2a-d). Vehicle treated aged INK-ATTAC mice showed a 
deterioration in Stone T-Maze performance, performing at 150% of baseline (1.5x worse), while 
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AP20187 treated mice remained comparatively constant (90-100% of baseline), and DQ treated mice 
showed an improvement (60% of baseline) (Figure 4.1.3.2c,d).  
The improvements in performance do not seem to be linked to a greater ability to memorise the maze, 
as the rate of improvement seen across training are comparable. Instead senolytic treated aged INK-
ATTAC mice performed better from the first trials, indicating better overall memory function (Figure 
4.1.3.2c,d). Together this implies that the clearing senescent cells protects aged male INK-ATTAC mice 
from age-dependent declines in memory, and possibly even an improvement with DQ treated mice. 
This was observed at both a group, and individual level, so does not appear attributable to survivorship 
bias from the improved survival of senolytic treated groups.  
  
157 
 
 
 
Figure 4.1.3.1: Memory function in young and old INK-ATTAC mice after AP20187 and 
Dasatinib & Quercetin treatment  
(a-b) young (5 month) and (c-d) aged (27-32 month) male INK-ATTAC mice were tested in the Stone T 
Maze, after two months of intermittent treatment with AP20187 and DQ. Memory function in the 
Stone’s maze is defined by (a, c) the frequency of errors they make during the test session and (b, d) 
the escape time from the maze. All data are mean ± s.e.m. with n=7-8 for young males, n=9-11 for old 
males. Significance between groups shown by * P<0.05 (two-way ANOVA). Reproduced with 
permission form Mikołaj Ogrodnik. 
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Figure 4.1.3.2: Performance of INK-ATTAC mice in the Stone’s Maze normalized to the 
baseline  
As the outcome of the AP20187, D&Q or vehicle treatment on memory function parameters (a, c) 
frequencies of errors and (b, d) the time to finish the maze were normalized to the baseline tests taken 
prior to the start of treatment and analysed. All data are mean ± s.e.m. with n=7-8 for young males, 
n=9-11 for old males. Significance between groups shown by *P<0.05 (two-way ANOVA). Reproduced 
with permission from Mikołaj Ogrodnik.  
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4.2 - Dasatinib and Quercetin reduces senescence-associated markers in 
hippocampal neurons 
 
To assess if there was clearance of senescent-like neurons with senolytic treatment, a number of 
senescence- associated markers were assessed. The hippocampus was selected as the primary target 
of investigation in aged INK-ATTAC mice following treatment with AP20187 (which induces apoptosis 
of p16 expressing cells through dimerization of FKBP-fused Casp8 in INKATTAC mice) and DQ. These 
mice showed an improvement, and a prevention of age-associated decline, in the Stone T-Maze 
following treatment with DQ and AP20187. The Stones T-Maze is dependent on the septo-
hippocampal system [521]. In the last chapter, I observed deficits in hippocampal gamma oscillations 
and hippocampus-dependent spatial memory tasks in mice, with increased levels of senescence-like 
neurons in this region. 
To assess the rates of senescent cells requires the use of multiple markers, as even the most accurate 
only show 90% accuracy [121]. The expression of p16 and p21 were assessed, as was the loss of 
HMGB1 from the nuclear compartment. Measurement of the DNA damage, and telomere associated 
damage as a persistent DNA damage, were also assessed, as these have proved to be good markers of 
cellular senescence and clearance of p16 senescent cells has decreased telomere-associated foci in 
liver [516]; aorta [354]; Cardiomyocytes (Anderson et al. unpublished) and predict mouse lifespan 
[127].  
4.2.1 - Dasatanib and Quercetin, but not AP20187, significantly reduces p16 positive cells 
in the CA3 of the Hippocampus 
p16 is a cyclin-dependent kinase inhibitor that binds to Cdk4/6 to inhibit the formation of the Cyclin 
D-Cdk4/6 and progression from G1 to S-phase. It is activated in response to various mitotic and 
senescence inducing stressors [118, 216]. p16 is expressed in many senescent cell-types and increases 
can be seen in multiple mouse tissues, including the heart and cortex [349]. It provides a secondary 
‘lock’ to p53 signalling in establishing a permanent exit from the cell-cycle [216, 522] and blocks 
cytokinesis (even in the event of cell-cycle slippage and DNA synthesis by p53 and pRb inactivation) 
via suppression of mitotic exit network kinase by a ROS-PKCd positive feedback loop [216]. An increase 
in p16, amongst other cell-cycle markers, has previously been observed in Alzheimer’s disease [276, 
277, 279, 291, 359], but their exact contribution to the disease and cognitive deficits is not yet known. 
It is widely accepted in the senescence scientific community that most commercially available 
antibodies against p16 do not work in mice tissues. For that reason, I had to use an alternative method 
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to detect p16 positive cells and performed RNA in situ hybridization (RNAISH). Cells positive for p16 
mRNA foci, detected by RNAISH, were analysed in the pyramidal layer of CA3 (including CA2) and CA1, 
and the granule layer of the DG (Figure 4.2.1.1A).  
In this experiment, I analysed brain tissues from aged INK-ATTAC mice (age 27-32) treated either with 
AP20187 to mediate pharmacogenetic clearance of p16 expressing cells, or pharmacological 
treatment with the senolytic cocktail DQ. I found that with DQ treatment there was a significant 
reduction in the number of p16 mRNA foci positive cells in the pyramidal layer of CA3 compared to 
vehicle treated mice (Figure 4.2.1.1A). However, while AP-treated mice had a lower median number 
of positive cells when compared to vehicle treated mice, the reduction was less than that seen with 
DQ, and was not statistically significantly. In the CA1 layer, a lower median number of p16 mRNA foci 
positive cells could be seen with DQ and AP20187 compared to vehicle treated animals, but this was 
not statistically significant (Figure 4.2.1.1B). No changes could be seen with DQ treatment compared 
to vehicle treated animals in the granule layer of the DG, and interestingly, AP treated animals showed 
a trend for increased number of positive cells (Figure 4.2.1.1D). When correlated with average number 
of errors in the final 3 trials of the Stone T-Maze, while there was a slight trend with the CA3, no 
significant differences could be observed with number of p16 mRNA positive cells in any of the 3 areas 
(Figure4.2.1.1E-G). 
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Figure 4.2.1.5: Treatment with Dasatinib and Quercetin, but not AP20187, reduces p16 
mRNA positive cells in the CA3 layer in aged INK-ATTAC mice 
A) Representative images of p16 RNAISH staining in the hippocampus B) Quantification of p16 mRNA 
positive cells in the pyramidal layer of the CA3+CA2 region hippocampus C) Quantification of p16 
mRNA positive cells in the pyramidal layer of the CA1. D) Quantification of p16 mRNA positive cells in 
the granule layer of the DG.  E) Comparison of p16 mRNA positive cells in the CA3 and CA2. Kruskal-
Wallis, Dunns Post-Hoc (Vehicle control), n=6-7 animals per group. Significant differences between 
treatment groups displayed by by (* p<0.05, ** p<0.005).  
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4.2.2 - Dasatinib and Quercetin treatment significantly reduces the number of Telomere-
associated yH2A.X foci (TAF) in the CA3 layer 
A DNA damage response located at telomeres regions appears to be persistent during senescence, 
with data suggesting that telomere regions (particularly components of shelterin complex) inhibit non 
homologous end joining repair[209, 211]. A persistent DDR signalling has been shown to be important 
for the maintenance of the cell-cycle arrest during senescence and also contributes to the induction 
of the SASP (since the central initiator of the DNA damage response –ATM has been shown to be a 
SASP regulator (Rodier et al.)[86, 177, 209, 211]. I previously observed increased in telomere 
associated DNA damage foci with age in neurons from wild-type and nfkb1-/- mice in neurons, which 
was associated with the presence of p21, the loss of HMGB1 from the nucleus and increased lipofuscin 
levels. For these reasons, I investigated whether pharmacogenetics clearance of p16 positive cells or 
treatment with senolytic drugs impacted on telomere dysfunction in aged mice. The total number of 
yH2A.X foci, the number of foci co-localising with telomeres, and the number of cells with 2 or more 
TAFs were analysed in the CA3 and CA1 of mice treated with Vehicle, DQ or AP20187 (Figure 4.2.2.1A). 
In CA3 neurons DQ treated mice showed a trend for a lower median value of mean yH2A.X foci per 
cell compared to vehicle treated mice, but this was not significant (Figure 4.2.2.1B). The median value 
forAP20187 treated animals fell between these two values; this was not significantly different to 
vehicle treated control mice and a higher degree of variation could be observed. However, I observed 
a significant reduction in the mean number of TAFs per neuron in DQ, but not AP, treated mice (Figure 
4.2.2.1C). 
In the CA1, there was a similar pattern to the CA3, with a trend for reduced mean yH2A.X foci per cell 
in DQ animals, with AP treated animals falling in between (Figure 4.2.2.1D). Neither of these trends 
was significant. A trend for a reduced mean number of TAFs per cell was observed with DQ treatment, 
but not with AP20187 treatment (Figure 4.2.2.1E). 
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Figure 4.2.2.1: Dasatinib and Quercetin reduces Telomere associated DNA damage in CA3 
pyramidal neurons in aged INK-ATTAC mice 
A) Representative images of TAF stainings in the CA3 and CA1 of the hippocampus, yH2A.X in green, 
telomere probe in red and nuclear stained with DAPI in blue. Quantification in NeuN positive CA3 cells 
of B) total yH2A.X  foci per neuron, C) Average TAF. Quantification in NeuN positive CA1 cells of D) 
total yH2A.X foci per neuron, E) Average TAF. Box and whiskers show the median of the means -Min 
to +Max. Kruskal-Wallis, Dunns Post-Hoc (Vehicle control), n=5-10 animals per group, significant 
differences between genotype, as well as treatments, at each age point are displayed by (* p<0.05). 
Imaged and quantified by Patrick Krüger. 
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4.2.3 – p21 positive cells positively correlate with cognition, but are not modified 
significantly by senolytic treatment. 
In the last chapter I observed an upregulation of p21 protein in neurons, with ageing in wild-type mice 
and in nfkb1-/- mice. p21 is activated downstream of the DDR through p53 [178, 181]. It silences the 
expression of Cdk2, and inhibits both Cyclin E-Cdk2 and Cyclin A-Cdk2, preventing transition into S-
phase and ensuring that Rb remains hypo-phosphorylated and inactive [88, 89]. In S-phase, it can 
displace polymerase from PCNA and prevent DNA-synthesis [179, 180]. In senescent cells, in addition 
to its roles in inhibition of the cell-cycle, it has a role in the initial stabilisation of the senescent-
phenotype [177, 222]. It was hypothesised that ROS generated downstream of p21 contributed to a 
positive feedback loop which stabilised the DDR thereby stabilising the cell-cycle arrest during 
senescence [177]. 
The number of cells positive for p21 by RNAISH was also analysed in the pyramidal layer of CA3 
(including CA2) and CA1, and the granule layer of the DG (Figure 4.2.3.1A). In contrast to p16 mRNA 
foci, far more cells were positive for p21 mRNA foci in all 3 areas analysed (Figure 4.2.3.1B-D). With 
DQ treatment, there was a trend for a reduced number of cell positive for p21 mRNA in the CA3 of the 
hippocampus compared to vehicle treated controls, with the median value for AP20187 treated 
animals falling in between these values (Figure 4.2.3.1B). No significant differences were observed in 
the CA1 (Figure 4.2.3.1C) or DG (Figure 4.2.3.1D) between either DQ, or AP20187, treated mice and 
vehicle treated controls. In contrast to p16 mRNA, while there was no significant difference between 
groups in the percentage of cells positive for p21 mRNA foci in the 3 areas. However, there was a 
significant correlation between number of errors made in the final 3 trials of the Stone T-Maze and 
the number of p21 positive cells in the CA3 (Figure 4.2.3.1E), and CA1 (Figure 4.2.3.1G) when 
comparing all groups. This was not significant in the DG (Figure 4.2.3.1G). 
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Figure 4.6.3.1: No significant effects with Dasatinib and Quercetin, or AP20187, on p21  
RNAISH positive cells in the hippocampus 
A) Representative images of p21 RNAISH staining in the hippocampus B B) Quantification of p21 mRNA 
positive cells in the pyramidal layer of the CA3+CA2 region hippocampus C) Quantification of p21 
mRNA positive cells in the pyramidal layer of the CA1. D) Quantification of p21 mRNA positive cells in 
the granule layer of the DG.  E) Comparison of p21 positive cells in the CA3 and CA2. Kruskal-Wallis, 
Dunns Post-Hoc (Vehicle control). n=6-8 animals per group. Significant differences between treatment 
groups displayed by by (* p<0.05, ** p<0.005).  
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4.2.4 - Dasatinib and Quercetin, and AP20187, reduce percentage of HMGB1 negative cells 
in the pyramidal layer of the CA3 
As previously discussed, HMGB1 is a chromatin binding protein that can be relocated from the nucleus, 
to the cytosol and extra-cellular space, where it can act as a pro-inflammatory cytokine [493, 494]. Its 
release from neurons and glial cells can mediate inflammation related tissue damage [494-496], and 
it is a key regulator of senescence and the SASP following nuclear export [491]. Previously I observed 
increased release of HMGB1 from neurons in nfkb1-/- mice compared to wild-type mice, and with age, 
in pyramidal neurons of the hippocampus.  
The presence of nuclear HMGB1 was analysed in the pyramidal layers of CA3 to CA1 and granule layer 
of the DG in mice treated with Vehicle, DQ and AP (Figure 4.2.4.1A). 3 sections were counted per 
animal, and the average taken for each area. Dark neurons were not counted, as we could not exclude 
the possibility that these were a fixation artefact [514].   
In CA3 neurons, aged mice treated with both DQ and AP20187 showed a significant reduction in the 
percentage of HMGB1 negative neurons compared to vehicle treated controls (Figure 4.2.4.1B). The 
change in median percentage of cells was slightly greater in DQ treated animals, and with less 
variation. In the CA1, a trend for reduced percentage of HMGB1 negative neurons could be seen with 
DQ, but not with AP20187 (Figure 4.2.4.1C); however, neither was significantly different to vehicle 
treated animals. There was a lesser trend in the Dentate Gyrus, although both DQ and AP treated 
animals showed a trend for reduced median percentage of HMGB1 negative neurons.  
When correlated with the average number of errors in the final 3 trials of the Stone T-Maze, a 
significant correlation could be seen with percentage of HMGB1 nuclear negative neurons in the CA3 
(Figure 4.2.4.1E), and a slight, but non-significant trend with HMGB1 negative neurons in in the CA1 
(Figure 4.2.4.1F) and DG (Figure 4.2.4.1G). 
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Figure 4.2.4.1: Dasatinib and Quercetin, and AP20187, reduce the percentage of HMGB1 
negative neurons in the CA3 
A) Representative images of HMGB1 staining in the hippocampus, HMGB1 stained by NovaRed 
(Brown) and counterstained with Haematoxylin (Blue). B-D) Quantification of neurons with no HMGB1 
in the nucleus in the pyramidal layer of the B) CA3+CA2, C) CA1 and D) DG regions of the hippocampus. 
Kruskal-Wallis, Dunns Post-Hoc (Vehicle control). n=6-9 animals per group. Significant differences 
between treatment groups displayed by (* p<0.05, ** p<0.005). E-G) Correlation between number of 
average number of errors in trials 7-9 of the Stones Maze and percentage of neurons with no HMGB1 
in the nucleus in the pyramidal layer of the E) CA3+CA2, F) CA1 and G) DG regions hippocampus. Red 
line shows linear regression, dotted blue lines show 95% confidence intervals. Significance tested by 
two-tailed Pearson correlation coefficient (* p<0.05). 
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4.3 - Discussion 
 
In this work we hypothesised that senescent cells may contribute to loss of function in the brain. To 
assess this, we aged INK-ATTAC mice and induced clearance of p16 positive cells by pharmacogenetics 
means (through the administration of AP20187) and through use of a drug combination (Dasatinib 
and Quercetin) has previously been shown to eliminate senescent cells in vitro and in vivo. 
Prior to the experiments we predicted three possible outcomes: one was that clearance of senescent 
neurons may be detrimental for ageing mice, since senescence is characterised by resistance to 
apoptosis [250-252, 523] and its existence in neurons may be a mechanism to avoid neuronal cell 
death with age [196]. Another, would be that senescent neurons are detrimental during ageing due 
to loss of function and by induction of paracrine damage. Consistent with this hypothesis, previous 
data has indicated that whole body clearance of senescent cells lead to marked improvements in 
healthspan in aged  mice [124] and in several models of age-related diseases (such as osteoarthritis, 
liver disease, bone loss, atherosclerosis and pulmonary fibrosis). The third possibility is that any effects 
of clearance of senescent cells is due to non-cell autonomous mechanisms and that elimination of 
senescent cells in others parts of the body, besides the brain, contributes to any observed phenotype. 
Initial reports of cognitive testing in 18 month INK-ATTAC mice (C57Bl/6 and mixed background) 
treated with AP20187 by Baker et al. suggested no significant effect in memory function using novel-
object recognition (NOR) [124]. These data suggested that there was no outright damaging effect, but 
NOR is a form of non-spatial memory testing and sensitive to changes in visual and olfactory function. 
While there are defects in mice with hippocampal lesions, the contribution of hippocampal memory 
to novel object recognition is still unclear [524]. Furthermore, the mice used in Baker et al. were at 
comparatively young age, at 18 months (compared to the mice we used which were 25 to 30 months 
of age at the start of the 2 month treatment). While defects can be seen by this age in parameters of 
spatial memory such as the Barnes Maze, the NOR appears more resistant [525]. In NOR, using same-
day testing parameters, there is no significant change in ageing C57Bl/6 mice compared to 4 month 
control mice, even by 28 months when using short rest periods (1 minute, compared to 5 minutes in 
Baker et al.) [525]. Differences are observed when using a 24 hour delay though. As such, the method 
used by Baker et al. may not have been sensitive enough to adequately detect any changes. In contrast 
the Stone T-Maze is understood not to be affected by changes in visual and olfactory function, and 
has been used successfully to assess age-related changes in cognition [520]. 
Our data on performance in the Stone T-Maze in aged INK-ATTAC mice following treatments with DQ 
or pharmacogenetic clearance of p16 positive cells through AP20187 suggests that senescent cells 
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may contribute to declines in cognitive performance. In young mice, we observed no significant 
changes in cognitive function, suggesting that neither pharmacogenetic clearance with AP20187 or 
DQ had any outright damaging effects on cognition. In aged INK-ATTAC mice, AP20187 treatment held 
performance comparatively stable compared to baseline testing prior to testing, suggesting that 
clearance of senescent cells in the body prevents further deterioration. Intriguingly, DQ treated mice 
actually showed improvements in performance compared to baseline testing, suggesting that this 
compound may not simply delay further deficits.  
My data suggests that treatment with DQ is capable of reducing the numbers of senescent-like 
neurons in the pyramidal layer of the hippocampus. There was a significant reduction in the 
percentage of p16 positive cells detected by RNAISH in the CA3 of DQ treated INK-ATTAC mice 
compared to vehicle treated animals. There was a similar trend in CA1, but no observable difference 
in DG.  
In contrast, AP20187 was less effective, and did not show significant differences to vehicle treated 
INK-ATTAC mice in many factors. There was no significant rescue in the CA3-CA1 in numbers of p16 
mRNA foci positive cells, and median values typically fell between those of vehicle treated and DQ 
treated mice. This is a similar pattern to the results found in the Stone T-Maze. This was surprising 
since AP20187 should be a more specific intervention in promoting the killing cells expressing p16 
through the activation of caspase-8 [123, 124]. This may be explained by reduced BBB penetrance of 
AP20187, which will be discussed later in this section. 
The role of p16 in neurons is still not understood. In proliferation competent cells, p16 is expressed in 
late senescence and is associated with the maintenance of stable cell-cycle arrest after p21 levels 
subside [526]. Increases in p16 positive cells have been observed in vulnerable areas of the brain, such 
as the hippocampus in Alzheimer’s disease [277, 279, 291, 527, 528]. pRb and p16 expression has been 
shown to be protective against apoptosis in neurons [360], which may explain the persistence of these 
cells in the disease. In  5XFAD Alzheimer’s model mice, increases could be seen in p16 expression in 
pyramidal neurons (some in astrocytes, none in microglia), with an association with cognitive deficits 
in spatial memory in [527].  
Activation of the DDR, and the presence of persistent DNA damage has been shown to trigger and 
maintain senescence in mitotic tissues [177, 209, 210]. Double-stranded breaks can be marked by DDR 
proteins such as yH2A.X and are potent inducers of the DDR [112, 129]. This can lead to downstream 
activation of either pro-apoptotic and pro-survival pathways [136, 137]. The data here did not show a 
significant decrease in the number of yH2A.X with senolytic treatment. There was a slight trend for 
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reduction with DQ, but no change with AP20187 in pyramidal neurons from CA3. In CA1 neurons there 
was a trend for reduction with DQ and AP20187. This is consistent with my previous data in ageing 
wild-type mice - while we observe a significant increase in TAF with age, we did not observe any age-
dependent changes in total γH2A.X. This may be due to the fact that double-stranded breaks located 
in non telomeric regions are quickly repaired; where as previously shown, telomere regions inhibit 
NHEJ [211]. It is possible that these non-telomeric foci are constantly being induced and rapidly 
repaired as shown in senescent fibroblasts grown in vitro [177, 209], therefore not accumulating with 
age. It should however be noted that studies indicate that the efficiency of NHEJ repair does decrease 
with age [147-149]. As mentioned previously, double stranded breaks have been shown to be 
physiologically generated by topoisomerase II in order to regulate the expression of neuronal early 
response genes required for synaptic plasticity and learning in hippocampal pyramidal neurons [207, 
208]. This factor may introduce an additional degree of variability into this measure, especially if the 
mice are exposed to novel environments prior to harvest, that may mask age and senescence-
associated differences [208]. Prior research, and my work in the previous chapter, suggests that 
damage located at telomeres is persistent in neurons. Data from the d’adda di Fagagna lab, has shown 
that 3 months after whole body irradiation, 40% of remaining DDR foci are located at telomeres [211]. 
I observed that TAF increase with chronological age, and in prematurely ageing nfkb1-/- mice. This was 
associated with activation of downstream DDR factors such as p21, and the accumulation of 
senescence associated markers in neurons. A significant reduction in the average number of TAFs in 
the CA3 could be seen with DQ, along with a similar trend in the CA1. If these breaks are persistent, 
then this would be consistent with the removal of cells, which is given partial support by a 
corresponding decrease in the number of cells positive for multiple TAFs. Furthermore, the same 
decrease was not observed with AP20187 treatment, which may be explained by poor blood-brain 
barrier penetrance.  
It should be noted that number of TAF was considerably lower in this cohort of mice than previously 
reported in the previous chapter. I believe this could be due to technical reasons related with 
difference in microscope parameters used during quantification by Patrick Krüger, and for that reason 
I am in the process of independently repeating these experiments. 
The presence of neurons positive for p21 detected by RNAISH could be seen in a large number of cells 
in the CA3-CA1 pyramidal layer, where there was a trend for decrease in DQ treated animals. However, 
there was substantial variability and this was not significant. Yet, I did find a significant association 
with the increased number of p21 mRNA positive cells in the pyramidal layer in CA3-CA1 and 
decreased performance in the Stone’s maze in aged mice. In this analysis I quantified the number of 
174 
 
cells containing at least 1 p21 focus. Future work should be conducted to analyse the number of p21 
foci (detected by RNAISH) per cell. This may allow a more sensitive detection of differences between 
experimental groups. p21 has additional roles, apart from its role in senescence, in suppressing 
apoptosis [181, 260], single-strand break repair [181] and limited G0-G1 re-entry for NHEJ [281]. These 
may operate at a ‘sub-senescence’ level and would explain basal levels in neurons. It may take 
prolonged DDR, such as that from TAFs, or pro-mitotic signalling to induce the senescence-associated 
aspects of p21 activation.  
Decreases in the number of CA3 pyramidal layer cells without HMGB1 in their nucleus were also seen 
with DQ and AP20187 treatment. HMGB1 translocates out of the nucleus in senescent cells and is 
considered a senescent marker [121]. It can be released from the cytoplasm into the extra-cellular 
space where it acts as a pro-inflammatory cytokine [493, 494]. Release of such factors by neurons may 
promote microglial activation by disrupting the balance ‘on’ and ‘off’ signals that control microglial 
function and activation [529]. Indeed, several of the known ‘on’ signals are associated with the SASP, 
including CXCL10/IP-10 and MMP-2 [529], and if senescence-like neurons are secreting these factors 
it may contribute to microglial priming and activation.  
Increased microglial priming and activation with age is an important mediator of cognitive dysfunction 
[108, 109], and is associated with age-related reductions in long-term potentiation [110]. HMGB1 has 
a significant role in activating microglia and driving chronic inflammation and degeneration [496, 511] 
and appears to mediate age-related neuro-inflammatory priming [510, 512]. Lowered HMGB1 release 
in the brain could desensitise microglia to further activation, and possibly counter any inflammatory 
positive feedback loops that drive degeneration [510]. It is not yet known if HMGB1 is consistently 
released from these neurons. While nuclear exclusion appears permanent in senescent cells, it may 
also that if removing the source of stress in neurons would allow relocation to the nucleus. This would 
make it difficult to assess if neurons are directly cleared. 
It is still possible that these neurons were not cleared directly, and that instead the reduced amount 
represents a reduced rate of generation from an improved tissue micro-environment. The reductions 
in p16 mRNA and average TAF suggest that it might be related to clearance. Although the exact kinetics 
of telomere associated damage repair in neurons damage are still unknown, but Fumagalli et al. 
observed a significantly elevated level 3 months after whole-body irradiation, suggesting that they are 
persistent for at least this time [211], while the treatment here was for 2 months. Additionally, the 
reduction in median for the average number of TAFs was greater than the decrease in non-TAFs in DQ 
treated animals compared to vehicle treated animals. In DQ treated animals compared to vehicle 
treated animals, there was a 62% reduction in the median average number of TAFs, there was only a 
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21% reduction in the median average number of non-TAF yH2A.X.  In AP treated animals, this was only 
a 33% decrease in TAFs, and the same reduction in the number of non-TAF yH2A.X foci as DQ. Again, 
this would support the idea that DQ is actually more effective at clearing TAF carrying cells, while both 
AP20187 and DQ are reducing the generation of yH2A.X, possibly by improving the whole-body 
environment or removing senescent glial cells. Although the yH2A.X from damage may still be masked 
by the afore mentioned physiological break generation. This would be consistent with the clearance 
of senescent-like neurons by senolytic treatment. 
If these cells are killed by senolytic treatments, then this will likely lead to an effect on microglia, which 
as the resident phagocytic cell would help clear the debris. This may present some difficulties in the 
assessment of microglia in these brains. Careful characterisation of the mode of microglial activation 
is needed, in addition to counts in density. It is quite likely that increased microglial presence, and 
activation will be observed to deal with cellular debris.  
A possible explanation for the differences between DQ and AP20187 is the penetrance of these drugs 
through the blood-brain barrier (BBB). AP20187 has been long used to activate fusion proteins with 
F36V mutant FKBP domains, and there is existing literature on its BBB penetrance. Currently, there is 
mixed evidence on the BBB penetrance of AP20187. To my knowledge, there is one paper that 
suggests AP20187 can penetrate the blood-brain barrier [530], and 5 papers that suggest it cannot 
[531-535]. This could explain the lack of significant effects in INK-ATTAC treated mice on senescent-
like neuron number. In contrast, both compounds in DQ appear to have effective penetration in the 
brain. Dasatinib effectively crosses the blood brain barrier and has been used clinically for the 
treatment of CNS leukæmia [536]. Orally administered Quercetin also appears to be effective in 
penetrating the blood-brain barrier [537]. 
However, other factors may affect our interpretation of the results- particularly when using aged mice. 
C57Bl/6 mice show increasing BBB dysfunction with age [538, 539]. By 24 months chronologically aged 
mice show increased capillary permeability and a decline in BBB tight junction protein expression [538, 
539] and increased junction breaks compared to young control mice [539]. Furthermore, cellular 
senescence in vascular appears to contribute to this loss of integrity in progeroid mice [540]. It is not 
clear if AP20187 would have increased penetrance in the event of a compromised BBB, but if it does, 
then differing rates of BBB integrity would affect clearance and increase heterogeneity of the results. 
The effect of senolytic treatment on BBB senescence and integrity are not yet known, but warrants 
further investigation.  
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Interestingly, imatinib (a close relative of Dasatinib) treatment has shown effectiveness in preserving 
BBB integrity following subarachnoid hæmorrhage, with a decreased permeability and decreased 
production of metalloproteinases [541]. Quercetin has also been linked to protection of endothelial 
cells in the microvasculature of the brain from AB fibrils, increasing cell viability, decreasing ROS 
production and improving BBB integrity [542]. This suggests that DQ therapy may improve BBB health, 
potentially through senolytic effects, which could improve the brain microenvironment. However, this 
requires further work. Staining for markers of neurovasculature, such as the scaffold protein zonula 
occludens-1, and looking for breaks [539] would provide some post-mortem evidence. Additionally, 
tracking blood and oxygen flow with neuroimaging before and following senolytic treatment could 
provide evidence of changes in neurovasculature and blood flow that would aid cognitive function. 
Indeed, it is difficult to say if the improvements in cognitive function are directly related to the 
clearance of senescence-like neurons, or through the elimination of senescence in other brain cells, 
and the whole body. In the previous chapter I showed that they can be seen to increase in areas 
vulnerable to age-associated declines, and a change in cognitive function could be observed with 
spatial memory and in the generation of gamma oscillations. However, the brain is incredibly complex 
and there are no doubt a large number of contributing processes. Investigating if there are alterations 
in gamma oscillations in ageing mice and in models with known deficits, after senolytic treatment, 
would provide additional evidence of improvements in hippocampal function.  
It should also be noted that neurons are not the only population of cells within the brain that undergo 
senescence [347]. Despite the lack of a DNA damage response in terminally differentiated astrocytes 
[507], cultured astrocytes display a number of senescence associated features in vitro after H2O2, 
including p16 and p21 expression, altered morphology, Sen--Gal expression, and release of SASP 
factors after both H2O2 and irradiation [543, 544].  
Senescence in microglia may also play a role in the process [347]. With age, there appear to be 
reductions in microglia’s ability to respond appropriately and a resistance to regulation [109]. 
Dystrophic microglia morphology has been observed, with deramification and fragmentation of 
processes, and has been suggested as a sign of microglial cell senescence [545]. Both X-ray irradiation 
(a known inducer of senescence) and ageing have been shown to induce similar changes in the 
transcriptome of murine microglia [546]. When microglia are isolated from mouse brains 1 month 
after 10Gy cranial irradiation, they showed the upregulation of M1 macrophage-associated genes, as 
might be expected from activated inflammatory microglia. However, the expression of extra-cellular 
matrix factors, such as matrix metallo-proteinases, and fibrosis associated pathways was also 
observed [546]. These were not previously associated with M1 or M2 activation, and re-analysis of 
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transcriptomes of microglia from aged mice showed that these genes were highly enriched [546]. 
These are factors associated with cellular senescence and the SASP [86, 121], and this suggests the 
possibility of DNA damage and ageing induced microglial senescence contributing towards 
inflammation.  
However, these changes may also reflect increased microglial priming with age [109]. Both aged, and 
accelerated ageing, models of mice show increased priming of microglia with age [109, 424] and many 
of age-associated changes in microglia gene expression overlap with those for primed microglia [547]. 
Additionally, in 5XFAD Alzheimer model mice, while some p16 expression can be seen in astrocytes, 
there was none in observed in microglia, with the strongest changes in neurons [527]. We have not 
yet characterised changes in senescence markers in astrocytes, or microglia in ageing mice, and with 
senolytic treatment. 
AP20187 treated mice, also showed improvements in the number of errors, despite the weaker 
evidence of senescent-like neuron clearance, and issues with blood brain barrier penetrance of the 
compound. Senolytic treatment should counter ageing, and partially rejuvenate the whole body [124]. 
A reduction in age-associated systemic factors in the blood and choroid plexus (together with any 
changes in BBB integrity with senolytic treatment) could lead to improvements in the brain, through 
modulation of factors such as neurogenesis and decreased systemic inflammation. Work done by Tony 
Wyss-Corey’s lab suggest that circulating factors in aged mice can have a significant effect on brain 
function in ageing [412, 548, 549]. The addition of plasma from young mice into aged mice improved 
synaptic plasticity, neurogenesis and performance in the radial arm water maze [412, 548]. Senolytic 
drugs may also improve neurogenesis, as p16 knockout mice show increased signs of neurogenesis in 
the olfactory bulb and subventricular zone, and proliferation of isolated progenitor cells [550]. While 
no differences were seen in p21 or p16 mRNA positive cells in the granule layer of the DG, 
neurogenesis in the DG, olfactory bulb, and subventricular zone, has not yet been investigated yet in 
these mice. 
However, the improvements observed with young blood appear to be primarily mediated through the 
improvements in synaptic plasticity via activation of cyclic AMP response element binding protein, 
rather than neurogenesis [548, 549], with the addition of TIMP2 from human umbilical cord giving 
similar results for synaptic plasticity and spatial memory, without modulation of neurogenesis [549]. 
Further work could focus on testing plasma concentrations of such factors, and seeing if similar 
changes in gene expression are observed.  
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Plasma inflammatory cytokine array data by Mikołaj Ogrodnik from our lab (not shown here), 
however, has suggested only a mild improvement in the circulating environment, at least in terms of 
inflammatory factors, following clearance of senescent cells by AP20187 and DQ. Further, the 
improvements in AP20187 treated mice were mild, and when normalised to baseline appear to show 
that they come from prevention of further age-related decline, rather than an improvement in 
cognition. In contrast, DQ treated mice show an approximate 40% improvement in their performance 
after treatment compared to base-line. Which could suggest that clearance of senescent cells in the 
brain has an additional positive effect on cognition.  
Together, these data suggest that senescent-like neurons can be cleared by pharmacological 
treatment. This treatment and the clearance of senescent-like neurons does not appear to be 
detrimental for cognitive function at this age point. Indeed, there was prevention of further age-
related decline and even improved performance in cognitive function. This provides evidence against 
the hypothesis that clearance of senescent neurons would be detrimental for ageing mice due to the 
loss of neurons. The data provides evidence that the prevention of further decline, and improvements 
in cognition, may be the result of elimination of senescent cells in both the brain and in other regions 
of the body. 
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5.0 – Conclusions 
 
Work in this thesis addresses important questions regarding senescent-like neurons in ageing, and 
their impact on cognition, in prematurely and naturally aged mice. The definition of senescence was 
originally limited to proliferation competent cell types. However, recent data indicates that 
phenotypes characteristic of senescent cells, such as telomere dysfunction and expression of cyclin 
dependent kinase inhibitors can also be present in post-mitotic cells. The relevance of this phenotype 
for the ageing process is still not understood. The introduction of this thesis highlights existing 
literature which may be applied to the understanding of a senescent-like phenotype in neurons; 
including the role of DNA damage, cell-cycle re-activation and progression in neurons, as well as the 
use of therapies specifically targeting senescent cells and its by-products.  
In neurons, re-entry into the cell-cycle from G0 to G1 has been implicated in activating DNA repair 
machinery; however, unless restrained, further progression can lead to the apoptotic death of the 
neuron. Despite the ‘post-mitotic’ name, neurons require a functional and active cell-cycle control 
network. There is evidence of this re-activation and arrest through the cell-cycle inhibitors p21 and 
p16, both key proteins in senescence induction, in ageing and neurodegenerative diseases such as 
Alzheimer’s. These neurons appear to be survive for long-periods following cell-cycle re-entry and 
arrest, which is consistent with senescence induction. Furthermore, phenotypic changes and 
inflammatory signalling may represent a neuronal mimic of the changes seen in senescence in mitotic 
cells, like the associated secretory phenotype.  
Yet, little is known directly about the relationship between senescent-like neurons, and neuro-
inflammation or cognitive dysfunction. In this thesis, I presented evidence of increasing age-associated 
neuro-inflammation and microglial proliferation in nfkb1-/- mice compared to age-matched wild-types. 
I showed deficits in spatial memory and discrimination of nfkb1-/- mice, compared to the wild-type, as 
assessed by the Y-maze. In these mice, first long-term spatial memory declined by 7 months, then 
both short- and long-term memory were affected by 18 months, as assessed by the Barnes Maze. This 
expands on previously observed alterations in learning in younger nfkb1-/- mice; however, these have 
previously only discussed the model in relation to intrinsic effects of p50 and NF-κB signalling, and not 
ageing or inflammation. 
Partial amelioration of neuro-inflammatory and cognitive deficits with dietary ibuprofen treatment 
suggest that a NF-κB-COX-2 mediated pathway is important in regulating these effects. Previously, in 
mitotic tissues of nfkb1-/- mice, this pathway was shown by our lab to promote telomere dysfunction 
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and senescence through the generation of ROS. I found a similar accumulation of telomere associated 
damage in neurons with age, both in wild-type mice, and with increased levels in nfkb1-/- mice. Further, 
I show that damage is preferentially located in longer telomeres, suggesting that it is not uncapping 
of short-telomeres that is driving the activation of a DDR, but instead accumulation of damage. 
Telomere damage was associated with increased p21 and senescence-associated markers. I propose 
that increased persistent DDR signalling results in the induction of downstream DDR signalling 
pathways such as p21, mediating the onset of senescence-associated features. This is can be seen in 
mitotic cells, and in neurons may potentially be a by-product an anti-apoptotic cell-cycle arrest.  
Increased levels of telomeric damage could be observed in CA3 of the hippocampus in nfkb1-/- mice, 
compared to CA1 levels and wild-type mice. This is accompanied by increased proliferation and 
hypertrophy of microglia. A deficit in the generation of Carbachol-induced gamma frequency 
oscillations in the CA3 was also observed. These oscillations couple the firing of CA1 to CA3 during 
memory tasks, and a decrease in propagation and coherence between these two areas could be seen 
in nfkb1-/- mice. Dysfunction in this area may explain some of the observed deficits in spatial memory 
tasks. It is possible that the induction of the DDR and senescence-associated pathways may drive the 
phenotypic changes that can be seen in this area, such as morphological changes and the loss of 
parvalbumin expression in interneurons. This could affect their firing and account for the observed 
deficits. Additionally, release of pro-inflammatory factors, such as HMGB1, may account for the 
increased proliferation and priming of microglia. However, this data is mostly associative and does not 
establish a cause-effect relationship. 
Targeting and clearing senescent cells is a promising avenue in preventing and treating age-related 
pathologies, but it is not known if these treatments clear senescent-like neurons. My work provides 
novel evidence that pharmacological treatment with Dasatinib and Quercetin can clear senescent-like 
neurons. Reductions in telomere dysfunction, p16 positive cells and HMGB1 translocation have been 
observed. This is associated with improvements in cognitive function, as assessed by the Stone T-
Maze. Using INK-ATTAC mice, clearance of senescent cells was not effective in the brain and this may 
be due to low efficiency of the drug AP20187 in penetrating the blood-brain barrier.  
Together, my data supports the role of senescent-like neurons in neuro-inflammation and age-related 
cognitive deficits. Additionally it suggests that removal of senescent cells may be an option for 
countering cognitive decline.  
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